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SUMMARY 
Pentameric ligand gated ion channels (pLGICs) are transmembrane receptors integral in 
excitatory and inhibitory chemical transmission of nerve signals. As such they have a 
central role in cognitive, sensory and motor function and have been linked to a wide variety 
of medical conditions. They represent an important class of therapeutic targets. 
This study focuses primarily on the glycine receptor, one of the most widely expressed 
inhibitory pLGIC in the central and peripheral nervous system. Structural data for these 
receptors is limited to various homologues, and as of yet there are few compounds known 
to directly modulate their function. 
The objectives of this project were to gain a recombinant source of glycine receptor or 
homologues and surrogates of these proteins. This material would then be used for 
crystallographic studies that could yield greater insight into the structure and function of 
these receptors. Alongside this, a relatively new label-free optical biosensor technique, 
biolayer interferometry, was assessed and developed as a means of high throughput 
screening of pLGICs.  
Expression and purification of pLGICs proved problematic and resulted in a large number 
of constructs being created and tested. These constructs included sub-domains, chimeras 
and fusion partners, many of which either did not express, were liable to aggregation or did 
not purify in a monodisperse state. However, a construct of the glycine receptor was 
expressed and partially purified from the Pichia pastoris and baculovirus expression 
systems. This lays the foundation for future crystallisation and ligand screening studies.  
More success was made with developing BLI as a means to screen compound libraries 
against pLGICs. The bacterial pLGIC, ELIC, was screened against a library composed of 
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3241 compounds. The results of this screen yielded a compound that was capable of 
modulating ELIC channel currents, as measured by patch-clamp electrophysiology. This 
compound was also found to have an antagonistic effect on human GABAA receptors. 
Crystallographic studies of ELIC resulted in a low resolution structure, though as no ligand 
was detectable, it yielded no new information. 
Following bioinformatic analysis and homology modelling, potential surrogates for glycine 
receptors were designed based on the soluble protein AChBP, which is a homologue of 
pLGIC extracellular domains. The mutations incorporated into AChBP to create these 
surrogates lead to a compromised thermal stability as measured by differential scanning 
fluorimetry. Despite this instability the surrogates retained ligand binding as demonstrated 
by an increase in thermal stability in the presence of strychnine. Wild type AChBP and one 
of these surrogates, were screened in tandem with various compounds identified that were 
specific for either receptor. Though validation of these hits is still required, BLI appears to 
be useful in screening these targets. 
A crystal structure of one of these surrogates is reported in Chapter 5. Though no ligand 
was present, the structure revealed aspects of the mutations that led to a reduced stability of 
the surrogates when compared to the wild type. Based on these observations, a surrogate 
was designed that had greater stability than previous proteins, and retained the ability to 
bind the ligand, strychnine. This surrogate could be used for future validation of the 
screening results, with crystallographic studies to try and gain a structure with the ligands 
identified, and a complementary screening technology such as tryptophan fluorescence.   
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SI units are used throughout with the exception of Å representing 10-10 m. Standard 
abbreviations follow International Union of Pure and Applied Chemistry (IUPAC) 
guidelines (http://www.iupac.org/).  
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1 Introduction 
1.1 Pentameric ligand gated ion channels and fast neuronal 
transmission 
Neurotransmission is the method by which neurons communicate and is therefore integral 
in sensory and motor function, memory and maintaining primary processes such as 
heartbeat and breathing. Signaling between neurons proceeds by either electrical or 
chemical transmission. Electrical transmission utilizes gap junctions in the cell membrane 
to directly signal between adjacent neurons. Chemical transmission on the other hand relies 
on the release of neurotransmitters into the synapse between two neurons to carry the signal. 
The release of neurotransmitters occurs when an action potential reaches the terminus of 
the pre-synaptic neuron triggering an influx of Ca2+ into the neuron. This promotes 
exocytosis of neurotransmitters, contained in vesicles, into the synaptic cleft. These 
neurotransmitters diffuse across the synaptic cleft then interact with distinctive receptors on 
the post-synaptic neuron. Upon binding of the neurotransmitter to these receptors, an 
intrinsic ion channel pore opens allowing ions to cross the membrane. Depending on the 
receptor, this serves to either promote the creation of a new action potential in the post-
synaptic neuron, or inhibit action potential formation (Miller and Smart 2010). From pre-
synaptic neurotransmitter release to post-synaptic response takes less than a millisecond to 
complete (Sine and Engel, 2006).  
Chemical transmission is responsible for the communication of motor and sensory signals, 
such as vision, auditory and pain sensing. Three major families of neurotransmitter binding 
ligand gated ion channels are known, the tetrameric ionotropic glutamate receptors, the 
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trimeric P2X receptors and the pentameric ligand gated ion channels (pLGICs, Lemoine et 
al., 2012). The tetrameric ionotropic glutamate receptor family includes the NMDA (N-
methyl-D-aspartate) and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) 
receptors and are named after their preferred agonists. These receptors are characterized by 
a large extracellular amino terminus and ligand binding domain linked to a transmembrane 
domain composed of three transmembrane helices (Mayer, 2005). The P2X receptors are 
gated by ATP, and as with the NMDA and AMPA receptors, are cation selective (Jarvis 
and Khakh, 2009). These receptors are trimeric with each subunit composed of N and C-
terminal intracellular domains and a transmembrane domain composed of two membrane-
spanning helices. A loop joining the two membrane helices forms a cysteine rich 
extracellular domain containing them orthosteric binding-site. This project focused on 
pLGICs and these are discussed in more detail in further chapters. A large number of 
disorders have been linked to each of these receptors, and many drugs and anaesthetics are 
known to modulate their function. These receptors therefore constitute important drug 
targets and a growing body of research into their function and compounds that modulate 
their behavior is being generated.  
1.2 The Cys-loop receptor family 
1.2.1 Function 
In the mammalian nervous system the pLGICs responsible for fast chemical transmission 
belong to a group of proteins known as the Cys-loop receptor family. The term Cys-loop 
refers to the conserved motif of a 13 amino acid loop formed between two cysteine residues. 
These receptors can be further grouped into either excitatory or inhibitory receptors. The 
excitatory receptors include the nicotinic acetylcholine receptor (nAChR), the serotonin 
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receptor (5-HT3), and the zinc activated channel (ZAC) and are cation selective (Le and 
Changeux, 2001; Lester et al., 2004; Thompson et al., 2010). These have an integral role in 
fast excitatory synaptic transmission wherein the binding of the neurotransmitter triggers 
the opening of the pore, allowing cations to cross the membrane. This results in a 
membrane depolarisation that can then initiate a neuronal action potential. These receptors 
are found throughout the central nervous system (CNS) and peripheral nervous system 
(PNS). 
The inhibitory receptors consist of the γ-aminobutyric acid receptor (GABAA) and the 
glycine receptor (GlyR). Upon binding of either GABA or glycine, an intrinsic chloride 
channel opens, allowing chloride to enter the cell, travelling down the electrochemical 
gradient. The hyperpolarization caused by this means that for a new action potential to form, 
a higher stimulus from excitatory receptors is needed. Hyperpolarisation is therefore an 
inhibitory effect. 
These receptors are vital in the correct functioning of neuronal pathways and defects in 
them have been linked to a wide variety of medical conditions including Alzheimer’s 
disease (AD), Parkinson’s disease (PD), epilepsy, schizophrenia and myasthenia gravis 
(Bouzat, 2012). AD is a neurodegenerative disease that causes a gradual cognitive decline 
and is thought to affect 25 million people worldwide. In AD many of the symptoms that 
develop have been linked to a loss of cholinergic synapses in various regions of the brain. 
Dysfunction of nAChRs has been noted in early stages of the disease and amyloid plaques 
have been shown to interact and modulate nAChRs (Lemoine et al., 2012). PD sufferers 
similarly exhibit a decrease in cholinergic synapses, with nAChRs also playing a role in 
side effects of L-DOPA treatment. GABAA receptors may play a role in sleep disorders that 
are non-motor symptoms of PD (Brickley and Mody, 2012). nAChRs are also the target of 
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autoimmune antibodies in myasthenia gravis, which block acetylcholine receptors at 
neuromuscular junctions, resulting in muscle weakness and fatigue (Vrolix et al., 2010). 
Certain forms of epilepsy have been attributed to mutations in GABAA receptors, leading to 
a loss of function and ultimately an increase in neuronal hyperexcitability. One form of the 
disease, temporal lope epilepsy, has been linked to in increase in inhibitory 
neurotransmission, highlighting the complex relationship between pLGIC pathology and 
disease (Eichler et al., 2008; Lemoine et al., 2012).  Many drugs such as barbiturates, 
benzodiazepines, propofol and ethanol are known to modulate pLGIC receptor function 
(Olsen et al., 1986; Hales et al., 1991; Ye et al., 1998). Further detail of how these drugs 
interact with pLGICs is discussed below. 
1.2.2 Morphology of pLGICs 
pLGICs are composed of five subunits arranged in a ring, forming a membrane-spanning 
pore. All of the Cys-loop receptor subtypes have various subunit isoforms, for example 
GABAA receptors have six α, three β, three γ, single δ, ε, θ, π and three ρ subunits (Chebib 
and Johnston, 1999; Olsen and Sieghart, 2008). These subunits share roughly 70% 
sequence homology between isoforms and 30% between subunit class (Olsen and DeLorey, 
1999). Receptors can be formed by homo and heteropentamers, with the various 
compositions affecting agonist affinity, gating and conductance. For example allosteric 
modulation of GABA receptors by benzodiazepines requires the presence of an α and γ 
subunit interface (Rudolph and Knoflach, 2011).  
Each subunit can be divided into three distinct domains, the extracellular domain (ECD), 
the transmembrane domain (TMD) and the TM3-TM4 intracellular loop domain (ILD, 
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Corringer et al., 2000). Structural studies of pLGICs and their homologues have given 
insight into these domains. A list highlighting a number of these is shown in Table 1.1. 
Table 1.1 Known structures of pLGICs and homologues. 
Name Species Resolution (Å) Reference 
 
AChBP 
 
Lymnaea stagnalis 
Aplysia californica 
Capitella teleta 
Bulinus truncatus 
2.19 
1.75 
1.88 
2.00 
Ussing et al., 2013 
Hibbs et al., 2009 
Billen et al., 2011 
Celie et al., 2005 
GLIC Gloeobacter violaceus 2.40 Sauguet et al., 2013a 
ELIC Dickeya dadantii 2.91 Pan et al., 2012 
GluCl Caenorhabditis elegans 3.20 Althoff et al., 2014 
nAChR Torpedo marmorata 4.00 Unwin et al., 2005 
5-HT3 Mus musculus 3.50 Hassaine et al., 2014 
GABAA β3 Homo sapiens 2.97 Miller and Aricescu, 2014 
AChBP – acetylcholine binding protein, a soluble protein homologue of pLGIC ECD. GLIC and ELIC – 
bacterial pLGICs. GluCl – glutamate chloride channel. nAChR – nicotinic acetylcholine receptor. 5-HT3 – 
serotonin receptor. GABAA β3 – homomeric GABAA receptor.  
One of the first structural insights into these receptors came with the 4 Å structure of 
Torpedo marmorata nAChR, Figure 1.1A (Unwin, 2005). This structure, solved by electron 
microscopy, clearly shows the ECD and TMD. Until recently this was also the only 
structure to contain part of the ILD, with a recent structure of mouse 5-HT3A confirming 
the extension of the TM4 helix into the cytoplasm, forming an intracellular vestibule 
(Hassaine et al., 2014).  
The crystal structure of soluble homologues of the ECD of pLGICs from several species of 
gastropod mollusks have been solved, Figure 1.1 C. These proteins, labeled acetylcholine 
binding proteins (AChBP), are released into the synapse of the mollusks to suppress 
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cholinergic transmission (Smit et al., 2003). These structures have given detail of the ECD 
and ligand recognition. 
 
Figure 1.1 The top and side view of two pLGICs and a soluble homologue of the ECD. 
A The structure of a nAChR showing the ECD, TMD and a part of the ILD (PDB 2BG9, 
Unwin, 2005). B The structure of GABAA β homopentamer with ECD and TMD present 
(PDB 4COF, Miller and Aricescu, 2014). C A soluble homologue of the ECD, AChBP 
(PDB 2BYN, Hansen et al., 2005). The grey box represents the membrane lipid bilayer. 
 
Higher resolution structures of several bacterial and eukaryotic pLGICs have recently 
become available, giving more detailed information on the morphology of these receptors, 
Figure 1.1 B. The bacterial pLGICS do not have an ILD and to gain the structure of 
eukaryotic receptors a strategy of replacing the ILD with a short linker sequence was often 
employed, as with the structures of GluCl and GABAA β3 (Hibbs and Gouaux, 2011; Miller 
and Aricescu, 2014).  
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1.2.3 The extracellular domain 
The N-terminal end of pLGICs forms the ECD and is composed of around 200 amino acids. 
This region forms the neurotransmitter-binding site, which is located at the interface 
between two subunits (Brejc et al., 2001). Each interface is labeled either the principle or 
complementary face. Binding of an agonist in this site results in a conformational shift, 
which is transduced to the TMD causing a gating event. 
The ECD secondary structure is primarily formed of β-strands and contains the eponymous 
Cys-loop. A single α-helix found at the N-terminus has been implicated with antibody 
recognition, notably with the autoantibody produced in suffers of myasthenia gravis that 
blocks nAChR function (Luo et al., 2009). Traditionally the orthosteric-binding site has 
been described as being composed of six loops (Sine, 2002; Thompson and Lummis, 2006). 
Loops A-C contribute to the principle side of the binding site, whereas loops D-F contribute 
to the complementary side, Figure 1.2. The structures of pLGICs and AChBPs revealed that 
segments D-F were actually β-strands rather than loops (Thompson et al., 2010).  
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Figure 1.2 Pentameric assembly and ECD loops implicated in ligand binding. 
A. The GABAA β3 homomeric receptor showing the pentameric assembly (Miller et al., 
2014). Lines mark the subunit interface and intersect the orthosteric binding site location. B. 
Loops from the principle subunit that form the binding site are A (purple), B (yellow) and 
C (red). The complementary subunit contributes loops D (green), E (cyan) and F (dark 
blue). 
 
 
Many pLGICs require ligands to bind at two or more orthosteric sites to facilitate gating 
(Rayes et al., 2009).  Certain ligands can also cause positive or negative cooperativity 
wherein the binding of a ligand in one site can increase or decrease the chances of a ligand 
binding at another orthosteric site within the pentamer (Kaczanowska et al., 2014).  Each 
pLGIC has a number of aromatic residues that line the orthosteric binding site creating an 
aromatic cage. Using unnatural amino acid mutagenesis, aromatic residues on the principle 
subunit have been shown to form a cation-π interaction with the natural ligands for pLGICs 
(Beene et al., 2002; Lummis et al., 2011; Pless et al., 2008). 
The binding of ligands at the orthosteric-binding site results in conformational changes that 
can then be transmitted to the TMD, resulting in gating. At a resting state, loop C of the 
receptor is said to be in an “open” conformation. When an agonist binds, this loop is then 
pulled inwards blocking the entrance to the binding site and trapping the agonist (Ulens et 
al., 2006). Generally antagonists of pLGICs are larger than their natural agonist and 
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therefore this results in an outward movement of loop C (Brams et al., 2011b; Nys et al., 
2013). Movement of loop C has been linked to gating by causing a rotation in the ECD that 
links to the TMD, though recent studies have called this into question (Purohit and 
Auerbach, 2013). Loop F has also been highlighted as important in gating and ligand 
recognition with structural rearrangements identified in this region upon ligand binding 
(Bourne et al., 2005; Celie et al., 2007; Hansen et al., 2005). It is possible that a 
combination of structural changes involving the various loops are important for gating to 
occur (Thompson et al., 2006). This view recently gained support when structures of GluCl 
in the apo and activated states were solved, showing a rigid body twist in the whole of the 
ECD during gating (Althoff et al., 2014).  
1.2.4 ECD-TMD interface 
The transition zone between the ECD and the TMD has several features that transmit 
structural changes from the ligand-binding site to the pore. The importance of this region 
was highlighted by the coupling of AChBP, which has no TMD, and the TMD of 5-HT3A. 
Upon ligand binding, no pore opening was observed with this chimera. Incorporating 
amino acid sequences from the 5-HT3A receptor ECD-TMD interface into the 
corresponding regions of AChBP resulted in a functional channel, gated with ligand 
binding (Bouzat et al., 2004).  
Further studies revealed which regions were responsible for coupling of ECD-TMD and 
were important in gating. Interaction of loops between β strands in the ECD (β1-2, β8-9 and 
the Cys-loop), the ECD-TMD linker and a loop in the TMD between the second and third 
helices (TM2-TM3), have all been linked to gating, Figure 1.3 (Bouzat et al., 2008).  
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Figure 1.3 The ECD-TMD interface. 
The loops from the ECD highlighted are implicated in the transmission of structural 
rearrangement in the ECD upon ligand binding to the TMD, resulting in channel gating. 
Structure shown is that of the GABAA β3 homomeric receptor (PDB code 4COF, Miller 
and Aricescu, 2014) 
 
The recent structure determination of the GABAA β3 receptor describes a number of polar 
and van der Waals interactions of the TM1-TM2 loop with the β1-2 loop and Cys-loop. A 
lysine residue, conserved between GABAA receptors and GlyRs, in the TM2-TM3 loop is 
well ordered in the structure (Miller and Aricescu 2014). This residue in HsGlyR (K304) 
has been linked to the disease hyperekplexia, with mutation of it causing slower gating 
(Lape et al., 2012). In the GABAA β3 structure this lysine reaches across to an adjacent 
subunit, possibly resulting in inter-subunit interaction that could facilitate gating. The 
possible interactions of K304 in GlyR and the implications in gating are discussed in 
Chapter 3.  
 Chapter 1 - Introduction 
11 
1.2.5 The transmembrane domain 
The transmembrane domain is composed of four helices per subunit, aligned perpendicular 
to the membrane (Noda et al., 1982; Unwin, 2005). The second helix (TM2) forms the pore 
lining, with each TM2 from the five subunits arranged symmetrically in a ring. An outer 
ring is formed of TM1, 3 and 4, shielding TM2 from the membrane, Figure 1.4 (Miyazawa 
et al., 2003).  
The GABAA β3 structure shown in Figure 1.4 is thought to be in the desensitised, closed 
conformation. The TM2 helices taper toward the intracellular side, with a constriction zone 
diameter of 3.15 Å near the end (Miller and Aricescu, 2014). Structures of the bacterial 
pLGIC, ELIC, from Dickeya dadantii, and the eukaryotic T. marmorata nAChR, thought to 
describe a closed resting state show TM2 helices in a vertical conformation with a number 
of bulky hydrophobic side chains blocking the channel (Hilf and Dutzler, 2008; Unwin, 
2005). The bacterial pLGIC from Gleobacter violaceus, known as GLIC, structure has been 
solved in what is thought to be an open state. Similarly to the GABAA β3 receptor, TM2 
helices were tilted with a diameter of 12 Å at the extracellular end, narrowing to 5 Å at the 
cytoplasmic end (Bocquet et al., 2009). This suggests that an open conformation is adopted 
by the tilting of TM2, separating the bulky hydrophobic residues and allowing ions to pass. 
Desensitization then occurs when the cytoplasmic end of the channel narrows effectively 
blocking the channel (Nyes et al., 2013).  
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Figure 1.4 The TMD of GABAA β3 in a desensitized state. 
TM2 helices of each subunit are highlighted in red, with the TM2-3 loop highlighted in 
yellow. TM2 forms an inner ring of pore lining helices. TM1, TM3 and TM4 form an outer 
ring in contact with the lipid membrane. An intra-subunit binding site is indicated by the 
blue circle and an inter-subunit binding site shown in green. The lipid bilayer interface of 
one subunit is marked in purple. 
 
 
Though the ECD and ILD play a role in the ion permeation pathway, the main determinant 
of ion selectivity is the TMD. Residues at the base of TM2 contribute to the selectivity 
filter, resulting in either cation or anion selective channels (Corringer et al., 1999). In 
cationic receptors this selectivity filter is a ring of negatively charged residues. Anionic 
selective receptors lack these charged residues, though a mechanism of selectivity 
involving a structural rearrangement at the intracellular end of TM2 could produce this 
effect. When gating occurs, a conserved proline at the position of the selectivity ring in 
cationic receptors is thought to cause a structural shift, resulting in a buried arginine at the 
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base of TM2 shifting and the guanidinium side chain becoming protonated, potentially 
conferring anionic selectivity (Cymes and Grosman, 2011).  
1.2.5.1 Allosteric binding sites in the TMD 
pLGIC function can be modulated by ligands binding at three allosteric sites within the 
TMD.  pLGIC function is known to be modulated by general anaesthetics (GA) such as 
propofol and desflurane (Hales and Lambert, 1991; Garcia et al., 2010). Structures of GLIC 
with propofol or desflurane reveal they bind in an intracellular cavity at the top of the TMD 
(Nury et al., 2011). This cavity, the intra-subunit binding site, lies in the center of the four 
α-helical bundle of each subunit and is accessible from the lipid bilayer. GLIC is inhibited 
by both these GAs in a similar way to that seen with nAChRs, therefore this cavity may be 
responsible for allosteric modulation in nAChRs (Weng et al., 2010; Nury et al., 2011; 
Violet et al., 1997). 
GlyR and GABAA receptors are potentiated by certain GAs and residues found to be 
important in this interaction have been linked to an inter-subunit binding site. Similarly to 
the intra-subunit cavity this is accessed from the lipid bilayer side of the receptor. This site 
is also thought to be where alcohols such as methanol and ethanol bind. A crystal structure 
of GLIC in the presence of ethanol reveals it binds in the inter-subunit site, making contact 
with polar residues on TM2 and stabilizing the open conformation of the receptor (Sauguet 
et al., 2013b). Similarly the anaesthetic, etomidate, has been shown to interact with a 
residue in the inter-subunit binding site. This drug is specifically modulates GABAA 
receptors containing β2 and β3 subunits, with no activity seen with the β1 isoform. An 
asparagine residue on TM2 of β2 and β3 has been shown to be important in etomidate 
sensitivity. The corresponding residue in β1 subunits is a serine (Ser 290), and mutagenesis 
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of the asparagine in β3 isoforms to a serine resulted in a loss of sensitivity to the drug 
(Belelli et al., 1997).  
Neurosteroids have also been shown to modulate pLGIC function by binding in the inter-
subunit binding pocket (Belelli and Lambert, 2005). This was shown to be the case by 
creating chimeric constructs of various GABAA receptors, wherein the TM1 and TM2 
sections of α1 subunits where replaced with the corresponding sequence from Drosophila 
melanogaster RDL receptor. The RDL receptor is insensitive to certain neurosteroids that 
are active against GABAA receptors. By showing the chimeric GABAA α1 containing 
receptors were not modulated by allopregnanolone and tetrahydro-deoxycorticosterone as 
seen with wild type receptors, it was shown that neurosteriods act on the TMD, at the inter-
subunit interface (Hosie et al, 2006).  
Ivermectin, a broad-spectrum antiparastic drug is known to allosterically modulate pLGICs 
and the structure of Caenorhabditis elegans GluCl shows the drug bound in the intersubunit 
cavity (Hibbs and Gouaux, 2011). In GluCl ivermectin interacts with a serine residue linked 
to alcohol binding in GlyR receptors (S295), resulting in the stabilization of the open 
channel state (Yévenes and Zeilhofer., 2011). 
1.2.6 The intracellular loop domain 
The ILD consists of between 70 and 150 amino acids situated between TM3 and TM4. 
Bacterial pLGICs do not have an extensive ILD, with a short linker loop of around six 
amino acids being present instead. Structurally little is known of this domain though low 
resolution studies of T. marmorata nAChRs suggest it forms a hanging basket type 
structure, with lateral portals that could be for ion exit/entry (Unwin, 1993; Hales et al., 
2006). A more refined structure of this nAChR revealed that this hanging basket structure 
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was formed by an α-helix, which is an extension of TM4 (Unwin, 2005). A recent crystal 
structure of a mouse 5-HT3A receptor shows this helix as extending uninterrupted into 
TM4. This structure is missing 62 amino acids from the mid-section of this domain 
(Hassaine et al., 2014). The missing region is attributed to protein interaction sites, 
assembly and ion trafficking in Cys-loop receptors. The portals are blocked by the 
polypeptide after TM3, though whether this represents a physiologically relevant form is 
unknown. The bottom of the ILD helices form a tight hydrophobic bundle suggesting ions 
do not exit the receptor in this region. Mutagenesis studies also correlate with ion exit/entry 
via the portals, and along with the mouse 5-HT3 receptor structure, suggests movement in 
this region may be needed for conductance (Carland et al., 2013, Hassaine et al., 2014). 
 
Figure 1.5 The intracellular loop domain. 
A. The intracellular loop domain of T. marmorata nAChR (PBD code 2BG9, Unwin, 2005). 
The TMD is in cyan, with the ILD in red. The portals thought to be the entrance/exit for 
ions can be seen between subunits. B. ILD of mouse 5-HT3A (PDB code 4PIR, Hassiane et 
al., 2014). The TMD is in blue, with ILD helix in red. The loop post TM3-loop is coloured 
in grey and is seen blocking the portals.  
 
This influence of the ILD on channel conductance was highlighted with studies on various 
5-HT3 receptors. The homopentameric 5-HT3A receptor has a channel conductance of ~1 
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pS, compared to ~16 pS for heteromeric 5-HT3A/B receptors. By mutating several arginine 
residues in the ILD helix of 5-HT3A, thought to form the portals, so that they corresponded 
to more polar or negatively charged residues seen in the 5-HT3B receptor, a marked 
increase in conductance was observed (Kelley et al., 2003;  Hales et al., 2006).  
Alongside conductance, the ILD has protein interaction sites and phosphorylation sites that 
may play a role in allosteric modulation (Yévenes and Zeilhofer, 2011). Deletion of this 
region also affects desensitization kinetics and therefore it represents an important region 
for the correct biological function of pLGICs (Baptista-Hon et al., 2013). Further structural 
information is required to gain a better understanding of this region. 
1.3 The glycine receptor 
GlyRs form an integral part of fast inhibitory neurotransmission in the spinal cord, 
brainstem and mediate a number of sensory functions such as audition and vision (Dutertre 
et al., 2012). Early knowledge of their role in disease came from the neurological disorder, 
hyperekplexia. This rare disease is characterized by an exaggerated response to tactile or 
acoustic stimuli, with temporary, complete muscle rigidity. This often results in injuries 
caused by an unprotected fall (Lynch, 2004). The symptoms are most obvious in infants 
and generally diminish during the first year of life. In rare cases, a sudden failure in 
respiratory function linked to the disease has resulted in infant death (Giacoia and Ryan, 
1994). Disruption of GlyR α1 surface expression or reduction of GlyR chloride 
conductance due to a variety of mutations has been shown to be responsible for this disease 
(Bakker et al., 2006). This results in an increase in excitability of motor neurons causing 
the symptoms mentioned above. Treatment generally consists of using benzodiazepines, 
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such as clonazepam (Zhou et al., 2002). This drug increases inhibitory responses by 
potentiating GABA receptors, dampening the symptoms (Schaefer et al., 2013). 
1.3.1 Subunit assembly 
Five different subunits have been identified, with four α and a single β subunit. α 1-3 are 
capable of forming functional homopentamers, with the gene encoding α4 being a 
pseudogene due to a premature stop codon (Simon et al., 2004). The β subunit on the other 
hand is incapable of forming functional homopentamers. There is a high sequence identity 
between α1-3 subunits at around 80% with the β subunit having an identity of around 45% 
with each of the α-subunits.  
Heteromers of α1 and β subunits are the most abundant GlyRs in the CNS of adults, with a 
stoichiometry of 2 α1 to 3 β subunits arranged in a β-α-β-α-β arrangement (Yang et al., 
2012). In contrast, α2 homomers are most common throughout the CNS early in 
development, but are replaced by α1β heteromers shortly after birth (Becker et al., 1988; 
Lynch, 2004). A number of sites retain α2 expression, most notably in the retina and 
auditory brain stem (Lynch, 2004). The α3 subunit is primarily expressed in the respiratory 
network of the brainstem and the superficial laminae of the dorsal horn. This subunit has 
been linked to the pain-sensing pathway, and could be a potential target for future 
analgesics (Lynch and Callister, 2006). 
Though the β-subunit does not form functional homopentamers, it has an important 
influence on ligand binding and is responsible for post-synaptic membrane clustering 
(Grudzinska et al., 2005; Dutertre et al., 2012). β-subunits have a larger molecular mass (58 
kDa) compared to α-subunits (around 45 kDa), due to an extended ILD. This domain binds 
the scaffold protein, gephyrin, with a high affinity (Meyer et al., 1995). Gephyrin is a 93 
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kDa cytoplasmic protein that interacts with a large number of binding partners, one of them 
being tubulin. Binding of β-subunits to gephyrin links the receptor with the 
submembranous cytoskeleton and anchors GlyR in the post-synaptic membrane (Kirsch and 
Betz, 1995).  
Alongside glycine, β-alanine and taurine are known agonists of GlyRs, with potency 
decreasing in that order, Figure 1.6 (Lewis et al., 2003). A well-characterized antagonist of 
GlyRs is the plant alkaloid, strychnine, a poison that causes convulsions and eventual death 
by asphyxiation. This compound acts as a competitive antagonist with a dissociation 
constant of 5-10 nM. No other compound is known to have as high an affinity for GlyR as 
strychnine. Due to its high affinity, strychnine is the most definitive means of 
differentiating glycinergic from GABAergic currents, and is used for radioligand studies 
into potency studies of various ligands (Lynch, 2004). Other compounds shown to be 
antagonists of GlyRs are picrotoxin and caffeine, Figure 1.6 (Lynch, 2004; Duan et al, 
2009).  
 
Figure 1.6 Agonists and antagonists of glycine receptors. 
 Chapter 1 - Introduction 
19 
A range of compounds have been found that cause allosteric modulation of GlyR These 
include alcohols, neurosteroids, cannabinoids, tropeines and certain general anaesthetics. 
Ethanol potentiates GlyR currents at concentrations consistent with moderate intake in 
humans. The changes in motor control and respiratory rhythms associated with ethanol 
intake have been linked to the drug increasing the amplitude of glycinergic postsynaptic 
currents (Eggers et al., 2004). Mutagenesis studies highlighted two residues that conferred 
ethanol sensitivity in GlyR α1, S295 in TM2 and A316 in TM3. These are present in the 
inter-subunit cavity (Mihic et al., 1997, Yévenes and Zeilhofer, 2011). Residues in the 
TM3-TM4 loop have also been identified as affecting ethanol sensitivity of GlyRs. This 
may be through intracellular signaling and interaction with other ethanol sensitive proteins 
(Jiang and Ye, 2003; San Martin et al., 2012). 
Volatile general anaesthetics such as isoflurane and halothane also potentiate GlyR currents 
by reducing the EC50 of glycine on the receptors. The location of glycinergic synapse 
suggests the loss of consciousness caused by these GAs is not due to GlyR potentiation, 
though they could be responsible for the loss of mobility observed (Yévenes and Zeilhofer, 
2011). Intravenous GAs may not have a major effect on GlyRs at clinically relevant 
concentrations, though propofol has been shown to have a modulatory effect on various 
GlyR subunits (Hales and Lambert, 1991; Pistis et al., 1997).  
Cannabinoids have been shown to potentiate GlyR currents and several studies have shown 
that residues integral to ethanol sensitivity (S295 and A316) are also implicated in 
cannabinoid interaction (Hejazi et al., 2006). Interestingly, cannabinoids may exert an 
analgesic effect through their interaction with GlyR α3 receptors. A study has shown that 
mice without the GlyR α3 showed a large reduction in analgesia from the cannabinoid, Δ9-
THC (Xiong et al., 2011). 
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1.4 The glycine receptor as a therapeutic target 
GlyRs have the potential to be an attractive drug target for a number of physiological 
pathologies and diseases. A role in motor control and sensory perception has long been 
established and recent studies are highlighting contributions to other processes. For 
example the role of high affinity GlyRs have been linked to temporal lobe epilepsy. These 
high affinity GlyRs are formed due to RNA editing, producing α2 and α3 GlyRs with a 
point mutation, changing a proline (P192 in α2 and P185 in α3) to an isoleucine. This 
allows for the activation of GlyR in the presence of ambient glycine concentrations in the 
forebrain (Eichler et al., 2008). Potential inhibitors of high affinity GlyRs may therefore be 
useful in the treatment of this form of epilepsy.  
GlyR α3 receptors are primarily expressed in the superficial laminae of the dorsal horn 
where nociceptive afferent nerves terminate. α3 containing receptors are involved in 
inflammatory and neuropathic pain sensitization (Harvey et al., 2004; Xiong et al., 2012). 
In inflammation, prostaglandin E2 (PGE2) inhibits glycinergic neurotransmission through a 
protein kinase A-dependent phosphorylation. This occurs when PGE2 acts on prostaglandin 
E2 receptors, which in turn triggers an associated G-protein to increase cAMP production, 
activating the protein kinase. Direct phosphorylation of GlyRs has been implicated though 
phosphorylation of an intermediate effector may also cause the inhibition of GlyRs 
(Ahmadi et al., 2002). The α1 subunits do not contain a protein kinase A-dependent 
phosphorylation site whereas α3 does. This suggests that drugs that modulate GlyR α3 
specifically may provide a treatment for pathological pain.  
As previously stated cannabinoids have been linked with α3 potentiation and possible use 
in the treatment of neuropathic pain. The central role of α3 was revealed when knockout 
mice without two cannabinoid receptors (CB1 ad CB2) presented no decrease in the 
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analgesic effect of cannabinoids whereas mice lacking α3 receptors showed a marked 
reduction in this analgesia (Xiong et al., 2012).   
As α3 subunits are mainly expressed in the dorsal horn they make excellent drug targets as 
off target effects may be limited. If drugs that specifically modulate α3 containing receptors 
can be found, then analgesics could be discovered that do not have an effect on motor 
control associated with α1 subunit potentiation.  
1.4.1 Drug discovery for GlyR targets 
Focus on GlyRs as therapeutic targets has been limited by the lack of pharmaceutical 
compounds that specifically modulate GlyRs in a clinically relevant way. With more 
information being discovered of the role GlyRs play in sensory function, the more interest 
is being generated in finding modulators that could be used for analgesia and anaesthetics. 
One limitation of drug discovery with these targets is the lack of high throughput assay for 
screening large libraries of compounds.  
Traditionally, electrophysiology has been used to characterize the effects of ligands on ion 
channels. This technique has the advantage of giving rich biophysical information and real 
time data acquisition, but is labour intensive and requires highly skilled operators. In the 
past this technique did not have the capacity for screening large numbers of compounds 
quickly. Recent developments in automated, high throughput electrophysiology may allow 
for compound screening on a larger scale, though this requires expensive, specialized 
equipment (Dunlop, 2009; Clare, 2010).  
As a means of high throughput screening (HTS) of these targets, several technologies were 
developed utilising the membrane potential, Ca2+ and anion sensitive dyes or by measuring 
ion flux. These technologies have the advantages of measuring the effects of compounds on 
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the receptor in a cellular environment but still have a number of drawbacks. Ion flux 
measurements require the use of radioactive tracer molecules or ions that are inconvenient 
in HTS and fluorescent dyes have high variability in signal (Wolff et al., 2003). These 
techniques also remain relatively low throughput compared to techniques such as optical 
biosensor based systems.  
The use of label-free optical detection technologies such as surface plasmon resonance 
(SPR) and biolayer interferometry (BLI) is becoming increasing common in the 
identification of new compounds for drug discovery (Myszka DG and Rich RL, 2000; 
Wartchow et al., 2011). These techniques use protein immobilized on sensor chips or 
biosensor fibres to measure biomolecular interactions. The advantage of label-free optical 
detection is the rate at which compounds can be screened. They can also be used to perform 
a range of kinetic studies of protein-ligand interactions, with data collection in real time 
allowing for association and dissociation rates to be measured (Geschwinder et al., 2012). 
A disadvantage with these technologies is the reliance on a supply of purified, recombinant 
proteins. Especially with membrane proteins, where stability can be an issue, and where the 
state of the protein may not represent the active, native form. Despite this the technique has 
successfully been used in determining ligands for a range of proteins, including membrane 
proteins such as G protein-coupled receptors (GPCRs, Navratilova et al., 2011).  
These technologies have the potential to be an integral part in a high throughput drug 
discovery pipeline. Initial compounds of interest can be detected from large compound 
libraries using techniques like BLI, with promising leads tested for efficacy using patch-
clamp electrophysiology.  
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1.4.2 The theory of biolayer interferometry  
BLI is a recently developed optical analytical technique that can be used for measuring 
biomolecular interactions. The technology employs glass fibre biosensors to which the 
target protein can be immobilized, Figure 1.7 A. These fibres are then used in a dip and 
read assay format, screening compounds in 96 or 384 well format. White light is sent down 
the glass fibre and is then reflected back into the instrument from two surfaces. The first is 
an optical layer at the interface between the glass fibre and the bio-compatible surface. The 
second is the interface between the immobilized protein biolayer and the solution. The 
reflected light from the two surfaces creates a distinctive pattern due to constructive and 
destructive interference, Figure 1.7 B. When the sensor is introduced to a solution 
containing a ligand, binding of the ligand to the protein results in an increase in the optical 
thickness of the interface between the bio-compatible surface and the solution. This change 
in path length results in a change in the interference pattern of the reflected light, which can 
be compared to the reference interference pattern measured without the presence of the 
ligand, Figure 1.7 C and D. By measuring the change in interference pattern in real time, 
kinetic data on association and dissociation can be inferred (Dayne, 2012; Wartchow et al., 
2011).  
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Figure 1.7 An overview of biolayer interferometry. 
A. An optical biosensor consisting of the optical layer and the bio-layer consisting of the 
biocompatible matrix and immobilised protein. B. In a reference well containing buffer, 
white light is reflected from the reference optical layer and the bio-layer, creating 
interference patterns. C. When the biosensor is moved to a solution containing a ligand, 
binding of ligand in the bio-layer causes a shift in the interference pattern. D. By comparing 
the reference interference pattern with the one produced in the presence of ligand, binding 
events can be observed. Images obtained from www.fortebio.com. 
 
An advantage of using BLI is that it requires only a small quantity of protein, and screens 
can be completed in a relatively short amount of time. Comparison of binding curves and 
kinetic constants can also be used to differentiate between non-specific or non-ideal 
interactions and ideal responses. This is advantageous in reducing the number of false 
positives observed (Abdiche et al., 2008). Studies have shown that BLI results are 
comparable with SPR, with a high level of agreement seen when screening compounds for 
a kinase and a protein-protein interaction target (Wartchow et al., 2011). BLI has many 
advantages over SPR including the cost of instrumentation and biosensors. At the time of 
writing, a tray of 96 super streptavidin sensors for the octet red system (FortéBio) cost 
around £1000 (~ £10.50 per sensor). The price for three streptavidin sensor chips for SPR 
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2.7.5 Bio-layer interferometry (BLI) 
Bio-layer interferometry (BLI) is a label free optical analytical technique used to 
analyse biomolecular interactions. This technique monitors in real time the interference 
pattern of white light reflected from two surfaces within a biosensor (Wartchow et al., 
2011). The first surface is an internal reference layer, while the second surface is a layer 
of immobilised protein (Figure 2.4A). As the immobilised protein on the biosensor tip 
binds to the analyte in solution (Figure 2.4B), an increase in optical density occurs 
resulting in a shift in wavelengths (Figure 2.4C).  
 BLI was used to screen biotinylated PaIMPDH and BpPBP3 against the DDU 
fragment library, using streptavidin biosensors to immobilise protein at 25 µg mL-1 for 
10 mins. Biocytin at 10 µg mL-1 was then used to block any remaining free streptavidin 
binding sites for 60 sec prior to washing and equilibrating the biosensors in buffer for 5 
mins. The fragments were screened at a final concentration of 200 µM in 384-well 
format using an Octet Red system (Fortebio) in 16-channel mode. The temperature of 
the chamber was set to 25 °C. 
 
 
 
Figure 2.4 Bio-layer interferometry 
(BLI). 
Light is applied down a biosensor and an 
internal reference (A) is used to compare 
the wavelength of the light generated upon 
the binding of the analyte (B). This binding 
results in a shift in wavelengths (C) from 
the change in optical density at the 
biosensor surface. Figures obtained from 
www.fortebio.com.  
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(Biacore, GE Healthcare) the cost is around £550 (~ £185 per sensor). SPR also uses 
complex microfluidics to deliver compounds to the sensors for recording binding data 
(Myszka DG and Rich RL, 2000). BLI on the other hand uses 96 or 384 well plates, with 
sensors moved to the wells. This also has the advantage of allowing for up to 16 sensors 
being used in parallel, increasing the rate at which a screen can be conducted (Abdiche et 
al., 2008). Simplicity of the instrumentation should also limit the maintenance costs and 
downtime of the Octet system compared to SPR.  
The fact that only small quantities of protein are needed also makes BLI a potentially useful 
tool in screening of pLGICs. Used in conjunction with electrophysiology to validate 
potential leads, this technique could aid in the discovery of compounds that modulate 
receptor function.  
1.5 Objectives 
Recent insights into the role of GlyRs in many physiological pathways have emphasized 
their importance as potential targets for novel drugs (Lynch and Callister, 2006; Yévenes 
and Zeilhofer, 2011). Despite this evidence, early stage drug discovery has been hindered 
by the lack of specific GlyR modulators, a suitable method for high throughput screening or 
high resolution structural data.  
The initial aim of this study was to gain recombinant protein that could be used in structural 
and ligand binding studies. The main target was human GlyR, though several homologues 
and surrogates were also investigated. Homology modeling was also employed to gain 
insights into residues of importance and to aid in construct design. 
With a source of recombinant protein, crystallographic studies could then be conducted. 
The successful reporting of a structure of a pLGIC or surrogate would potentially inform on 
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overall morphology of the receptor, gating mechanisms and give insights into ligand 
recognition.  
Another aim was the development of BLI as a means to screen compound libraries against 
pLGICs. Validation of compounds found to bind to the receptors using this technique, 
could then be validated using electrophysiological studies. The use of BLI may lead to a 
method for HTS, allowing for the discovery of novel chemical modulators of pLGIC 
function.  Along with structural insights, this information could be used for future structure-
based drug design (Anderson, 2003). 
 
 Chapter 2 – Materials and methods 
27 
2 Materials and methods 
2.1 General materials 
2.1.1 Reagents  
Reagents and chemicals were of analytical grade and procured from Sigma-Aldrich, VWR 
and Merck. Restriction endonucleases and associated buffers were purchased from New 
England Biosciences (NEB). Polymerase enzymes for PCR were purchased from Promega 
and Agilent. TOPO blunt and Strataclone cloning vector kits were purchased from 
Invitrogen and Agilent respectively. A histidine tagged tobacco-etch virus (TEV) protease 
was made in-house and aliquoted at 3 mg ml-1.  
Mini Protean TGX stain free gels, Precision Plus Protein Unstained and All Blue standards 
as well as 10x tris-glycine-SDS buffer from Bio-Rad were used for protein analysis by 
SDS-PAGE. NativePAGE Novex 4-16% Bis-Tris gels from Invitrogen were used for native 
gel analysis. Trans-blot Turbo polyvinylidene fluoride (PVDF) transfer packs by Bio-Rad, 
Pierce enhanced chemical luminescence (ECL) western blot substrate from Thermo-
scientific and Lumi-Film Chemiluminescent Detection film from Roche were used for 
western blot.  
2.1.2 Bacteria 
All competent cells, with the exception of Overexpress C43(DE3) cells (Avidis) and 
Rosetta-gami 2 (DE3) (EMD Millipore), were purchased from Agilent. Growth media was 
produced and provided by the media kitchen in the College of Life Sciences, University of 
Dundee. 
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2.1.3 Pichia pastoris 
Four strains of Pichia pastoris, a protease wild type and three protease knock out strains, 
were provided in the PichiaPink expression system kit (Life Technologies). Expression 
vectors were also supplied in this kit. Growth media was again produced and provided by 
the media kitchen, College of Life Sciences, University of Dundee. 
2.1.4 Baculovirus 
All materials and vectors were used following the supplier’s protocol (Life Technologies). 
LB agar plates containing 50 µg ml-1 kanamycin, 7 µg ml-1 gentamicin, 10 µg ml-1 
tetracycline, 100 µg ml-1 Bluo-gal, and 40 µg ml-1 IPTG, were supplied by the media 
kitchen. 
2.1.5 Screening 
The ion channel library set of compounds (Mok and Brenk 2011) were provided by the 
Drug Discovery Unit, College of Life Sciences, The University of Dundee. Compounds 
DDD00106009, DDD00105795 and the analog of DDD00104826, N-(4-methylphenyl)-1-
[(3-methylphenyl)methyl]-3,6-dihydro-2H-pyridine-4-carboxamide, were purchased from 
Molport. Screening plates in 96 and 384 well format were purchased from Greiner. Octet 
sensors were purchased from Forté-Bio. 
2.2 General methods 
2.2.1 Sequence analysis and homology modelling 
Gene and protein sequences were taken from the National Center for Biotechnology (NCBI 
www.ncbi.nlm.nih.gov/), UniProt (www.uniprot.org/) and Pfam (http://pfam.xfam.org/) 
databases. Signal sequences were determined using SignalP (Peterson et al., 2011). 
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Molecular weights, theoretical isoelectric points and extinction coefficients were calculated 
using ProtParam (Gasteiger et al., 2005). Sequence alignments were made using ClustalW 
(Larkin et al., 2007). Alignment figures were produced using ALINE (Bond and 
Schüttelkopf, 2009). Phyre2 (Kelly and Sternberg, 2009) was used to produce homology 
models. 
2.2.2 Cloning 
Various constructs were created by subcloning from cDNA (Source BioScience), or 
synthetic genes (Genscript) using Pfu DNA polymerase. A typical protocol with 
heating/cooling cycles used is given in Table 2.1 
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Table 2.1 Typical subcloning PCR protocol. 
Reaction Mix 
Order of addition Reagent Quantity 
1 Sterile MilliQ water For final volume 50 µL 
2 Pfu buffer x10 5 µL 
3 Deoxynucleotide triphosphates 
(dNTPs) 2 mM 
5 µL 
4 Dimethyl sulfoxide (DMSO)100% 2.5 µL 
5 Primers 10 pmol µL-1 2.5 µL (forward and reverse) 
6 Pfu polymerase 1 unit µL-1 1 µL 
7 Template DNA 200 ng 
PCR thermal cycles 
Step Temperature (°C) Time (sec) Number of Cycles 
Initial Denaturation 95 120 1  
Denaturation 95 30   
Annealing 50-65 45  36  
Extension 72 60 sec per kbase  
Final extension 72 600 1  
 
2.2.2.1 Preparation of chimeric constructs 
Chimeric constructs, those with fusions of partners from different subunits or proteins, 
were created using a technique detailed in Lynch and Shan 2010. Briefly, several primers 
were designed including some that overlap a junction in the chimera. Using multiple 
templates and sequential PCRs a chimeric construct could be created without the need for 
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addition of restriction sites. An outline of this process is shown in Figure 2.1. This 
procedure was used to create such constructs as HsGlyR ECD–T4 lysozyme chimera, 
Figure 2.1 (A), and HsGlyR α1 with the β subunit intracellular loop, Figure 2.1 (B).  
 
Figure 2.1 Overview of multiple 
template based sequential PCR for 
chimeric construct creation. 
The parent genes of each example in A 
and B are in white and grey, with the 
resultant gene shown to the right. P1 P2 
and P3 are primers. 
(A) PCR of a chimera where a segment 
from each parental sequence is at the N or 
C-terminus, such as HsGlyR ECD–T4 
lysozyme. (B) Chimeras that have a 
section of one sequence in the middle of 
different sequence require an extra step 
and two junctioned primers. The parent 
gene that encodes the N and C-terminus 
must be in two different plasmids to avoid 
cloning of just the parent sequence. 
HsGlyR α1 with the β subunit intracellular 
loop was created in this way. 
 
 
 
 
 
The primers used to create the gene that encodes for the HsGlyR ECD–T4 lysozyme 
chimera are as follows. P1: GGATCCATGTACAGCTTCAATACTCTTCG, which anneals 
to the 3’ end of the HsGlyR gene.   
P2: CGCAGCATTTCGAAGATGTTCTGCCGCTCCAGGTGGAACC, the sequence in 
bold anneals to the 5’ end of the oligonucleotide encoding the HsGlyR ECD and the other 
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Fig. 1. Schematic illustration of chimera construction protocols. Unfilled and grey bars represent different parental cDNA . Solid, dashed and dotted lines represent sequences
from pUC19, pGEMHE and pcDNA3.1zeo+ vectors, respectively. P1, P2, P3 and P4 represent primers. Panels A, B and C illustrate different protocols as shown diagrammatically
in the top row of each panel.
segment to be taken from each parental protein occupies either its
N- or C-terminal, in which case one junction is required (Fig. 1A
and B). The other is that the segment from one parental protein is
placed in themiddle of another parental protein, inwhich case two
junctions are required (Fig. 1C).
To construct a chimera with one junction, three primers, P1,
P2 and P3, are required (Fig. 1A and B). P1 and P3 are the primers
used to anneal to the 5′ and 3′ ends, respectively, of the resultant
chimeric cDNA. P2 is a 35–45 base long primer overlapping the
junction of two parental cDNAs. This primer is a merge of two
simple primers, either of which can anneal to one side of the
cDNAs flanking the resultant chimeric junction (see examples in
Table S1, Supplementary material). As described next, only that
part corresponding to the simple primer anneals to the template
in any PCR, therefore both simple primers should be designed
following the general primer-designing rules such as appropriate
melting temperature, G/C at the 3′ end, etc. As shown in Fig. 1A and
B, P1 and P2 are used first to amplify the N-terminal cDNA (PCR1),
the product of which contains the sequences flanking the desired
chimeric junction. Theplus strandof thePCR1product thenacts as a
mega-primer in the second PCR (PCR2), in which this mega-primer
together with P3 is used to amplify the C-terminal cDNA. Since the
mega-primer has a much lower concentration than optimal, P1 is
also added to achieve enough yield. An issue to consider is that if
both P1 and P3 in PCR2 could anneal to the same parental cDNA,
one or both of the parental cDNAs would be amplified. This would
cause the PCR2 product to be contaminated with parental cDNAs.
To avoid this possibility, P1 and P3 can be designed to anneal to
the very beginning and the very end, respectively, of the parental
cDNAs (Fig. 1A). In such a case, no cross-reaction could occur as
long as the cDNA sequence homology of the N- and C- terminals
between the two parental cDNAs is not high. If the homology is
high, P1 or P3, or both, would have to be designed to anneal to
the vector sequence flanking the parental cDNAs (Fig. 1B). In this
case, P1 and P3 would usually be the 5′ and 3′ sequencing primers,
respectively. In order to avoid cross-template reaction, the two
parental cDNAsmustbe constructed indifferent vectors, otherwise,
P1 and P3 in PCR2 would amplify the full-length parental cDNAs,
either present in PCR2 or transmitted from PCR1. This would cause
the PCR2 product to be composed mainly of both parental cDNAs.
Single-junction chimeras are needed only when studying either
the N- or C-terminal domains of a protein (Fig. 1A and B), how-
ever, more often, a domain in the middle of a protein needs to be
investigated. In such a case, this domain is usually placed into the
middle of another protein and two junctions are required to create
the chimera (Fig. 1C). This can be achieved by using the protocol for
introducing one junction, described above, except that it is done in
two steps, i.e. one junction is introduced each step. However, this
is time-consuming. Here we have developed a more efficient pro-
tocol for introducing two junctions by using three-template-based
sequential PCRs. As shown in Fig. 1C, similar to the case of introduc-
ing a single-junction, the first PCR (PCR1) uses the 5′ primer P1 and
the junction primer P2 to amplify the N-t rminal of the host cDNA.
The P2 overlaps the first junction and therefore the PCR1 product
can be used as a mega-primer for the second PCR (PCR2). In PCR2,
this mega-primer and another junction primer (P3) are used to
amplify the insert cDNA, the product of which is maximized by the
addition of the P1. Again, since P3 contains the sequence overlap-
ping the second junction, the PCR2 product can be used as a mega-
primer in the next PCR (PCR3). In PCR3, through the same mecha-
nism as in PCR2, P1, the PCR2 product and the 3′ primer P4 are used
to amplify the C-terminal of host cDNA,which produces the desired
chimeric cDNA. The 5′ and 3′ primers, unlike in the case of intro-
ducing one junction,must anneal to the vector rather than theN- or
C-terminal cDNA sequences, otherwise, in PCR3, P1 and P4 would
anneal to the host cDNA directly and eventually contaminate the
PCR3 product. Therefore, to avoid cross-template reaction, the host
cDNA needs to be subcloned into two different plasmid vectors and
the insert cDNA needs to be constructed into a third one (Fig. 1C).
3. Results
Examples of the construction of chimeras with one and two
junctions will now be described. First, by using 5′KpnI/3′EcoRI, the
A) 
B) 
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segment to be taken from each parental protein occupies either its
N- or C-terminal, in which case one junction is required (Fig. 1A
and B). The other is that the segment from one parental protein is
placed in themiddle of another parental protein, inwhich case two
junctions are required (Fig. 1C).
To construct a chimera with one junction, three primers, P1,
P2 and P3, are required (Fig. 1A and B). P1 and P3 are the primers
used to anneal to the 5′ and 3′ ends, respectively, of the resultant
chimeric cDNA. P2 is a 35–45 base long primer overlapping the
junction of two parental cDNAs. This primer is a merge of two
simple primers, either of which can anneal to one side of the
cDNAs flanking the resultant chimeric junction (see examples in
Table S1, Supplementary material). As described next, only that
part corresponding to the simple primer anneals to the template
in any PCR, therefore both simple primers should be designed
following the general primer-designing rules such as appropriate
melting temperature, G/C at the 3′ end, etc. As shown in Fig. 1A and
B, P1 and P2 are used first to amplify the N-terminal cDNA (PCR1),
the product of which contains the sequences flanking the desired
chimeric junction. Theplus strandof thePCR1product thenacts as a
mega-primer in the second PCR (PCR2), in which this mega-primer
together with P3 is used to amplify the C-terminal cDNA. Since the
mega-primer has a much lower concentration than optimal, P1 is
also added to achieve enough yield. An issue to consider is that if
both P1 and P3 in PCR2 could anneal to the same parental cDNA,
one or both of the parental cDNAs would be amplified. This would
cause the PCR2 product to be contaminated with parental cDNAs.
To avoid this possibility, P1 and P3 can be designed to anneal to
the very beginning and the very end, respectively, of the parental
cDNAs (Fig. 1A). In such a case, no cross-reaction could occur as
long as the cDNA sequence homology of the N- and C- terminals
between the two parental cDNAs is not high. If the homology is
high, P1 or P3, or both, would have to be designed to anneal to
the vector sequence flanking the parental cDNAs (Fig. 1B). In this
case, P1 and P3 would usually be the 5′ and 3′ sequencing primers,
respectively. In order to avoid cross-template reaction, the two
parental cDNAsmustbe constructed indifferent vectors, otherwise,
P1 and P3 in PCR2 would amplify the full-length parental cDNAs,
either present in PCR2 or transmitted from PCR1. This would cause
the PCR2 product to be composed mainly of both parental cDNAs.
Single-junction chimeras are needed only when studying either
the N- or C-terminal domains of a protein (Fig. 1A and B), how-
ever, more often, a domain in the middle of a protein needs to be
i v stigated. In such a case, this domain is usually placed into the
middle of another protein and two junctions are required to create
the chimera (Fig. 1C). This can be achieved by using the protocol for
introducing one junction, described above, except that it is done in
two steps, i.e. one junction is introduced each step. However, this
is time-consuming. Here we have developed a more efficient pro-
tocol for introducing two junctions by using three-template-based
sequential PCRs. As shown in Fig. 1C, similar to the case of introduc-
ing a single-junction, the first PCR (PCR1) uses the 5′ primer P1 and
the junction primer P2 to amplify the N-terminal of the host cDNA.
The P2 overlaps the first junction and therefore the PCR1 product
can be used as a mega-primer for the second PCR (PCR2). In PCR2,
this mega-primer and another junction primer (P3) are used to
amplify the insert cDNA, the product of which is maximized by the
addition of the P1. Again, since P3 contains the sequence overlap-
ping the second junction, the PCR2 product can be used as a mega-
primer in the next PCR (PCR3). In PCR3, through the same mecha-
nism as in PCR2, P1, the PCR2 product and the 3′ primer P4 are used
to amplify the C-terminal of host cDNA,which produces the desired
chimeric cDNA. The 5′ and 3′ primers, unlike in the case of intro-
ducing one junction,must anneal to the vector rather than theN- or
C-terminal cDNA sequences, otherwise, in PCR3, P1 and P4 would
anneal to the host cDNA directly and eventually contaminate the
PCR3 product. Therefore, to avoid cross-template reaction, the host
cDNA needs to be subcloned into two different plasmid vectors and
the insert cDNA needs to be constructed into a third one (Fig. 1C).
3. Results
Examples of the construction of chimeras with one and two
junctions will now be described. First, by using 5′KpnI/3′EcoRI, the
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half to the 3’ terminus of the T4 lysozyme gene. P3: 
GCTAGCCTTGTAGGCGTCCCAGGTTCC, anneals to the 5’ terminus of the T4 
lysozyme gene. 
2.2.2.2 Site directed mutagenesis 
Mutants such as the AChBP with five mutations (AChBP-B) were created by site directed 
mutagenesis. Primers were designed using the QuickChange primer design tool 
(www.genomics.agilent.com/primerDesignProgram.jsp). PCR was conducted using Pfu 
Turbo and reaction mix set up as in Table 2.1, with the exception that three quantities of 
template DNA were used, 5 ng, 25 ng and 50 ng. Extension temperature was set to 68°C, 
and the number of cycles for denaturation, annealing and extension was 16. 
2.2.2.3 Cloning and expression vectors 
PCR products were ligated into StrataClone Blunt PCR cloning vectors and subsequently 
digested using appropriate restriction enzymes. Digested genes were then ligated into the 
applicable expression or transfer vector using the Clonables ligation kit (MerckMillipore). 
Plasmid preparation was conducted using QIAprep Spin Miniprep kit (Qiagen) as per 
manufacturer’s protocol.  
The integrity of all cloning products was confirmed by sequencing carried out by the DNA 
Sequencing Unit, University of Dundee.   
Table 2.2 lists the various constructs created, the expression vectors and systems used. The 
outcome of expression, whether it expressed, if it was soluble or formed inclusion bodies or 
if purification was completed is also noted. The numbering of the amino acids relates to the 
full sequence from the Uniprot code or the Pfam code for Dr5-HT3A. These are given at 
the bottom of Table 2.2.  
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Table 2.2 Constructs created, expression system used and outcome of test expression. 
General pLGIC architecture. 
 
E. coli 
Construct Amino acids Vectors Outcome Cell lines 
HsGlyR ECD 29-242 
pET15b-
pET23a 
pET15b-pelB 
Insoluble 
Refolding 
unsuccessful 
C43, Arctic 
express, 
Rosetta-gami 
HsGlyR Full 
length 29-457 pET15b-pelB Insoluble Rosetta-gami 
DrGlyR ECD 23-249 pET15b-pET23a 
Insoluble 
Refolding 
unsuccessful 
C43, Arctic 
express 
CiGlyR ECD 24-287 
pET23a, 
pET15b-pelB 
Insoluble C43, Rosetta-gami 
ELIC 22-343 pET15b-pelB-MBP Purified C43 
ELIC BAP-tag 
22-311 
(GLNDIFEAQKIEWHE) 
312-343 
pET15b-pelB-
MBP Purified C43 
FLIC 23-351 
pET15b-pelB, 
pET15b-pelB-
MBP 
Aggregation  C43 
GephE 320-736 pET15b-MBP Purified BL21 (DE3) 
ELIC ECD 
HsGlyR TM 
22-220-(247-338 VESQPA 
419-457) 
pET15b-pelB-
MBP No expression C43 
ELIC HsGlyR β 
loop 22-311 (355-478) 312-343 
pET15b-pelB-
MBP No expression C43 
ELIC short      
5-HT3A 
intracellular 
loop 
22-311 (337-374 411-446) 
314-343 
pET15b-pelB-
MBP 
Low 
expression 
level 
C43, RIL 
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Baculovirus 
Construct Amino acids Vectors Outcome Cell lines 
DrGlyR full 
length 23-444 pFastBac HTb Insoluble Sf9 
DrGlyR ECD 23-249 pFastBac HTb No expression Sf9 
CiGlyR ECD 24-287 pFastBac HTb No expression Sf9 
CiGlyR full 
length 24-471 pFastBac HTb No expression Sf9 
HsGlyR ECD-
T4 lysozyme 29-242 (1-161) pFastBac HTb Aggregation  Sf9 
CiGlyR ECD-
T4 lysozyme 24-287 (1-161) pFastBac HTb Aggregation Sf9 
HsGlyR Con4 31-338(VESQPA) 418-449 pFastBac HTb Purified Sf9 
HsGlyR T4 
lysozyme 
intracellular 
loop  
1-342 (2-161) 407-449 pFastBac HTb No expression Sf9 
HsGlyR α1 – β 
intracellular 
loop 
1-332 (351-469) 412-449 pFastBac HTb No expression Sf9 
CiGlyR 
HsGlyR β 
intracellular 
loop 
24-377 (351-469) 444-474 pFastBac HTb No expression Sf9 
AcAChBP WT 1-236 pFastBac HTb Purified Sf9 
AcAChBP-A 1-236 (T53F, Y110A, I135S, W164F) pFastBac HTb Purified Sf9 
AcAChBP-B 1-236 (T53F, Q74R Y110A, I135S, W164F) pFastBac HTb Purified Sf9 
AcAChBP-C 
1-236 (T53F, Y72F, Q74R 
Y110A, I135S, W164F, C207T, 
C208G, Y212F) 
pFastBac HTb Purified Sf9 
AcAChBP-D 1-236 (T53F, Q74R Y110A, I135-S, G162E) pFastBac HTb Purified Sf9 
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Pichia pastoris 
Construct Amino acids Vectors Outcome Cell lines 
DrGlyR full 
length 23-444 
pPinkα-HC, 
pPIC9 No expression 
PichiaPink 1-
4, GS115, 
KM75 
CiGlyR full 
length 24-471 pPinkα-HC No expression 
PichiaPink 1-
4 
HsGlyR Con4 31-338(VESQPA) 418-449 pPinkα-HC, pPIC9 Purified 
PichiaPink 1-
4, GS115, 
KM75 
CiGlyR Con4 24-377(VESQPA) 444-474 pPinkα-HC, pPIC9 No expression 
PichiaPink 1-
4, GS115, 
KM75 
CiGlyR  T4 
lysozyme 
intracellular loop 
24-377 (2-161) 444-474 pPinkα-HC No expression PichiaPink 1-4 
HsGlyR T4 
lysozyme 
intracellular loop  
29-342 (2-161) 407-449 pPinkα-HC No expression PichiaPink 1-4 
HsGlyR α1 – β 
intracellular loop 1-332 (351-469) 412-449 pPinkα-HC No expression 
PichiaPink 1-
4 
ELIC ECD 
HsGlyR TM 
22-220-(247-338 VESQPA 
419-457) pPinkα-HC No expression 
PichiaPink 1-
4 
Hs – Homo sapiens, Dr – Danio rerio (zebrafish), Ci – Ciona intestinalis (sea squirt), BAP – biotin acceptor 
peptide, MBP- maltose binding protein, T4 – Bacteriophage T4. 
 
Gene Code Gene Code 
HsGlyR α1 P23415 HsGlyR β P48167 
DrGlyR α1 O93430 CiGlyR α1 D2KU21 
Dickeya dadantii 
pLGIC, ELIC 
E0SJQ4 Francisella tularensis 
pLGIC, FLIC 
Q14GQ1 
Hs5-HT3A P46098 Dr5-HT3A XP_700338.3 
T4 lysozyme P00720 (C54-T, C97A) HsGephyrin Q9NQX3 
AcAChBP Q8WSF8   
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T4-lysozyme was mutated with site directed mutagenesis to disrupt a disulphide bond. Two 
cysteines, C54 and C97 were mutated to threonine and alanine respectively. This was 
performed in order to make the lysozyme have the same sequence as that previously used to 
crystallise GPCRs (Haga et al., 2012, Kruse et al., 2012). 
2.2.3 Aminostrychnine-agarose preparation 
The aminostrychnine-agarose resin was prepared for use in affinity purification of GlyRs, 
following the protocol set out by Laube and Betz (1999). To prepare 20 ml of Affi-Gel 15 
(Bio-Rad) for coupling, 60 ml of dimethylformamide was washed over the resin. 500 mg of 
2-aminostrychnine (Manchester Organics) was added along with 20 ml of 
dimethylformamide, and the mixture incubated at 4°C for 2 days with gentle agitation. 
After the 2 days, 200 ml of ethanolamine was added to the mixture and left to incubate at 
4°C for 2 hours. This step blocked any excess sites that had not been coupled to the 
aminostrychnine. The resin was then washed with 40 ml dimethylformamide followed by 
150 ml 50 mM potassium phosphate buffer pH 7.4 0.02% sodium azide. The resin was then 
transferred to a column washed with a further 50 ml of buffer and stored in the absence of 
light until needed. 
2.2.4 Recombinant expression 
2.2.4.1 Preparation and use of E. coli expression systems  
Competent cells were transformed by heat shock, wherein 10-50 ng of the gene of interest 
in an expression vector was added to the E. coli, left to incubate on ice for 30 min, heat 
shocked at 42°C for 45 sec then left on ice for 5 min. 250 µL super optimal broth with 
catabolic repression (SOC) media was then added and the culture incubated with shaking 
 Chapter 2 – Materials and methods 
37 
for an hour. Cells were then spread onto agarose plates containing the required antibiotic. 
Plates were kept at 37°C overnight to allow colonies to grow.  
A single colony was picked and added to ten ml LB media supplemented with the selected 
antibiotic. This starter culture was grown for between 6 and 18 hours at 37°C with shaking. 
The starter culture was then used to inoculate 1 L LB media that had been supplemented 
with a suitable antibiotic.  Cells were left to grow at 37°C until the cells had reached their 
growth log phase, which was monitored by measuring the OD600 of the culture. Once an 
OD600 of between 0.6-1 was reached, the temperature was dropped to 20°C and gene 
expression initiated with addition of 1 mM IPTG. Cells were left to grow overnight at 20°C. 
Arctic express starter cultures were set up as above, with the addition of 20 µg ml-1 
gentamycin to the media. This starter culture was then used to inoculate 1 L of media 
supplemented with selected antibiotic and cells were grown at 30°C until an OD600 of 1-1.2 
was achieved. Temperature was then reduced to 12.5°C and after an hour 1 mM IPTG was 
added and cells left for 72 hours with shaking.   
2.2.4.2 Preparation and use of Pichia pastoris expression systems  
Genes of interest inserted into a PichiaPink expression vector were linearised using the 
restriction enzyme Spe1. The linearized DNA was then concentrated by ethanol 
precipitation and re-suspension in sterile MilliQ water.  
Each of the four PichiaPink strains provided were grown by picking a single colony and 
inoculating 10 ml of yeast extract peptone dextrose media (YPD) in a 125 ml flask. This 
was incubated with shaking at 300 rpm, 30°C for 24 hours. 1 ml of this starter culture was 
then used to inoculate 100 ml YPD media in a 1 L flask. This was grown at 30°C until an 
OD600 of 1.3-1.5 was reached.  Cells were then centrifuged at 1500 g at 4°C for 5 min 
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before being resuspended in 250 ml ice cold sterile water. This step was repeated with 50 
ml of ice cold water used. Cells were centrifuged again, resuspended in 10 ml, 1 M sorbitol 
and centrifuged again. The cells were then resuspended in 500 µL 1 M sorbitol. 
To an electroporation cuvette, 80 µL of the cells were added along with 5 µg of linearised 
plasmid DNA. The cells were pulsed using the Bio-Rad Gene Pulser II for 5 seconds at 1.5 
kV, 200 ohms, 25 µF capacitance. Immediately after, 1 ml of YPD supplemented with 1 M 
sorbitol was added to the cuvette and cells left at 30°C without shaking for 2 hours. Cells 
were then plated onto Pichia adenine dropout (PAD) selection plates and incubated at 30°C 
for 3-6 days. After this time any white colonies were picked and streaked onto fresh PAD 
plates.  
White colonies were tested for expression by inoculating 10 ml of buffered glycerol-
complex media (BMGY) with a single colony and incubating with vigorous shaking at 
30°C overnight. The next day cells were centrifuged at 1500 g for 5 min and resuspended in 
10 ml buffered methanol-complex media (BMMY). Cells were then left to grow at 20°C for 
5 days. Every 24 hours methanol was added to a final concentration of 0.5%. 
Large-scale expression was conducted in a similar way but with 500 ml media per 2 L flask. 
2.2.4.3 Preparation and use of baculovirus expression systems  
The gene of interest, ligated into a pFastBac HTb vector modified to remove the sequence 
encoding the N-terminal His tag, was heat shock transformed into E. coli DH10Bac cells. 
Cells were spread onto agar plates as mentioned in the section 1.1.4 and left to grow at 
37°C for three days. White colonies were re-streaked and left for a further three days. The 
DH10Bac cells contain a shuttle vector that can combine with the pFastBac vector to create 
an expression bacmid carrying the gene of interest. The bacmid was purified by growing 50 
 Chapter 2 – Materials and methods 
39 
ml cultures of the white colonies at 37°C overnight and purifying the DNA using the 
Maxiprep kit (Qiagen) with the resultant pellet. 
For transfection, 1 ml of Sf9 cells at 8 x 105 cells ml-1 were seeded in 35 mm plates. The 
cells were then left for 1 hour to adhere to the plate. During this time 6 µL InsectGeneJuice 
was mixed with 1 ml Sf900 II media and vortexed. To this, 500 ng of the bacmid DNA was 
added and the mixture left to incubate for 30 min.  
The supernatant was then removed and the transfection mix gently added. This was 
incubated at 27°C for 24 hours after which 1 ml of Sf900 II media was added. The plate 
was then left for 6 days before the virus was harvested by pipetting off and keeping the 
media containing the budded P0 virus.   
The baculoviral stock was amplified by adding 125 µL of the P0 stock to 50 ml Sf9 cells at 
15 x 105 cells ml-1. This was incubated at 27°C, 135 rpm for 1 week. This viral stock was 
known as the P1. Further amplification, for P2 stocks, was performed by adding 500 µL P1 
stock to cells at 15 x 105 cells ml-1 and again incubating for 1 week. Virus was harvested by 
centrifugation at 1500 g for 10 min and removing supernatant which was kept at 4°C.  
Expression of recombinant protein was undertaken by addition of 5% (v/v) virus, to Sf9 
cells at 15x105 cells ml-1, and incubating at 27°C, 135 rpm for 2-3 days. Cells were 
monitored for infection by measuring cell size, viability and counting cell numbers. After 
2-3 days, infected cells were harvested and if the protein was membrane bound, cells were 
kept for protein purification. If protein was secreted, such as with AChBP, cells were 
discarded and the supernatant processed using a SartoJet with 5 kDa filter (Sartorius). 
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2.2.5 Protein purification from E. coli expression systems 
2.2.5.1 Buffers 
A list of buffers used in the purification of proteins expressed using E. coli is given in 
Table 2.3. For more detail regarding the constructs, see Chapters 3 and 4. 
Table 2.3 Buffers used for purification of proteins expressed in E. coli. 
Name Buffer Constructs 
A 50 mM Tris-HCl, pH 7.5, 250 mM NaCl ECD domain constructs, Gephyrin 
B 50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 500 mM imidazole ECD domain constructs, Gephyrin 
C 50 mM Tris-HCl pH 8, 250 mM NaCl FLIC derivatives 
D 50 mM Tris-HCl pH 8, 250 mM NaCl, 0.02% DDM FLIC derivatives 
E 50 mM Tris-HCl pH 8, 250 mM NaCl, 500 mM imidazole, 0.02% DDM FLIC derivatives 
F 50 mM HEPES pH 6.9, 250 mM NaCl ELIC derivatives 
G 50 mM HEPES pH 6.9, 250 mM NaCl, 0.02% DDM ELIC derivatives 
H 50 mM HEPES pH 6.9, 250 mM NaCl, 500 mM imidazole, 0.02% DDM ELIC derivatives 
2.2.5.2 Lysis and purification 
Cells were harvested by centrifugation at 3500 g and supernatant discarded. Each cell pellet 
from 1 litre of culture was then resuspended in approximately 10 ml buffer (A, C or F; 
Table 2.3) with 0.2 mg DNase I and an EDTA-free protease inhibitor tablet (Roche). Lysis 
was carried out either using a Pressure Cell Homogeniser (Stansted) with a pressure of 20 
kpsi, or a One-Shot cell disruptor (Constant systems Ltd) at 30 kpsi. For protein expected to 
be soluble such as the various ECD constructs, cellular debris was removed with a 
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centrifugation step at 39000 g for 25 min at 4°C. Supernatant was then kept to be used for 
affinity purification of the protein.  
After lysis, membrane proteins were purified by centrifugation at 13000 g for 20 min at 
4°C to remove larger cell debris. The supernatant was then centrifuged at 150000 g for 45 
min at 4°C to pellet the membranes. The membrane pellet was homogenised using a Potter-
Elvehjem homogeniser. To the homogenised membranes, 2% w/v n-dodecyl β-D-
maltopyranoside (DDM) was added. The membranes were then left to solubilise at 4°C for 
2 hours with gentle agitation. After this time a second centrifugation at 150000 g, for 45 
min at 4°C was conducted to pellet insoluble material. The supernatant was then kept for 
affinity purification of the protein.  
All the proteins had either N or C-terminal hexa-histidine tags used for affinity 
chromatography. A 5 or 1 ml HisTrap HP column (GE Healthcare) pre-charged with Co2+ 
was equilibrated with buffer (A, D or G; Table 2.3) followed by loading of the supernatant 
from the previous step. Non-bound protein was washed from the column using several 
column volumes (CV) of buffer (A, D or G; Table 2.3). The protein of interest was then 
eluted using a linear gradient of an imidazole containing buffer (B, E or H; Table 2.3). To 
confirm the purity and approximate mass of the protein in each fraction eluted, SDS-PAGE 
was employed.  
Several ELIC and FLIC constructs had a maltose binding protein (MBP) fusion partner at 
the N-terminus connected by a TEV protease cleavage site. This was cleaved by addition of 
1 mg TEV protease for each 10 mg of protein, and the mixture left to incubate at 4°C 
overnight. TEV and MBP were later separated by size exclusion chromatography (SEC). 
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2.2.5.3 Protein refolding 
The HsGlyR and DrGlyR ECD constructs formed inclusion bodies when expressed with E. 
coli C43 and ArcticExpress cells. In an attempt to gain soluble, correctly folded protein, the 
inclusion bodies were dissolved in a chaotropic solution for refolding experiments 
(Breitinger et al., 2004). The pellet from the initial centrifugation step after lysis was 
resuspended in 50 mM Tris-HCl pH8.2, 0.5% Triton X100 then centrifuged at 13000 g for 
10 min at 4°C. The supernatant was discarded and the above steps repeated twice. The 
remaining pellet was then dissolved in 100 mM sodium phosphate, 10 mM Tris-HCl pH 8 
and 8 M urea. The dissolved pellet was then dialysed in a 1:1 mix of the urea buffer and the 
refolding buffer, 50 mM Tris-HCl pH 8.2 and 7 µM CuCl2. Every 3 hours 30% of the 
buffer mix was removed and replaced with refolding buffer. After 12 hours the sample was 
centrifuged to remove any precipitated protein.  
2.2.6 Protein purification from Pichia pastoris expression systems 
2.2.6.1 Test expressions 
Owing to the large number of colonies that needed to be screened for adequate expression 
levels, a crude purification was conducted. Cultured Pichia was pelleted, supernatant kept 
and pellet lysed with YeastBuster (MerckMillipore) supplemented with DNase I. This mix 
was left to incubate with gentle mixing for 2 hours. Cell debris was pelleted and the media 
supernatant, lysis supernatant and pellet were analysed by SDS-PAGE and western blots. 
2.2.6.2 Glycine receptor α1 construct 4 purification 
A previous study has shown that a modified construct of the human glycine receptor α1 
could be expressed and purified from P. pastoris (Wöhri et al., 2012). This construct had 
N-terminal truncations and replacement of the intracellular loop domain with a shortened 
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loop found in the bacterial pLGIC GLIC (see Chapter 3). Purification of construct 4 was 
conducted following the published protocol with some minor differences. Briefly, cells 
were pelleted by centrifugation at 1500 g for 10 min at 4°C. Cells were resuspended in 50 
mM Tris-HCl pH 8.1, 10 mM glycine, 200 mM KCl, 5% w/v glycerol, 5 mM DTT 
supplemented with one EDTA-free protease inhibitor tablet per litre of culture. Cells were 
lysed by multiple passes through the Pressure cell Homogeniser (Stansted) with an initial 
run at 20 kpsi followed by another at 35 kpsi. Cell debris was pelleted by centrifugation at 
5000 g for 10 min at 4°C. 5% (w/v) PEG 8000 was added to the supernatant to precipitate 
the membranes that were then harvested by centrifugation at 12000 g for 20 min. 
Membranes were then resuspended in 30 mM potassium phosphate buffer pH 7.6, 10 mM 
glycine, 300 mM KCl and 20% (w/v) glycerol. This step was followed by a centrifugation 
step at 100000 g for 20 min at 4°C to pellet membranes. These were subsequently 
homogenised and solubilised by addition of 1.5% DDM and incubated at 4°C for 2 hours. 
Solubilised protein was separated from insoluble material with a centrifugation step at 
100000 g for 20 min at 4°C. The supernatant was then loaded onto an amino-strychnine 
column previously equilibrated with 30 mM potassium phosphate buffer pH 7.6, 750 mM 
KCl, 10% glycerol, 2 mM EDTA, 0.05% DDM and 0.025 mg ml-1 DOPC. The column was 
extensively washed with 12 CV of equilibration buffer to remove unbound protein. The 
receptor was then eluted with equilibration buffer containing 250 mM glycine. The receptor 
was concentrated using an Amicon Ultra 100 kDa cut-off centrifugal filter 
(MerckMillipore).  
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2.2.7 Protein purification from baculovirus expression systems 
2.2.7.1 Test expressions 
Small-scale test expressions were conducted by infecting 50 ml of Sf9 cells with 5% virus. 
After two days incubation the cells were harvested by centrifugation at 1500 g for 5 min at 
4°C and the supernatant discarded. Cells were resuspended in I-PER Insect Cell Protein 
Extraction Reagent (Pierce) supplemented with an EDTA-free protease inhibitor tablet. 
This mixture was left on ice for 10 min followed by separation of the cell debris by 
centrifugation at 15000 g for 15 min at 4°C.  Samples of the supernatant and pellet were 
analysed for protein expression by SDS-PAGE and western blots. 
2.2.7.2 Secreted Protein 
After concentration of the protein, it was loaded onto a 5 ml HisTrap HP column (GE 
Healthcare). The column was then extensively washed with 50 mM Tris-HCl pH 7.5 and 
250 mM NaCl to remove unbound protein. The protein of interest was then eluted by a 
linear gradient of imidazole. Fractions were monitored by SDS-PAGE to confirm the 
fractions contained the protein of interest and to monitor purity.  
2.2.7.3 Membrane bound protein   
Infected cells were harvested as above and resuspended in 10 ml, 50 mM HEPES pH 6.9, 
250 mM NaCl supplemented with an EDTA-free protease inhibitor tablet and 0.2 mg 
DNAse (per litre of culture). Lysis was carried out using the Pressure Cell Homogeniser at 
20 kpsi. Larger cell debris was pelleted by a centrifugation at 13000 g for 15 min at 4°C 
followed by the supernatant being centrifuged at 150000 g for 45 min at 4°C. The 
membrane pellet was then homogenised and solubilised using various detergents.  
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2.2.7.4 Detergent screening 
To determine which detergent would solubilize protein most effectively, solubilisation 
screening was conducted. Table 2.4 below lists the ten detergents and concentrations used. 
Table 2.4 Detergents and concentrations for detergent screening. 
Detergent Concentration Detergent Concentration 
Tween 20 1% CHAPS 5% 
Tween 80 1% NP40 2% 
Triton X100 1.5% Brij 58 0.01% 
DDM 1% FOS-12 1% 
BOG 1.4% CYMAL5 1% 
After homogenization of membranes, 200 µL of sample and detergent were mixed and 
incubated at 4°C for 2 hours. The mixture was then centrifuged at 150000 g for 45 min at 
4°C. The pellet and supernatant were then analysed by SDS-PAGE and western blots to 
identify the detergent that had extracted the protein from the membrane most effectively.   
2.2.7.5 Protein biotinylation 
The ELIC gene was altered to include a segment encoding for the biotin acceptor peptide 
(BAP) sequence, GLNDIFEAQKIEWHE, in the loop between TM2 and TM3 The gene 
was incorporated into a modified pET15b vector (Novagen), that produced an N-terminal 
MBP fusion protein linked by a TEV protease cleavage site. A gene encoding BirA, a 
biotin ligase, was ligated into a pACYCDuet-1 vector (Novagen). Both plasmids were 
transformed into OverExpress C43(DE3) cells and selected for with carbenicillin and 
chloramphenicol. The protein was expressed as with the wild type ELIC with the exception 
that 50 µM of biotin was added along with IPTG at the induction stage. Biotinylation was 
confirmed by western blot using an anti-biotin antibody (Abcam). 
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2.2.8 Size exclusion chromatography 
Further purification after an affinity purification step was conducted by SEC, wherein 
proteins are separated based on their dimensions and molecular weights. Smaller proteins 
interact with the matrix of the column to a greater extent than larger proteins. Therefore 
larger proteins elute at a lower volume than smaller proteins. A Superdex 200 26/60 for 
amounts greater than 10 mg of protein and a Superdex 200 16/60 for less than 10 mg of 
protein were pre-equilibrated with appropriate buffers. The protein elution was monitored 
by UV absorbance at 280 nm and presence and level of protein purity monitored by SDS-
PAGE. 
2.2.9 Ion exchange chromatography 
In an attempt to improve the purification of FLIC, ion exchange chromatography was 
conducted. After a SEC experiment was conducted with this receptor it was clear there was 
still a large amount of contaminating protein present. The receptor was therefore buffer 
exchanged into a low salt buffer, 50 mM Tris-HCl pH 8, 20 mM NaCl and loaded onto a 
HiTrap Q FF column (GE Healthcare). A linear gradient of increasing NaCl concentration 
was then applied to the column to a final salt concentration of 500 mM. Elution was 
monitored by absorbance at 280 nm and protein identity confirmed by SDS-PAGE. 
2.2.10 Protein analysis 
2.2.10.1 Native gel 
Native gels were employed to determine the possible quaternary structure of the receptors. 
Protein samples were mixed with 5 µL NativePAGE sample buffer (x4) and 1 x 
NativePAGE Anode Buffer and Dark Blue Cathode Buffer made up. Gels were loaded and 
run at 150 V for 120 min. Gels were destained with a 30% ethanol 3% acetic acid mixture. 
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2.2.10.2 Western blot analyses 
Protein run on SDS-PAGE was transferred to a PVDF membrane using a Trans Blot Turbo 
(Bio-Rad). The membrane was blocked using 5% milk powder in phosphate buffered saline 
(PBS) and 0.5% Tween20 for 1 hour followed by incubation of the membrane with 5% 
milk powder PBS 0.5% Tween20 with the appropriate primary antibody. The membrane 
was then washed with PBS 0.5% Tween20 before a final incubation with the secondary 
antibody in PBS 0.5%Tween20. After a final wash step, the ECL substrate was added for 
protein detection. 
2.2.10.3 Differential scanning fluorimetry 
The stability of a protein can be inferred from its ability to resist denaturing with an 
increase in temperature. A fluorescent dye, SYPRO orange, binds to hydrophobic residues 
of a protein, resulting in a change in fluorescence. As a protein unfolds, more hydrophobic 
residues are exposed to the solvent and dye, resulting in an increased change in 
fluorescence. By utilising this dye, a melting temperature of the protein (Tm), when there is 
an equal population of folded and unfolded protein, can be determined. The extent to which 
buffers and ligands help improve the stability of proteins can also be measured using this 
technique (Pantoliano et al., 2001).  
Experiments were conducted with a solution of 10 µM protein, the required concentration 
of ligand and a 1000 fold dilution of SYPRO orange. To a 96 well PCR plate (Thermo), 40 
µL of this mix was added and experiments run on an Mx3005p qPCR machine (Stratagene). 
The machine used heating cycles from 25°C to 95°C at a rate of 1°C min-1. Excitation and 
emission wavelengths of 492 nm and 610 nm were used to measure fluorescence. The 
change in fluorescence against temperature was plotted to produce a melting curve for the 
protein.  
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2.2.11 Bio-layer interferometry 
 
Biotinylated ELIC at 0.5 mg mL-1 was immobilised on SuperStreptavidin (SSA) biosensors 
(ForteBio). Biocytin at 10 µg -1mL was used to block excess sites on the protein sensor and 
the reference sensors. Histidine tagged-AChBP was immobilised using Ni-NTA biosensors 
at 0.5 mg ml-1. TEV protease was used as a reference for the AChBP screens as this protein 
also contained a His-tag. 
The initial screen of the ion channel compound library (Mok and Brenk, 2011) was 
conducted at 10 µM. This library was created by searching the ChEMBL database for 
compounds known to modulate nine classes of ion channels. In total, 3241 compounds 
were used in the screen. Subsequent concentration dependent follow up screens were 
conducted with a top concentration of 50 µM. Five, 1 in 3 dilutions were then performed, 
giving final concentrations of 50 µM, 16.67 µM, 5.55 µM, 1.85 µM, 0.61 µM and 0.21 µM. 
Compounds were plated out by the compound handling team at The Drug Discovery Unit, 
The University of Dundee. 
The experiments were conducted using the Octet Red system (FortéBio) with a baseline 
measurement taken for 60 sec in buffer, a 120 sec association measurement in the 
compound containing wells followed by a 120 sec dissociation measurement in the buffer. 
All experiments were conducted with the chamber temperature set to 25°C.   
2.2.12 Electrophysiology 
2.2.12.1 Cell lines and receptor expression 
Human embryonic kidney 293 (HEK-293) cells were transfected by a calcium phosphate 
DNA co-precipitation step (Jordan et al., 1996) using 1µg cDNA encoding for the α1β3, 
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α1β2 GABAA receptors, GlyR and ELIC. Green fluorescent protein (GFP) cDNA at ten 
fold lower concentration was also included to identify cells expressing the receptors. Wss-1 
cells, HEK-293 cells stably expressing α1β3γ2 GABAA receptors, were also used (Davies et 
al., 2000). Cells were seeded on 35 mm dishes at low densities and used for electrophysical 
recordings between 48-72 hours post transfection.  
2.2.12.2 Electrophysiological recordings 
GABA evoked currents were recorded using the whole cell patch clamp technique (Hamill 
et al., 1981). Borosilicate glass was used to make the recording electrodes and had a 
resistance of between 1.5-2 MΩ when filled with the electrode solution, Table 2.5. Glycine 
receptor recordings in HEK-293 used the same intra and extracellular solutions as with 
GABA receptors, except without ATP in the intracellular solution. For HsGlyR Con4 
recordings in Sf9 cells different buffers were used as stated in Table 2.5. Cells were voltage 
clamped at an electrode potential of -60 mV unless otherwise stated. GABA/glycine and 
GABA/glycine with a compound were applied to the cell using the three pipe Perfusion 
Fast-Step solution exchange system (Warner Instruments) at a rate of 0.3 ml min-1. The 
flow rate was controlled by a syringe pump (Cole-Parmer, Vernon Hills, IL). Voltage 
clamped cells were lifted from the plate and located in the stream of extracellular solution. 
The perfusion pipes were then rapidly moved to expose the cell to gating solution and 
gating solution plus drug. Excess gating solution and drug were washed from the plate 
during recordings with extracellular solution. Data were collected using an Axopatch 200B 
amplifier (Molecular Devices) and was low pass-filtered at 2 kHz. pClamp8 software was 
used for data recording and analysis performed using pClamp10 software (Molecular 
Devices). 
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Table 2.5 Extracellular and electrode solutions for whole cell patch clamp 
electrophysiology. 
Solution Composition 
ELIC extracellular 140 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 0.2 mM CaCl2, 10 mM glucose, 10 mM HEPES-NaOH pH 7.4 
ELIC electrode 140 mM KCl, 2 mM MgCl2, 0.5 mM CaCl2, 5 mM EGTA, 10 mM HEPES-KOH pH 7.4 
GABA extracellular 140 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2, 10 mM glucose 10 mM HEPES-NaOH pH 7.4 
GABA electrode 140 mM CsCl, 2 mM MgCl2, 11 mM EGTA, 3 mM ATP,    10 mM HEPES-CsOH pH 7.4 
HsGlyR Con4 extracellular 
100 mM NaCl, 20 mM Na-gluconate, 20 mM TEA-Cl, 4.7 mM KCl, 1.2 
mM MgCl2, 2.5 mM CaCl2, 10 mM glucose, 10 mM HEPES-NaOH 
pH7.4 
HsGlyR Con4 intracellular 6 mM KCl, 114 mM K-gluconate, 20 mM TEA-Cl, 20 mM MgCl2, 11 mM EGTA, 3 mM Mg-ATP, 10 mM HEPES-KOH pH 7.4 
 
2.2.13 Protein crystallography 
2.2.13.1 Sparse matrix screening for initial crystallisation conditions 
Purified protein to be used for crystallisation trials was concentrated to 10 mg ml-1. Ligands 
were then added at an appropriate concentration and the mixture left to incubate on ice for 
10 min. For ELIC crystallisation, 0.5 mg ml-1 E.coli polar lipids were also added. The 
protein/ligand solution was then filtered using a 0.1 µm PVDF centrifugal filter 
(MerckMillipore).  
Initial screening was conducted using commercially available screens. Generally the 
Classic suite, PEG suite I (Qiagen), JCSG+ and MemGold (Molecular Dimensions) were 
used. These consist of a 96-well, sitting drop format and have various precipitant and salt 
concentrations and pH ranges.  
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A Phoenix Liquid Handling System (Rigaku, Art Robins Instruments) was used to dispense 
0.1 µL of protein into each well, to be mixed with 0.1-0.2 µL of reservoir. Plates were then 
sealed and stored at room temperature. Crystallisation progress was monitored using the 
Minstrel DT system (Rigaku) that takes images of each condition at regular time intervals, 
starting at an image a day for five images then once every three days. 
Once a condition that yielded crystals was observed, an optimisation screen was set up by 
varying the PEG size and concentration, salt and precipitant concentration, as well as the 
pH of the initial condition. Using either the 96 well sitting drop or 24 well hanging drop 
plates, the optimum condition to improve crystal size and morphology was investigated.  
For hanging drop crystallization experiments, a reservoir of 500 µL of the crystallisation 
condition was made. On a siliconised glass cover slip, 0.75 µL of protein was then mixed 
with various volumes of the reservoir. Generally ratios of 1:1 protein to reservoir, 1:2 and 
2:1 were used for experiments. The cover slip was then inverted over the reservoir solution 
and sealed with paraffin grease.   
2.2.13.2 Crystal structure determination of ELIC 
Crystals of ELIC were cryoprotected by transfer to a drop containing reservoir adjusted to 
include 30% glycerol before being frozen in liquid N2. Reservoir conditions yielding 
crystals are detailed in Chapter 4. Diffraction data were collected at the Diamond Light 
Source, Harwell on beamline I03 equipped with a PILATUS3 6M detector. 
The data were indexed and integrated using XDS (Kabsch, 2010) and scaled with Aimless 
(Evans and Murshudov, 2013). MOLREP (Vagin and Teplyakov, 1997) was used for 
molecular replacement, using a previously solved isomorphous structure of ELIC (2.91 Å 
resolution) (PDB code 3RQW). One subunit from the PDB, with waters and ligands 
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removed was used in molecular replacement. The asymmetric unit contained ten subunits 
making up two identical pentamers, as in 3RQW. After a round of refinement conducted 
with Refmac (Murshudov et al., 2011) and analysis of the (2Fo-Fc) and (Fo-Fc) maps with 
COOT (Emsley et al., 2004), it was clear the data were not good enough to distinguish if 
the ligand bicuculline was present and further refinement was not conducted. For further 
details and crystallographic statistics see Chapter 4.  
2.2.13.3 Crystal structure determination of AChBP-A 
The crystal of AChBP-A used for data collection grew in conditions containing a one:one 
ratio (0.1 µl:0.1 µl) of reservoir solution and protein at 10 mg ml-1 in the purification buffer 
with 5 mM bicuculline. The reservoir solution was composed of 0.2 M di-ammonium 
hydrogen citrate and 20% PEG 3350. Crystals were frozen directly from the drop. 
Diffraction data from the AChBP-A were collected on beamline ID-23-1 at the European 
Synchrotron Radiation Source, Grenoble, equipped with a PILATUS 6M-F detector. Data 
were indexed, integrated and scaled using XDS and Aimless as above. Matthews 
coefficient calculations were determined using Matthews_coef in the CCP4 suite 
(Matthews, 1968, Kantardjieff and Rupp, 2003). The result was consistent with five 
subunits in the asymmetric unit with a Vm of 2.86 Å3 Da-1 and an estimated solvent content 
of around 60%. This falls within the typical range of observed values for protein crystals, 
being 1.68-3.53 Å3 Da-1 and a solvent content of between 27-65% (Matthews, 1968).  
Molecular replacement was performed with Phaser_MR (McCoy et al., 2007). A previously 
solved isomorphous structure of the wild type AChBP at a resolution of 2.02 Å. (PDB code 
2BYN) was used as the basis for the model. The waters and ligands were removed and only 
chain A kept for use as the model in molecular replacement. Initial rigid body refinement 
was followed by several rounds of restrained refinement using automatically generated, 
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non-crystallographic symmetry restraints. After each round of refinement, (2Fo-Fc) and (Fo-
Fc) maps were inspected with manual refinement and model building conducted using 
COOT (Emsley et al., 2004). Rotamers and side chains with dual conformations were 
placed into positive density during this step.  When the model for AChBP-A was suitably 
refined, waters were added by finding difference Fourier peaks of approximately the correct 
size (2Fo-Fc at 1 σ, Fo-Fc at 2.5 σ) and in the correct environment for hydrogen bonding 
(2.5-3.5 Å from donor/acceptor). N-acetylglucosamine was added into density at 
glycosylation sites and PEG placed where appropriate. B-factors for these placed molecules 
was monitored after refinement and deleted if the value was overly high.   
Geometric validation of the model using MOLPROBITY (Davis et al., 2007) was 
employed and Ramachandran plots generated. Issues with outliers and unfavourable 
rotamers identified with MOLPROBITY were addressed during the final round of 
refinement.  
For further details and crystallographic statistics see Chapter 5 
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2.2.13.4 Crystallography study of AChBP-B 
A crystal of AChBP-D that diffracted to 4 Å resolution was grown in a sitting drop plate 
with a one:one ratio (0.1 µl:0.1 µl) of 10 mg ml-1 protein with 0.5 mM strychnine and 
reservoir solution containing 0.3 M MgCl2, 15% PEG 3350. Crystals grew after several 
weeks at 20°C. Diffraction was tested in-house using a Rigaku M007HF rotating anode 
generator (copper Kα, λ= 1.5418 Å) with a Saturn 944G+CCD detector. No cyroprotectant 
was used. .Two images, 90° apart with an exposure of 30 seconds, were taken during 
testing and used for indexing with iMOSFLM (Battye et al., 2011). Using MATTPROB, a 
Vm of 2.91 Å Da-1 and a solvent content of around 60% was estimated, consistent with a 
pentamer in the asymmetric unit. This crystal was then stored for future testing. 
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3 Homology modelling and heterologous expression and 
purification of pentameric ligand gated ion channels 
3.1 Synopsis 
The initial aim of this project was to produce recombinantly expressed target protein, in 
sufficient yields for structural and ligand binding studies. Homology modeling was 
employed to inform construct design, leading to the creation of various chimeras and 
mutants. The human GlyR α1 subunit was the main target, though homologues from the 
zebrafish, Danio rerio (DrGlyR), the sea squirt Ciona intestinalis (CiGlyR), and two 
bacterial pLGICs from Dickeya dadantii, ELIC, and Francisella tularensis, FLIC, were 
also studied.  
3.2 Homology modelling 
Though there is little structural information presently available for mammalian pLGICs, the 
3D structure of several homologues have been determined and during the writing of this 
thesis the human GABAA β3 and mouse 5-HT3A receptors structures were reported (Miller 
and Aricescu, 2014; Hassaile et al., 2014). The general fold of these related proteins is 
often very similar and by aligning the sequence of a protein with its homologues, a model 
can be built that estimates the 3D structure of this protein. Proteins with sequence identities 
as low as 15-25% can be used to achieve suitable models. These models can inform 
decisions as to which residues form which domains. They may also serve to give insights 
into mechanisms of gating and ligand recognition. 
The homology modelling server Phyre 2 (Kelley and Sternberg 2009) was used to create 
structural models of HsGlyR, DrGlyR and CiGlyR. The three deposited sequences returned 
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high confidence structures. However, one limitation of the models was that the TM3-TM4 
intracellular loop was either not modeled or was shown as an unstructured loop as in Figure 
3.1 A. This is simply due to the lack of any structural template for this region of the 
receptors.   
The model of HsGlyR had a confidence score greater than 90% for the 77% of residues that 
were modeled. The remaining 103 residues were modeled ab initio, using no homologous 
structural information. This is mainly from the intracellular loop domain (ILD) that is 
shown in the lower portion of the model in Figure 3.1 A, with little secondary structure 
predicted. The models of DrGlyR and CiGlyR had similar confidence scores of greater than 
90% for each and 77% and 68% of residues modeled respectively. 
Structural bias from the few deposited structures of pLGICs may be a problem with these 
models resulting in similar confidence scores. The structure of CeGluCl (PDB code 3RIF) 
was the highest ranked template for each model. Figure 3.1 C, shows the secondary 
structure elements of HsGlyR aligned with those of CeGluCl. Full length GluCl has a 
sequence identity of 33% to HsGlyR, though the structure used as the main template has 
the ILD removed, increasing sequence identity to 43%. The black and grey boxes in figure 
3.1 C highlight the conserved residues between the four sequences. The structures for 
human GABAA  β and mouse 5-HT3A receptors were not available at the time of modeling, 
though subsequent comparisons between these structures and models show comparable 
secondary structure and conserved residues in similar positions 
The percentage of β-strands in the ECD of the model (46%) is consistent with Fourier 
transform infrared spectroscopy studies that predicted 48% of the structure formed β-
strands (Breitinger et al., 2004). A second study using circular dichroism predicted a β-
strands content of 36%, α-helical content of 8% and disordered regions 43% (Vogel et al., 
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2009.) These data support the model, which has an α-helical content of 5% and disordered 
loops making up 46% for the ECD. These consistencies suggest the model could be a good 
representation of the structure of HsGlyR.   
The information garnered from these models was used for designing various constructs, 
helping to define which residues form the ECD, TMD and ICL. The residues potentially 
important for glycine binding were also identified and this guided the design of mutants to 
create GlyR surrogates.  
 
 Chapter 3 – Homology modeling and heterologous expression and purification of pLGICs 
58 
  
Figure 3.1 Homology model of HsGlyR 
A) The homology model of HsGlyR. B) A topology diagram created using TopDraw (Bond, 
2003). C) Sequence alignment of HsGlyR and three homologues. Secondary structure 
elements are shown in the same colours as the model. To highlight the similarity of the two 
structures, secondary structure elements of CeGluCl are shown in red and blue.  
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3.2.1 Mechanistic insights from homology models 
The homology model could also be used to give possible mechanistic insights. 
Superimposing two copies of the model onto adjacent subunits of the crystal structure of 
CeGluCl allowed for conclusions to be drawn about inter and intra subunit interactions. 
Common mutations in GlyRs found in sufferers of hyperekplexia can be investigated to 
ascertain how they disrupt receptor function. Two common mutations found at the interface 
between ECD and TMD are R246Q and K304E, which affect gating (Bakker et al., 2006). 
A glutamic acid, E81, located on the β1-β2 loop could potentially interact with the residues 
prone to the two mutations above, with mutation disrupting these interactions. The β1 and 
β2 strands contribute to the complimentary neurotransmitter-binding site. It is possible a 
binding event here causes a shift that is transmitted to E81, which can then interact with 
either R246 or K304 on the adjacent subunit. K304 is located on the TM2-TM3 loop and 
the interaction with E81 could potentially facilitate a gating event. Figure 3.2 shows the 
potential interaction of these residues. The recent structure of human GABAA β3 (PDB 
code 4COF) in the desensitized state shows a salt bridge formed between conserved E52 
and R216 residues in this site. A lysine, K274, is also conserved in the TM2-TM3 loop. 
The distance between E52 and K274 in this structure is 4.8 Å, similar to that seen in the 
model (5 Å). The intra-subunit interaction could potentially be the position adopted at 
resting and desensitisation, with E81 moving to interact with K304 between subunits during 
gating. The mutations R246Q and K304E would interrupt these interactions, with the loss 
of positively charged side chains limiting interactions with the negatively charged E81. 
This could lead to disruption of channel opening. These residues have been identified in 
other studies on GABAA receptors and mutations of them have been linked to epilepsy 
(Kash et al., 2002; Hales et al., 2006) 
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Figure 3.2 Possible gating interactions at the ECD-TMD interface of GlyR 
A view of two subunits and the interface between the ECD and the TMD. Intra-subunit 
interactions between E81 and R246 during resting and desensitized states. Inter-subunit 
interactions between E81 and K384 could potentially facilitate gating by shifting TM2 
outward, opening the pore.  
 
Another salt bridge is formed between R299 at the top TM2 and D312 at the top of TM3 
(not shown). Again this is conserved in the GABAA receptor structure. Though the GABAA 
structure is supposedly in the desensitized state, it could be that this bond facilitates gating. 
The salt bridge formation may assist in the tilting motion associated with TM2 during 
channel opening. Mutations of R299 to Q or L are found in hyperekplexia sufferers and 
have been linked to problems with channel gating (Bakker et al., 2006. 
The mechanisms of how glycine and various ligands bind in the ECD can also be 
investigated using the models. This is discussed in Chapter 5 along with how this 
knowledge was used to create GlyR surrogates.  
3.3 Construct design and expression 
Various constructs were designed in attempts to gain protein that was stable, homogeneous 
and could be used for crystallisation. These included sub-domains, chimeras and fusion 
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partners as well as full-length sequences. A full list of the constructs created, the amino 
acid composition, expression vectors and an overview of the outcome of expression tests 
are given in Chapter 2, Table 2.2. 
Alongside human GlyR several homologues were used. Two eukaryotic GlyRs were chosen, 
the well-characterized zebrafish GlyRα1 and a more recently discovered potential GlyR 
from the sea squirt Ciona intestinalis (David-Watine et al., 1999; Nishino et al., 2010). 
These proteins had sequence identities to HsGlyR of 86% (DrGlyR) and 50% (CiGlyR). A 
bacterial pLGIC from F. tularensis was identified in the UniProt database that had a 
sequence identity to HsGlyR of 20%, similar to that of ELIC (22%). This was also used to 
try and gain recombinant protein for structural studies.  
Signal peptides were identified using SignalP (Petersen et al., 2011) and were then either 
kept, for incorporation of protein into the membrane, removed if protein was to stay in the 
cytoplasm, or replaced with a non-native signal peptide. The non-native signal peptide, 
pelB was used for bacterial expression, directing the expressed protein to the membrane. 
The honeybee melittin signal sequence and Saccharomyces cerevisiae α-mating factor 
signal sequence were used instead of native signal sequences for baculovirus and Pichia 
expression systems, respectively. The efficiency at which these signal sequences direct the 
receptors to the membrane or for secretion is often better than the native sequences that 
may not be recognized (Futatsumori-Sugai and Tsumoto, 2010). 
To assist in affinity purification and a useful aid to monitoring expression by western blot 
analyses, all constructs had either N or C-terminal polyhistidine tags. Fusion partners were 
sought to improve stability and solubility of the receptors. MBP was incorporated onto the 
N-terminus of bacterial expressed receptors ELIC and FLIC. For full details of ELIC 
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construct design and purification see Chapter 4. The MBP aids in prevention of aggregation 
of protein to which it is fused (Kapust and Waugh, 1999). 
The following chapters, 3.1.1-3.1.3, cover strategies to gain recombinant protein that ran 
into difficulties, highlighting the problems faced expressing and purifying these receptors. 
Section 3.1.4 details the progress made in expressing a GlyR with the TM3-TM4 
intracellular loop replaced by a short linker sequence. This chapter lays the ground work for 
future large scale preparations of recombinant GlyR. 
3.3.1 Expression of sub-domains and bacterial pLGICs 
3.3.1.1 Refolding experiments of the ECD 
Refolding experiments were conducted on two constructs that expressed as inclusion bodies 
when expressed in E.coli, the ECD of HsGlyR and DrGlyR. By dissolving the inclusion 
body in a chaotropic reagent then slowly dialyzing into a refolding buffer it was hoped that 
correctly folded protein could be obtained. During dialysis of both constructs the protein 
precipitated.   
In an attempt to overcome the problem of insoluble expression, several cell lines were tried. 
For example, Rosetta gami (DE3), and ArcticExpress, were used. Rosetta-gami cell line 
contains mutations in the thioredoxin reductase and glutathione reductase genes, providing 
a less reducing environment and so enhancing the formation of disulfide bonds in the 
cytoplasm. ArcticExpress expresses chaperone proteins from Oleispira antarctica, a 
bacterium which has optimal growth at temperatures below 15°C. This allows for the 
expression of proteins at a lower temperature that can aid in correct folding.  Again these 
did not yield any soluble protein.  
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The lack of success with expression of eukaryotic GlyRs in bacterial systems may in part 
be due to the importance of glycosylation in the folding and oligomerisation of these 
receptors (Griffon et al., 1999). A conserved N-linked glycosylation site is present in each 
of the eukaryotic GlyR species used (N66 in HsGlyR). Due to this it may only be possible 
to express and correctly assemble such receptors using a eukaryotic expression system with 
appropriate glycosylation pathways. 
3.3.1.2 The bacterial pLGIC, FLIC 
Expression of bacterial pLGICs yielded better results. The pLGIC from D. dadantii, ELIC, 
was expressed purified and used for crystallisation and ligand screening. This is detailed in 
Chapter 4. A pLGIC from F. tularensis, known here as FLIC, was expressed in C43 (DE3) 
cells. Two expression vectors were tried, both modified pET15b vectors, one with the pelB 
signal sequence and an N-terminal His tag and another with the same but incorporating an 
N-terminal MBP fusion protein. In both cases the gene expressed and the protein was found 
to be membrane bound. Purification was conducted as detailed in Chapter 2. A solubility 
screen was performed by homogenizing the harvested membranes and treating them with 
ten different detergents. Solubilisation was monitored by SDS-PAGE and DDM was 
deemed to solubilise the receptor most effectively, having a higher proportion of the protein 
in the soluble fraction as opposed to the insoluble pellet. Therefore DDM was used in all 
further purifications. MBP was cleaved from FLIC by addition of TEV protease and 
incubation at 4°C for 12 hours.  
Affinity chromatography was used for initial purification, however the fractions containing 
the protein of interest still had a large amount of other protein present. In an attempt to gain 
protein of greater purity, SEC was conducted. Both constructs gave similar traces on SEC 
columns. The trace from a Superdex 200 10/300 SEC column and resultant SDS-PAGE for 
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FLIC (construct without MBP) is shown in Figure 3.3. For a pentamer, the expected 
volume of elution should be approximately 13.2 ml (200 kDa). The main peak occurs at 
around 12 ml (384 kDa), however, the size of the column is not optimal for this sample and 
it is difficult to determine an accurate size from the elution volume. Another factor is the 
effect of the detergent micelle increasing the apparent weight of the receptor, though 
without testing with a series of detergents the additional apparent mass from this 
component is difficult to estimate (Kunji et al., 2008). As the increase in mass attributed to 
the micelle is unknown it is difficult to draw conclusions on the oligomeric state of the 
protein, though the fact that a single, symmetric peak is not seen suggests in any case the 
sample is not monodisperse. An example of a SEC trace for a monodisperse sample is 
shown in Figure 4.1. 
 
Figure 3.3 Size exclusion chromatography of FLIC and resultant SDS-PAGE  
A. The absorbance at 280 nm (mAU) plotted against volume (ml), fraction number shown 
in red. B. SDS-PAGE of FLIC fractions. Lane 1 – Affinity column eluent, lane 2 – fraction 
8, lane 3 – fraction 10, lane 4 – fraction 11, lane 5 – fraction 12, lane 6 – fraction 13, lane 7 
– fraction 14, lane 8 – fraction 15, lane 9 – fraction 17. Bands corresponding to the protein 
of interest are boxed. These bands also showed on a western blot (not shown). 
 
Bands seen at around 35 kDa in lanes 3 and 4 after SDS-PAGE analysis, boxed in Figure 
3.3 B, are consistent with FLIC (theoretical mass of 38 kDa), and show on a western blot. 
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Lane 5, 6 and 7 correspond to fractions from the shoulder of the main peak. These have a 
band just below 35 kDa as well as faint bands consistent with the ones seen in lanes 3 and 4. 
This could be due to N-terminal degradation as the 35 kDa bands are visible in western 
blots of the gel whereas the lower bands are not. There is not a single symmetrical peak at 
the correct elution volume suggesting the protein is not homogeneous. The SDS-PAGE 
analysis also shows that there is degradation occurring and a large amount of non-target 
protein is co-purified along with FLIC.  
Ion exchange chromatography was used to try and remove these contaminants. An anion 
exchange column was used and the protein was eluted by using a NaCl gradient. A sharp 
peak was observed at 350 mM NaCl but when analysed by SDS-PAGE it was apparent the 
contaminant proteins were still present, with no difference seen between the pre-loaded 
sample and eluted sample (data not shown).  
A sample of the eluent from the ion exchange column was run on a native gel along with a 
sample of purified ELIC, Figure 3.4. The resultant band at 220 kDa closely matched those 
of ELIC, suggesting that FLIC formed a pentamer (boxed, Figure 3.4). A band is also 
visible at about 400 kDa, a size comparable to a decamer. This could be due to interaction 
between two pentamers. The inability to gain homogenous pure FLIC meant that it was not 
used for further experiments such as crystallisation trials.   
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Figure 3.4 Native gel of ELIC and FLIC 
A native gel of both ELIC and FLIC showing that 
they run to approximately the same weight. A 
monomer of ELIC is 36.8 kDa compared to 38.7 
kDa for FLIC. The band shown in the box at 
approximately 220 kDa in both lanes is consistent 
with a pentamer.  
  
 
	  
3.3.2 Fusion partner constructs 
3.3.2.1 ECD-T4-lysozyme fusion partner 
Another strategy for gaining protein suited for structural studies was to attach T4 lysozyme 
to the C-terminus of various ECD constructs. The idea was that this moiety would help 
keep the protein soluble and prevent association with the membrane. Another reason was 
that if this could be expressed and purified, the lysozyme would aid in crystallisation (Chun 
et al., 2012).   
HsGlyR ECD-T4 lysozyme and CiGlyR ECD – T4 lysozyme, were expressed using 
baculovirus. Both products retain their native signal sequence and were therefore expected 
to be secreted into the media. This was the case for CiGlyR ECD – T4 lysozyme. 
Unfortunately the protein precipitated while in the media and purification could not be 
conducted. 
 Surprisingly HsGlyR ECD-T4 lysozyme was not secreted and was found to be membrane 
associated. A large-scale 10 L culture of Sf9 cells was set up, and 5% virus encoding for the 
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protein added. After 48 hours the cells were harvested, lysed and the membranes isolated, 
as detailed in Chapter 2. The protein was solubilised with DDM and affinity 
chromatography conducted. The protein eluted in two separate peaks, firstly a major peak 
at 75 mM imidazole, peak 1, and a minor peak, at 175 mM, peak 2. The two peaks were 
pooled separately and SEC experiments conducted on each using a Superdex 200 16/60 
column. Both traces show the protein was not a homogeneous pentamer, with peaks 
possibly corresponding to a dimer, pentamer, decamer and a peak of highly aggregated 
protein. The distance between the first residue at the start of TM1, after which the lysozyme 
sequence was added, and the same residue in an adjoining subunits of the crystal structure 
of the GABAA β receptor is roughly 29 Å (Miller and Aricescu, 2014). This is comparable 
to the width of T4-lysozyme (30 Å). The presence of the T4-lysozyme at the C-terminus 
could therefore be causing steric interactions that destabilise the ability of the protein to 
form pentamers, leading to aggregation.  
3.3.2.2 Intracellular loop domain replacement with T4-lysozyme 
The replacement of an intracellular loop with T4-lysozyme has been successful in obtaining 
the crystal structures of several G-protein coupled receptors (GPCRs, Haga et al., 2012, 
Kruse et al., 2012).  The N and C terminus of T4-lysozyme are approximately 11.4 Å apart 
(Chun et al., 2012), making this an ideal candidate as a fusion protein for insertion into the 
intracellular loop domain. A potential issue could be that steric clashes between the 
lysozyme could hinder oligomerisation as predicted with the ECD-T4 lysozyme constructs. 
Two constructs, one of the HsGlyR and one of CiGlyR were made with this fusion partner 
for expression in baculovirus. No expression was observed with these constructs though 
future work could focus on changing the signal sequence in an attempt to gain the target 
protein. 
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3.3.3 Intracellular loop constructs 
Since all high resolution structures lack the TM3-TM4 loop, no structural information 
could be determined for the intracellular segment. The intracellular loop is also liable to 
degradation, making it difficult to gain suitable samples for further investigation. (Wöhri et 
al., 2012). To address this issue, several approaches were attempted in which the 
intracellular loop could be stabilised in the hope this would reduce degradation.  
3.3.3.1 Chimeric constructs of GlyR α and β subunits 
The intracellular loop of the β-subunit of HsGlyR binds the scaffold protein gephyrin 
(Kirsch et al., 1991, Kirsch and Betz, 1995). It was hypothesized that co-expression with 
gephyrin may stabilize the loop and reduce degradation. The β-subunit does not form 
homopentamers, therefore the intracellular loop was cloned into HsGlyRα1, replacing the 
native intracellular loop. Similar chimeras were made with the CiGlyR sequence and 
HsGlyR β intracellular loop and also ELIC with the HsGlyR β intracellular loop. The 
domain of gephyrin, GephE, that binds to the intracellular loop has previously been 
crystallised (Kim et al., 2006). In addition to stabilising the β-subunit TM3-TM4 loop there 
was potential that it could aid in forming crystal contacts, facilitating crystallisation of the 
complex.  
These constructs were created using a sequential PCR protocol with multiple templates 
(Shan and Lynch, 2010). The results of this process for the CiGlyR with the HsGlyR beta 
ILD is shown below in Figure 3.5. The three step PCR was successful with the final 
oligomer ligated into the pFastBac HTb vector for expression in baculovirus. This 
technique allowed for chimeric constructs to be created without requiring the insertion of 
restriction sites into the sequence and required only two to three simple subcloning steps. 
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Figure 3.5 Products from chimeric PCR of CiGlyR α-HsGlyR β ILD 
A. Product from first round of PCR. B. The band at around 1300 bp is consistent with the 
expected size of the PCR2 product. C. Final PCR product with a band at 1500 bp consistent 
with the expected size of the chimeric gene. 
 
None of these constructs showed any expression so the co-expression experiment was not 
conducted. Future work could focus on using different cell lines, signal sequences and 
possibly altering the native α1 intracellular loop to contain the gephyrin binding sequence 
found in the β-subunit. 
3.3.3.2 Shortened 5-HT3A intracellular loop domain 
A previous study of the intracellular loop from the 5-HT3A receptor had identified the 
minimum number of residues needed that would still allow for proper function (Baptista-
Hon et al., 2013). Daniel Baptista-Hon kindly provided a construct with the sequence for 
the shortened loop inserted between the TM3-TM4 helices in ELIC. This was then cloned 
into the modified pET15b-pelB-MBP vector for test expressions. It was hoped that the 
reduced loop would be less liable to degradation, and by placing it into a bacterial pLGIC, 
it could be expressed using E.coli. 
Initially four cell lines were used to test for expression, BL21 Gold (DE3), C43 (DE3), 
BL21 CodonPlus (DE3) RIL and Rosetta-gami (DE3). Of these BL21 Gold (DE3) and 
BL21 CodonPlus (DE3) RIL showed signs of expression. A western blot indicated that 
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BL21 CodonPlus (DE3) RIL gave a higher yield and was therefore used for a large-scale 
ten-litre preparation. The protein was affinity purified as with FLIC, and the fractions 
containing the protein of interest pooled and treated with TEV protease. The cleaved 
protein was then run on a superdex 200 16/60 SEC column. The trace suggested the 
receptor was not monodisperse, Figure 3.6 A.  
SDS-PAGE analysis of selected fractions show the protein was present in the broad peak 
and the shoulders either side, lanes 2-7 in Figure 3.6 B. Lanes 9 and 10 show elution of 
MBP and TEV protease respectively. Though relatively impure and not monodisperse, 
fractions under the peak were pooled, and concentrated to 10 mg ml-1 using an Amicon 
Ultra 100 kDa cut-off centrifugal filter for crystal screening. 
The yield of the protein was low with 0.5 mg of protein purified from 10 L of culture (0.05 
mg L-1). Protein concentration was estimated using a theoretical extinction coefficient of 
80120 M-1 cm-1 at 280 nm.  
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Figure 3.6 Size exclusion chromatography of ELIC - short 5-HT3A intracellular loop 
A. The pentameric protein is expected to be 225 kDa (45 kDa per subunit), a peak with 
broad shoulders elutes at a volume consistent with this size. Peaks for MBP and TEV 
protease can also be discerned. B. SDS-PAGE showing fractions from the broad peak 
contain the protein of interest, lane 2-7. Eluted MBP and TEV protease can be seen in lanes 
9 and 10.   
 
The concentrated protein was mixed with 0.5 mg ml-1 E. coli polar lipids and 5 mM 
bicuculline then filtered through a 0.1 µm PVDF centrifugal filter. Two sparse matrix 
screens for crystallisation conditions were then set up with the protein/ligand mixture. No 
crystals were seen in any of the conditions over a period of six weeks. Due to the fact the 
protein was not monodisperse, and the low yields were gained, follow up screens were not 
conducted. 
3.3.4 Construct 4  
A shortened intracellular loop from GLIC was used to replace the larger intracellular loop 
of various eukaryotic GlyRs. This strategy was used successfully with a construct of 
CeGluCl that yielded a crystal structure (Hibbs et al., 2011), and a construct of HsGlyR 
with this modification was successfully purified from P. pastoris (Wöhri et al., 2012). The 
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shortened loop allowed for the receptor to be expressed and purified without degradation 
occurring, a problem which had been linked to the intracellular loop region. A construct 
mimicking the one made in the above study and a similar one using the CiGlyR sequence 
were obtained. These constructs will be known as construct 4 (Con4), as this was the term 
given to the original construct (Wöhri et al., 2012).  
3.3.4.1 Construct 4 expression in Pichia pastoris 
HsGlyR and CiGlyR Con4 were initially tested for expression with P. pastoris strains 
GS115 and KM75. The genes were ligated into pPIC9 (Invitrogen) vector and the cells 
were transformed by electroporation. Overall, over 100 colonies from each combination of 
strain and gene were tested for expression with no success. The PichiaPink system was then 
used in order to try and better identify correctly transformed cells. Four cell lines are 
provided with this system, three protease knock out and a protease wild type. Each of these 
cell lines have a full deletion of the ADE2 gene that encodes for 
phosphoribosylaminoimadazole carboxylase, an enzyme integral in the de novo synthesis of 
purine nucleotides. The expression vector, pPinkα-HC, contains the ADE2 gene. Therefore 
correctly transformed cells will have the ability to grow on adenine lacking medium, 
whereas non-transformed cells without the vector will not. The level of expression of 
ADE2 and consequently the gene of interest can then be monitored by the colour of the 
cells growing on the plate. Low level transcription of the ADE2 gene results in the 
accumulation of purine precursors in the vacuole giving the colony a red appearance. This 
pigmentation phenotype can then be used as a means of selecting colonies that should be 
capable of expressing the protein of interest (Zonneveld and van der Zanden, 1995). 
Colonies that appear white should be expressing ADE2 and therefore the gene of interest at 
a reasonable level and these were then selected for test expressions. 
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After several attempts and despite testing over 50 white colonies, no expression of CiGlyR 
Con4 was identified. Better results were gained with HsGlyR Con4. A single colony from 
strain 2 of PichiaPink (pep4 knockout) that gave expression was identified after screening 
60 white colonies. This was then restreaked on PAD plates and glycerol stocks made.  
To ensure the target protein was membrane bound, which would suggest correctly folded 
protein had been produced, a one litre expression was conducted and membranes isolated. 
SDS-PAGE and a subsequent western blot showed that the protein was membrane bound.  
3.3.4.1.1 Solubility screening 
During initial attempts to extract HsGlyR Con4 from the membrane it was apparent that a 
large proportion of receptor had not been solubilized. A solubility screen was therefore 
conducted to determine an effective detergent for solubilisation.  
A one litre culture of Pichia were grown, cells harvested and lysed as usual. After 
homogenization, 200 µL was aliquoted into tubes with 200 µL of various detergents. In all, 
ten different detergents were tested. After incubation for 2 hours at 4°C, the samples were 
centrifuged at 150000 g for 45 mins at 4°C. Samples of the supernatant and the pellet were 
then analysed by SDS-PAGE and western blots. DDM and n-dodecylphosphocholine 
(FOS-12) were deemed to give the highest level of solubilisation, both to similar levels. 
Despite this a large quantity of the desired protein still remained in the insoluble pellet.  
3.3.4.1.2 Purification of HsGlyR Con4  
Two litres of culture were then grown and attempts made to follow a published purification 
protocol (Wöhri et al., 2012). An affinity step using the batch method and Ni-NTA resin 
was used for a first step purification. After incubation with the solubilized membranes, the 
resin was washed with buffer containing 20 mM imidazole, followed by elution of the 
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bound protein with buffer containing 300 mM imidazole. No protein was observed in the 
eluent. The protein was found to have precipitated possibly due to the high ionic strength of 
the imidazole used for elution.   
To avoid precipitation, the first step of purification for subsequent preparations was 
performed with the aminostrychnine column. GlyRs bind strychnine with high affinity, 
therefore using this affinity column would hopefully yield a protein that was highly pure.  
Solubilised material from one litre of culture was cycled over the aminostrychnine column 
for twelve hours. Unbound protein was washed off the column with ten column volumes 
(CV) of the equilibration buffer. HsGlyR Con4 was then eluted by cycling 1.5 CVs of 
equilibration buffer with 250 mM glycine over the column for 4 hours, followed by 
washing with a final CV of the same buffer. The eluent was then concentrated for SDS-
PAGE analysis. A band can be seen on the gel with a molecular mass of around 40 kDa 
consistent with the size of a single subunit, 42 kDa. To confirm this was HsGlyR Con4, an 
anti His-tag western was performed. The band seen on the gel was also visible on the 
western blot confirming the presence of the receptor, as shown in Figure 3.7. 
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Figure 3.7 SDS-PAGE and western blot of 
HsGlyR Con4 
Lane 1 is the flow through from the 
aminostrychnine column. Lane 2 is the eluent. 
Lane 3 is the protein standard. Lane 4 and 5 
show the western blot of lanes 2 and 3 
respectively. A band at around 40 kDa (boxed) 
is clearly visible in lane 2 and the western blot 
indicates the protein is HsGlyR Con4. The 
marker proteins at 75 kDa and above are His-
tagged and therefore are visible in the western 
blot. No bands were seen in the western blot for 
lane 1 suggesting the column efficiently binds 
the receptor.  
 
 
 
The yield of the protein was measured using the theoretical extinction coefficient of 62715 
M-1 cm-1 at 280 nm predicted using PROTPARAM. The yield from this experiment was 
roughly 0.05 mg L-1, much lower than the 5 mg L-1 reported previously (Wöhri et al., 2012) 
The oligomeric state of the Con4 was analysed using native-PAGE. A pentamer of HsGlyR 
Con4 would be expected to be 210 kDa in size, though the apparent mass reported using 
native-PAGE previously was much higher at 380 kDa (Wöhri et al., 2012). A band with a 
mass of 242 kDa is visible on the native gel shown within the red box in Figure 3.8. A band 
at around 380 kDa (black box) is also visible. This higher band is consistent with that 
previously reported and the lower band may be contamination or the receptor with a 
different composition of bound lipid/detergent and dye (Wittig et al., 2010) 
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Figure 3.8 Native PAGE analysis of HsGlyR Con4. 
The protein standard is shown in lane 1 with the sample of 
HsGlyR Con4 in lane 2. A band is seen in line with the 242 
kDa standard, red box. This is close to the expected weight of 
a pentamer (210kDa), though the band above at approximately 
380 kDa, in the black box, is consistent with a previous report.  
 
 
 
 
 
3.3.4.2 Expression of HsGlyR Con4 in baculovirus 
Effective lysis of P. pastoris took several cycles through the pressure cell homogenizer. 
This subjected the cells to heat that may have affected the protein. Solubilisation of the 
protein was also not efficient. This led to attempts to express HsGlyR Con4 in baculovirus. 
Previous attempts to express pLGICs in this system using native signal sequences were 
unsuccessful and so the gene encoding HsGlyR Con4 was ligated into a modified pFastBac 
HTb vector containing the sequence encoding the honeybee melittin signal sequence. Such 
a strategy has previously been successful in production of human-tissue plasminogen 
activator (Tessier et al., 1991). Test expressions confirmed the target protein was produced, 
and was membrane bound. Solubilisation of the protein was conducted with DDM, though 
this proved to be ineffective, with most of the protein remaining in the pellet after 
centrifugation.  
The detergent n-tetradecyl phosphocholine (FOS-14) was tested in comparison to DDM to 
see if this would be more effective at solubilisation. Equal amounts of homogenised 
membranes were solubilised with either 1.5% DDM or 1% FOS-14. This was conducted at 
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4°C for 12 hours. After centrifugation to remove insoluble material, samples of the 
supernatant and pellet were analysed by SDS-PAGE and western blots, as shown in Figure 
3.9. From the proportion of protein left in the insoluble pellet compared with the 
supernatant it is clear that FOS-14 solubilises HsGlyR Con4 more efficiently than DDM. 
For DDM the majority of the protein is in the insoluble fraction, whereas for FOS-14 only a 
small amount of the protein is visible in the insoluble fraction, shown in the black box 
Figure 3.9. The soluble fraction on the other hand has a large bands relating to the protein 
of interest, the red box in Figure 3.9. Future purification of this construct from Sf9 cells 
should therefore use FOS-14 for extraction of the receptor from isolated membranes. Two 
bands are present in the western blot in Figure 3.9. This is also seen when using P. pastoris 
to express HsGlyR Con4, though the second band is not present after affinity purification 
with the aminostychnine column. This second band may be a degradation product incapable 
of binding to the affinity resin.  
 
Figure 3.9 SDS-PAGE and western blot of solubilisation trials for HsGlyR Con4. 
Lanes 4 and 9 are the protein standards. Lanes 1 and 2 are the pellet and supernatant from 
solubilizing HsGlyR Con4 using DDM, with lanes 6 and 7 showing the western blot from 
these lanes. Lanes 3 and 5 are pellet and supernatant from solubilizing HsGlyR Con4 using 
FOS-14 with 8 and 10 being the western blot.  The black box shows the protein of interest 
left in the pellet, with the red box the protein seen in the supernatant showing the majority 
of the protein had been solubilized using FOS-14.   
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Due to time restrictions it was not possible to adequately compare yields of HsGlyR Con4 
expressed in P. pastoris and baculovirus. Both systems have their advantages but the fact 
that a high level of extraction was seen from the membrane of Sf9 cells may mean the 
overall yield could be higher. Lysis of Sf9 cells and isolation of the membrane is also more 
efficient compared to P. pastoris. 
3.3.4.3 Electrophysiology of HsGlyR Con4 in Sf9 cells 
Sf9 cells expressing HsGlyR Con4 were used in electrophysiology experiments to 
determine if they were functional. Infected cells were used 72 hours after infection with 
virus. The results show that the receptors are still functional, giving a maximal response at 
1 mM glycine, Figure 3.10 A. At 0.1 mM the response was around half maximal, similar to 
published data on wild type HsGlyR α1 (Jensen and Kristiansen, 2004). Uninfected cells 
were used as a control to ensure the glycine response was not from an endogenous receptor 
in Sf9 cells (Figure 3.10 A insert). The currents show rapid desensitization, not consistent 
with wild type receptors. This is unsurprising as the TM3-TM4 loop contains 
phosphorylation sites that are linked to desensitization kinetics in pLGICs (Gentet and 
Clements, 2002). Truncations of this loop domain have also shown to effect desensitization 
in 5-HT3A receptors (Baptista-Hon et al., 2013).  
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Figure 3.10 Electrophysiological studies of HsGlyR Con4 expressed in Sf9 cells. 
 A. Recordings at 0.1 mM, 1 mM and 10 mM glycine. A maximal response was seen at 
around 1 mM glycine. The insert shows uninfected cells gave no response to 1 mM glycine. 
B and C. The current-voltage relationship showing a linear response, consistent with 
previous work performed on HsGlyR. 
 
Using peak amplitudes of 1 mM glycine evoked currents at various holding potentials 
(Figure 3.10 B), the current-voltage relationship was found to be linear, with the current 
reversing from inward to outward currents between -40 and -20 mV, Figure 3.10 C. Again 
this is consistent with previous laboratory work on WT GlyR α1 receptors.  
3.4 Discussion 
The creation of a homology model of HsGlyR was invaluable for giving information on 
which residues form the different domains and which residues are potentially important in 
ligand binding and gating of the ion channel. With better templates available, modeling can 
produce homology models that reveal information to a similar degree as gaining a low-
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resolution structure, and though side chain positioning is difficult to determine the 
positioning of residues and their environment can be inferred (Xaing, 2008). Little 
information on the structure of eukaryotic receptors was available at the time of creation of 
the homology model, but subsequent publication of the human GABAA β3 receptor and the 
mouse 5-HT3A receptor structures show good agreement on conserved residue positioning 
(Miller and Aricescu, 2014; Hassaine et al., 2014). 
Recombinant production and purification of membrane proteins is notoriously difficult and 
this has been reflected in the challenges faced trying to gain a supply of GlyR or GlyR 
homologues. Many constructs did not produce the protein at an observable level, or formed 
insoluble aggregates from which correctly folded material could not be recovered.  
Of those constructs that did express, one of the major issues was with gaining a 
monodisperse sample. As with FLIC, ELIC with a shortened 5-HT3A loop and the GlyR 
ECD – T4 lysozyme constructs, SEC revealed that a range of oligomers and aggregates and 
potential degradation products are present. This is a major hindrance when trying to gain 
protein for crystallisation, which requires a homogeneous sample.  Future work for these 
constructs could focus on use of better fusion partners or various chimeric complexes that 
would help stabilize the receptor. A number of fusion partners of various sizes and 
morphologies have been reported, some of which may be used to create these new 
constructs that may not cause steric interactions, allowing for correct oligomerisation of the 
receptor (Chun et al., 2012).   
Success was gained in expression of HsGlyR Con4 construct in two eukaryotic expression 
systems, Pichia pastoris and baculovirus. The use of eukaryotic systems may be important 
as glycosylation appears to be a critical process in oligomerisation and folding (Griffon et 
al., 1999).  
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The use of the aminostrychnine column also aided greatly in purification. Affinity 
purification using the His-tag and Ni-NTA resin resulted in either no protein binding to the 
resin or precipitation. The inability to replicate the purification protocol described by Wöhri 
et al, could be due to many factors such as differences in the standards of reagents and 
equipment used. Despite this, using an aminostrychnine column as the first step in 
purification appears to be a more useful option, resulting in reasonably pure protein that 
could be further purified by SEC.  
Increasing the yields of HsGlyR Con4 would be imperative for future studies. This could be 
achieved by optimization of buffers and protocols for purification. Using different cell lines 
could also improve yield. Glycosylation in P. pastoris and Sf9 is distinct from that seen in 
mammalian cells, with differences in composition and extent of glycosylation (Macauley-
Patrick et al., 2005. Trometer and Falson., 2010). In P. pastoris initial glycosylation in the 
endoplasmic reticulum is identical to that of mammalian cells, though once transferred to 
the Golgi the pathways diverge and in P. pastoris the end result is hyper-mannosylated 
glycans. Modified cell lines of P. pastoris have been produced that are capable of 
producing sialated glycans as found in mammalian cells (Hamilton and Gerngross, 2007). 
 Strains of insect cells such as the Mimic Sf9 strain (Invitrogen), which expresses various 
glycosyltransferases, could also be used in future work to try and gain a protein with more 
mammalian like glycosylation. This may improve the yield and stability of the GlyR gained.   
This construct could also be used for future screening experiments. The insertion of the 
biotin acceptor peptide sequence into the intracellular loop region as done with ELIC could 
lead to GlyR being used for BLI studies and the potential discovery of compounds that 
modulate the function of these receptors. 
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One of the advantages of expressing HsGlyR Con4 in baculovirus was that the functionality 
of the receptor could be monitored by electrophysiology. These receptors were gated by 
glycine, though the rate of desensitization was increased compared to the wild type receptor. 
Previous studies had focused on binding studies with the purified protein, showing that the 
receptor could still bind strychnine (Wöhri et al., 2012). That the receptor is still capable of 
gating may mean that structural information that could be garnered from this construct 
would yield important insights into mechanisms of gating and ligand binding. The increase 
in rate of desensitization seen with HsGlyR Con4 may be due to the deletion of the 
intracellular loop. Phosphorylation has been shown to influence gating kinetics (Gentet and 
Clements, 2002), and as there are phosphorylation sites on the intracellular loop region of 
HsGlyR α1, it is not surprising deletion of this region alters desensitization kinetics. This 
highlights the need to gain more information on the intracellular loop region of pLGICs, 
and creation of constructs that stabilize this region to allow for structural studies.  
This work lays the foundation for future structural and ligand binding studies of HsGlyR 
Con4. The insertion of a BAP tag in the TM3-TM4 loop of HsGlyR Con4 could yield 
stable protein that could then be used for screening. The purified receptor can also be used 
for production of antibodies that could then be used to aid in crystallisation, a technique 
used to gain the structures of CeGluCl and mouse 5-HT3A receptors. 
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4 Development of BLI ligand screening for a membrane 
solubilised pLGIC  
4.1 Synopsis 
Ion channels are important therapeutic targets, though discovery of novel modulators by 
high throughput screening of pLGICs has traditionally been difficult to perform (Clare, 
2010). Electrophysiology is one of the most common ways of testing how compounds 
modulate receptor function. This technique has the advantage of providing a large signal to 
noise ratio, real time data acquisition and data that are rich in biophysical information. 
However conventional electrophysiology requires relatively large amounts of compound 
and is labour intensive. High throughput electrophysiology has been developed though this 
requires highly specialized and expensive equipment.  
In order to discover new chemical modulators of pLGICs an assay was developed that used 
BLI to identify hits. This technique has the advantage of only needing small quantities of 
material and can be used to screen large compound libraries. As purification of mammalian 
GlyR had proven difficult, the bacterial pLGIC, ELIC, was used as a surrogate and for 
protocol development. To date, there are no published data on BLI being used to screen 
membrane proteins for small molecule binding. Subsequent validation of hits was 
performed with conventional patch-clamp electrophysiology and attempts were made to 
crystallise protein/ligand complexes. 
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4.2 Construct design and expression 
Screening of small molecules with BLI requires immobilization of protein onto biosensors. 
Super streptavidin (SSA) biosensors (FortéBio) were used in screening experiments with 
ELIC.  These sensors have a high density of streptavidin sites and have been developed for 
fragment and small molecule screening. The streptavidin sensors immobilize the protein of 
interest by binding to biotin. Two possible methods of protein biotinylation are possible, 
either chemical or enzymatic. Chemical biotinylation results in surface lysine residues 
being biotinylated. This can lead to the protein binding in various alignments to the 
streptavidin sensor if there are a number of surface lysine residues. 
For a uniform binding alignment of the protein to the biosensors, enzymatic biotinylation 
was conducted. For this a biotin acceptor peptide (BAP) sequence was incorporated into the 
TM3-TM4 intracellular loop domain of ELIC. This construct (ELIC-BAP) was ligated into 
a modified pET15b vector with a pelB signal sequence, an N-terminal MBP and a TEV 
protease site to allow cleavage of the fusion protein. The construct was expressed using E. 
coli C43 (DE3) cells and biotinylation was conducted in vivo by co-expression of the biotin 
ligase, BirA. The protein was purified by affinity chromatography followed by cleavage of 
the MBP fusion protein. To ensure the insertion of the BAP sequence had no effect on the 
ability of the receptor to form pentamers, the affinity-purified protein was analysed with 
SEC. No difference was seen between SEC traces for wild type and BAP tagged protein 
suggesting the insertion of the BAP sequence does not affect the oligomerisation of ELIC, 
Figure 4.1. Biotinylation was monitored by western blots using an anti-biotin antibody, 
which confirmed the receptor had been biotinylated.  
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Figure 4.1 SEC trace from purification of ELIC-BAP. 
The absorbance at 280 nm (mAU) plotted against volume (ml) and SDS-PAGE of resultant 
peaks. A peak can be seen at volume of elution expected for a protein of 200 kDa, 
consistent with pentameric ELIC-BAP. The peaks at 45 kDa and 25 kDa correspond to 
MBP and TEV protease. Lane 1 is the protein standards, lane 2,3 and 4 are from fractions 
11, 12, 13 respectively. Lanes 5 and 6 are fractions 15 and 17. The bands in the box are the 
protein of interest. 
 
4.3 Screening 
4.3.1 Assay Development 
As BLI had not been used on this type of target before, initial development focused on 
ligands known to bind ELIC. For this purpose a range of compounds were assembled to test 
if this technique was applicable to these targets, and how sensitive the technology was.  
GABA and cysteamine are known agonists of ELIC (EC50 – 2.4 mM and 365 µM 
respectively), with acetylcholine a competitive antagonist (EC50 - 0.55 mM, Spurny et al., 
2012, Zimmerman and Dutzler., 2011, Pan et al., 2012). These compounds are relatively 
small, being 103 Da, 77 Da and 146 Da respectively. None of these compounds gave a 
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response against ELIC, with the highest concentration of 10 mM tested. The size of ELIC 
relative to these compounds, along with the distance from the sensor tip to the binding site 
may limit what can be detected.  
Larger ligands were then tested to see if their binding to ELIC was detectable using BLI. 
Three such ligands, flurazepam (387 Da), bicuculline (367 Da) and flumazenil (303 kDa) 
were used. Flurazepam and bicuculline have been shown to modulate ELIC activity, with 
flurazepam having a biphasic effect similar to that seen with GABAA receptors and 
bicuculline potentiating ELIC responses, similar to the effects seen with the compound 
against homomeric β3 GABAA (Spurny et al., 2012). The effects of flumazenil on ELIC 
have not been recorded, but as it binds to the benzodiazepine recognition site of GABAA 
receptors, it was thought it might also bind to ELIC.  
Five concentrations of each of these compounds were tested with the maximum 
concentration being 1 mM. The compounds were then serially diluted to gain 333 µM, 111 
µM, 37 µM and 12 µM. Data from the control sensor was subtracted from the ELIC sensor 
data to remove optical interference from the compounds. Curves were fitted using the 
ForteBio Data Analysis 7.0 program. The experimental data were fitted with binding 
equations for 1:1 interactions. This produces a dissociation constant, KD, based on the ratio 
of the association and dissociation rate constants, ka and kd, as shown in the equation below, 
where [A] and [B] are protein and ligand concentration and [AB] is the protein-ligand 
complex. 𝐾!   = ! ∙[!][!"] = !!!! (ka = M-1s-1   kd = s-1) 
The resultant traces produced for these compounds are shown in Figure 4.2. The KD 
calculated for each compound was: bicuculline – 0.67 mM, flumazenil – 0.49 mM and 
 Chapter 4 - Development of BLI ligand screening for a membrane solubilized pLGIC 
87 
flurazepam – 2.3 mM. Each compound produces traces that show fast on-off rates typically 
seen when screening compounds with this technology (Wartchow et al., 2011). Bicuculline 
and flumazenil both show curved steady state graphs, though they do not reach saturation. 
Flurazepam gives a somewhat more linear plot and the reference sensors for this drug also 
gave a large response. This may be due to interactions of the compound with the biosensor. 
On the basis of these results, bicuculline and flumazenil were identified as potential 
positive controls for use during the screening of compound libraries and, on the basis of 
availability, bicuculline was used for this purpose. 
 
Figure 4.2 BLI traces of compounds thought to bind to ELIC. 
The structures and BLI traces of A. bicuculline, B. flumazenil, and C. flurazepam. The 
traces show optical shift (nm) on the y axis against time (sec) on the x axis. The first 120 
seconds correspond to the association step followed by 120 seconds dissociation. On the 
right are the corresponding steady state graphs for each compound.  
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4.3.2 Ion channel compound library set screening 
The strategy for screening the 3241 compounds of the ion channel compound library was to 
initially screen ELIC with compounds at a concentration of 10 µM. Any primary hits were 
then rescreened with a six point concentration series of the compound. The primary screen 
was set up using 384 well plates. The final wells to be analysed in each plate contained the 
positive control, bicuculline, to monitor if the sensor and protein were still active. Generally 
new sensors and protein were used after every 4-5 plates to ensure the protein was in good 
condition. Double subtraction of reference sensor data to correct for optical interference of 
the compounds and buffer analysis for baseline drift corrections were conducted and hits 
ranked by response. The top 100 compounds were then clustered according to chemical 
similarity using MolSoft (MolSoft LLC). This calculates a distance matrix of the chemical 
fingerprint and makes a hierarchical tree of chemically similar compounds. From groups of 
chemically similar compounds, the one that gave the highest response with BLI was taken 
for secondary screening. A total of 56 compounds were identified in this way.  
Each compound was plated out with a maximum concentration of 50 µM and then 1 in 3 
serial dilutions conducted to produce a concentration range of 50, 16.66, 5.55, 1.85, 0.62 
and 0.21 µM. The resultant traces were then grouped by compound identity, data processed 
as before, with double subtraction and then curves fitted to establish the equilibrium 
dissociation constant (KD). Steady state kinetic analyses were then conducted to calculate 
the KD from the estimated response at equilibrium rather than ka and kd values. This is 
calculated by plotting analyte concentration against response at equilibrium, Req. The 
concentration of compound at 50% of the maximal response, Rmax, equates to the KD.  
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A variety of different trace profiles were seen with the secondary screen compounds. Two 
of the initial hits were false positives, giving no signal at any of the concentrations tried. 
The profiles were then examined for atypical binding characteristics such as a linear 
relationship between concentration and response, unreasonably high signals relative to 
positive control, incomplete dissociation during the experimental time period and biphasic 
binding profiles. Responses greater than three times that seen for the positive controls were 
deemed too high to be true binding responses, therefore anything above 0.45 nm was 
discounted (Wartchow et al., 2011). The high signals and those with linear relationship of 
signal to concentration could be caused by colloidal aggregates binding non-specifically 
(Coan and Shiochet 2008). Examples of an atypical binding profile and promising hits are 
shown in Figure 4.3.  
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Figure 4.3 Result of ELIC secondary screen against the ion channel compound library. 
A. An example of a trace deemed as not representing a true binding event. The signal at the 
top concentration is near the cut off of 0.45 nm and the correlation between concentration 
and response is linear as shown in B. C and D show the trace for DDD00104826 and its 
steady state graph. E and F are for DDD00106009. G and H are for DDD00105795. These 
three compounds were taken on for further testing. 
 
The hit rate was calculated by giving the number of compounds after each stage as a 
percentage of the total number of compounds in the screen. The initial hit rate from the 
primary screen was 3.1%, which was cut down to 1.7% after compound clustering. The 
secondary screen revealed a number of false positives and compounds that resulted in 
atypical binding, bringing down the final hit rate to 0.8%. A list of the compounds that 
made up this 0.8% is given in Appendix A. The best compounds were judged by the 
apparent KD, the appearance of the curves, whether they reached a saturating response and 
how well the curves were fitted. Three compounds, DDD00106009, DDD00104826 and 
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DDD00105795, were chosen for electrophysiological studies to validate the hits. 
DDD00106009 and DDD00105795 were both commercially available. DDD00104826 was 
not, though a close analogue was purchased instead. The structure of these compounds and 
the apparent KD values from BLI are shown in Figure 4.4.  
The steady state derived KD value for each compound correlates well with KD values 
calculated from the on and off rates. The goodness of curve fitting was measured by Full X2 
and Full R2, with each compound giving reasonable figures. An overview of these figures is 
given in Table 4.1. 
Table 4.1 BLI derived statistics for three compounds selected for further validation. 
Compound KD1 (µM) Full X2 Full R2 
Steady state 
KD (µM) 
DDD00106009 0.8 0.034 0.805 0.8 
DDD00105795 14.2 0.041 0.874 14.0 
DDD00104826 1.1 0.058 0.888 0.7 
1. KD calculated from the ratio of kd and ka value. 
Full X2 - Sum of the squared deviations, deviations being the difference between actual data             
point and the fitted curve. Values close to 0 indicate a good curve fit. 
Full R2 – Coefficient of determination. A value close to 1.0 indicates a good fit for the curve. 
 
The clustered hits from the primary screen were inspected to see if there were any 
analogues of the three compounds chosen for validation. An analogue of DDD00104826, 
DDD00104966, had been clustered with this compound and had been left out of the 
secondary screen. During the primary screen DDD00104966 had been screened at two 
concentrations of 50 µM and 10 µM. The KD values calculated at these concentrations were 
2.3 µM and 1.22 µM respectively. These correlate well with the KD for DDD00104826, 
suggesting they have a similar affinity and suggesting that BLI is detecting true binding 
events. The structure of this compound is also shown in Figure 4.4. DDD00104966 was 
also not commercially available at the time of experimentation.  
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Figure 4.4 Compounds selected from BLI screen for validation of the technique. 
The structure and KD of compounds identified from the screen of ELIC against the ion 
channel compound library. The compound DDD00104826 was not available commercially 
and so an analogue was purchased with a methyl group in the para-position of the benzene 
moiety adjacent to the amide.  
 
4.3.3 Electrophysiology 
4.3.3.1 ELIC electrophysiology 
In order to discover whether the compounds identified above were capable of modulating 
ELIC function, whole cell electrophysiological recordings from HEK-293 cells, transfected 
with cDNA encoding for ELIC, were performed. A GABA concentration-response 
relationship experiment against ELIC was conducted yielding an EC50 of approximately 10 
mM Figure 4.5. As the compounds tested could be acting at the orthosteric site, partial 
occupancy of the receptor by GABA would be required for the compound to bind and have 
an effect, therefore a sub-EC50  concentration of GABA was used (5 mM).   
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Figure 4.5 GABA concentration-response relationship against ELIC and the effects of 
flurazepam. 
A. Concentration dependent GABA induced currents recorded from a HEK-293 cell 
expressing ELIC. B. Plot of GABA-induced currents expressed as a percentage of response 
at 100 mM GABA. The EC50 of GABA was found to be 13.7 ± 2.9 mM (n=5). C. The 
effects of two concentrations of flurazepam on GABA evoked currents. On the left 30 µM 
flurazepam has no effect on GABA evoked currents. On the right 400 µM shows complete 
inhibition of GABA evoked currents. Flurazepam experiments were conducted by stepping 
from control solution into 5 mM GABA then back to control solution. The cell was then 
stepped into 5 mM GABA plus drug to record the difference in current. 
 
Flurazepam was used initially to investigate how this drug modulated ELIC response to 
GABA. Flurazepam at 400 µM showed complete inhibition of GABA evoked currents. A 
lower concentration of 30 µM was found to have no significant effect on ELIC responses. 
This is at odds with previous work performed using Xenopus oocytes expressing ELIC in 
which flurazepam had a biphasic effect, potentiating GABA currents at low concentrations 
(EC50 – 12.5 µM) and inhibiting at concentrations above 50 µM (Spurny et al., 2012). To 
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investigate if a biphasic response could be replicated, experiments with 100 µM and 3 µM 
flurazepam were conducted. At 100 µM, flurazepam was found to inhibit the ELIC 
response to GABA with 42.9 ± 3.73% (n = 7) of control activity. No potentiation of 
response was seen at the lower concentrations of flurazepam. The inhibition of ELIC 
currents by high concentrations of flurazepam was not voltage dependent. When switching 
between holding potentials of -60 mV and 60 mV, both inward current and outward 
currents were equally inhibited, suggesting the site of action may lie outside of the electric 
field. Further experiments will be required to determine whether the inhibition is caused by 
competitive antagonism. 
The compounds chosen for validation of BLI were tested. ELIC mediated responses were 
evoked with 5 mM GABA to gain baseline currents. The cell was then exposed to 5 mM 
GABA and an initial concentration of 10 µM for each compound. Both DDD00106009 and 
DDD00105795 had no effect on the GABA evoked currents. The same experiment was 
repeated with these compounds at 100 µM. Again no modulation of the current was 
observed.  
Currents evoked by GABA in the presence of the DDD00104826 analogue (10 µM) were 
163 ± 6.2% (n=6) of control. Conversely at 30 µM GABA evoked currents were 82.3% 
(n=2) of control. This apparent biphasic response is similar to that reported with flurazepam 
by Spurny et al. 2012. At 1 µM and 0.1 µM of the compound, no change in response was 
observed. Figure 4.6 A and B show the response traces for both 10 and 30 µM 
DDD00104826 analogue against GABA induced currents. To test whether the compound 
had any agonistic effects, the compound alone (10 µM) was tested but no current was 
observed, Figure 4.6 C. 
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Figure 4.6 The DDD00104826 analogue biphasically modulates GABA-induced 
currents. 
A. At 10 µM the compound causes a potentiation of the inward current. B. 30 µM of the 
compound causes inhibition of the GABA induced current. The timing of GABA 
application is indicated by the black bar. Compound application is designated by the dashed 
red line. C. The compound had no effect as an agonist.  
 
4.3.3.2 GABAA electrophysiology 
As ELIC is gated by GABA the compound was then tested against two different GABAA 
receptors to see if a similar effect could be observed. The human GABAA α1β3 and α1β3γ2 
receptors were tested to determine if the compound exhibits any subunit specificity. While 
α and β subunits combine in heteropentamers to produce GABAA receptors, 
benzodiazepines require the presence of a γ2 subunit for their characteristic positive 
allosteric modulation of GABA-evoked currents (Pritchett et al., 1989). 
Experiments on GABAA α1β3 receptors were conducted in the same way as with ELIC. A 
sub-EC50 concentration of GABA (10 µM) was used along with 10 and 30 µM of the 
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DDD00104826 analogue. Unlike with ELIC no biphasic response was observed, with both 
concentrations showing inhibition. At 10 µM the compound showed a percentage inhibition 
of 15.7 ± 1.2% (n=3), with 30 µM giving 34.8 ± 1.72% (n = 3).  
To determine if the γ2 subunit is important for modulatory effects of the compound, 
experiments were conducted with α1β3γ2 receptors. Using 10 µM of the GABA and 30 µM 
of the compound a % inhibition of 20.5 ± 2.26% (n = 3) was observed for α1β3γ2 receptors, 
Figure 4.7. The reduced inhibition could be due to the inclusion of the γ subunit, decreasing 
the number of binding sites between α and β subunits. Alternatively there may be combined 
positive and negative allosteric interactions. 
 
Figure 4.7 Inhibition of GABA induced currents with DDD00104826-analogue against 
α1β3 and α1β3γ2 GABAA receptors. 
A. GABA induced currents in α1β3 GABAA receptors inhibited by the 30 µM of the 
compound. B. GABA induced currents in α1β3γ2 GABAA receptors inhibited by the 30 µM 
of the compound. C. The compound appears to be more potent against α1β3 receptors than 
α1β3γ2 receptors. Data are mean ± SEM, n=3-5.  P < 0.05. 
 
To determine whether inhibition by the compound is voltage dependent, recordings of α1β3 
expressing HEK-293 cells were performed where the holding potential was changed from -
60 mV to 60 mV. The inhibition of the inward current at -60 mV was the same as that seen 
for the outward current at 60 mV and therefore the compound does not act in a voltage-
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dependent manner (data not shown). This is consistent with the compound not causing 
voltage dependent open channel block.  
In addition to its competitive antagonism activity at the GABAA receptor, bicuculline can 
act in the absence of an agonist as an inverse agonist (McCartney et al., 2007). To test 
whether the DDD00104826 analogue acts as an inverse agonist, an experiment was 
conducted wherein a cell expressing GABAA α1β3 receptors was stepped into a solution 
containing 10 µM of the DDD00104826 analogue, then into 10 µM compound plus 1 µM 
GABA. The resultant trace showed that the compound alone did not cause a change in 
holding current, but when stepped into a GABA containing solution a current was recorded.  
The apparent lack of effect when applied alone suggests that the compound does not have 
direct actions on the receptor in the absence of agonist. However, additional experiments 
will be required to determine the nature of the antagonism, not least to establish whether the 
inhibition is competitive or occurs through a site outside the orthosteric agonist binding site. 
4.3.3.3 GlyR electrophysiology 
In order to determine if the DDD00104826 analogue could modulate the function of other 
pLGICs, recordings were made from HEK-293 cells expressing GlyR α1 homomeric 
receptors. Experiments were conducted in the same way as with GABAA receptors, using 
100 µM glycine and three concentrations of the compound. At 10 and 30 µM no change in 
glycine-evoked current was seen. Likewise 100 µM had a negligible effect on response 
(94.9 ± 1.7% of control (n = 3)) as seen in Figure 4.8. This suggests that the compound is 
somewhat selective for GABAA receptors. 
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Figure 4.8 Effect of the DDD00104826 
analogue on GlyR α1 homomeric receptors. 
Recording of a HEK-293 cell expressing GlyR α1 
receptors. 100 µM glycine was used and addition 
of 100 µM of the compound had little effect. 
 
 
 
4.4 Crystallisation and low resolution structure of ELIC 
In order to investigate how the compounds identified from the screen might interact with 
ELIC, attempts were made to gain crystal structures of the receptor with the ligands present. 
Wild type ELIC was expressed with an N-terminal MBP fusion protein as with ELIC-BAP. 
After affinity chromatography the MBP was cleaved with TEV protease and the receptor 
further purified by SEC. The protein eluted in a symmetrical peak at a volume consistent 
with a pentamer and this oligomeric state was confirmed by native gel analysis, Figure 3.4. 
A typical preparation yielded 0.5-0.8 mg L-1 of pure protein.  
Purified protein was concentrated to 10 mg ml-1 and 0.5 mg ml-1 E. coli polar lipids added. 
Screening to identify crystallisation conditions was conducted with apo-protein or in the 
presence of 5 mM bicuculline. Commercial screens, PEG, MPD suite (Qiagen) and JCSG+ 
suite (Molecular Dimensions) were set up as described in Chapter 2. Multiple conditions 
from each plate produced crystals with similar morphologies, though none of these were of 
diffraction quality Figure 4.9 A-D. Optimization of these conditions was then conducted 
using the hanging drop technique. Ten conditions from the initial screening were taken for 
optimization. As well as changing reservoir conditions, several ligands were tested. 
Bicuculline, flumazenil, DDD00106009, DDD00105795 and the analogue of 
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DDD00104826 were all used in optimization trials. Crystallisation was conducted at 4°C 
and room temperature. Parallel to these studies, attempts were made to replicate conditions 
that had yielded diffracting crystals (Hilf and Dutzler, 2008, Pan et al., 2012).  
From these optimization plates over 250 crystals were tested for diffraction in-house and at 
the ESRF and Diamond synchrotrons. The conditions that gave the best diffracting crystals 
were from reservoir solutions containing 0.2-0.3 M potassium citrate, 20-35% PEG 3350 
and 0.15-0.25 M sodium citrate, 25-35% PEG 3350, mixed in a one to one ratio (0.75 
µL:0.75 µL) with the protein, an example is shown in Figure 4.9 E. These were all from 
hanging drop crystallisation plates utilizing vapour diffusion at 20°C, with crystals 
typically developing over 24-48 hours. Crystals from these conditions were cryoprotected 
with mother liquor adjusted to contain 30% glycerol prior to freezing in liquid nitrogen. 
The highest resolution achieved was 4 Å from a crystal grown in conditions containing a 
one to one mix of protein with 5 mM bicuculline and 0.25 M potassium citrate, 30 % PEG 
3350. These were long (~0.5 mm) flat needle-like crystals. The conditions used to replicate 
previous studies did yield crystals but these diffracted to only 10 Å. 
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Figure 4.9 Crystals of ELIC. 
A-D - Examples of crystals produced through initial screening. E – Optimised crystals 
formed in sodium citrate and PEG 3350 with bicuculline present. F, Crystals of ELIC in the 
presence of the DDD00104826-analogue that formed in an additive screen condition. 
 
In an attempt to gain crystals that diffracted to a higher resolution, an additive screen 
(Hampton) was conducted using the potassium citrate, PEG 3350 optimised conditions. 
Although crystals grew in the various additive conditions, including those containing the 
DDD00104826 analogue (Figure 4.9 F), no improvement in diffraction was noted. 
A data set was collected with the crystal that diffracted to 4 Å. An image of the 
crystallisation drop from which the crystal was harvested and an example of the diffraction 
pattern is shown in Figure 4.10. Two pentamers of ELIC were present in the asymmetric 
unit with each subunit having 309 residues modelled. Several of the previously solved 
structures in the PDB have the same space group and similar unit cell dimensions though 
where crystallised in different conditions (Hilf and Dutzler 2008, Pan et al., 2012, Spurny 
et al., 2012). The data collection and model refinement statistics are shown in Table 4.2. 
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Table 4.2 Crystallographic statistics 
Data collection  
Beamline Diamond I03 
Wavelength 0.976 Å 
Space group P21 
Cell dimensions  
a, b, c (Å) 103.09, 267.35, 109.05 
α, β, γ (°) 90.0, 112.82, 90.0 
Resolution (Å) 100.35-4.00 (4.22-4.00) 
No. reflections recorded 91771 (13822) 
Unique reflections 41825 (6086) 
Completeness (%) 91.4 (91.6) 
Multiplicity 2.2 
<I/σI> 4.3 (1.8) 
Wilson B (Å2) 123 
Residues 3090 
Rmerge a(%) 0.152 (0.5) 
Rmeas 0.195 (0.633) 
Refinement  
Resolution (Å) 95.03-4.02 
Rworkb / Rfreec (%) 38.97/39.47 
Average B-factors, whole chain (Å2) 128.5 
R.m.s deviations  
Bond lengths (Å) 0.0115 
Bond angles (°) 1.38 
Values in parentheses refer to the highest resolution shell. a. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i Ii(hkl); 
where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of Ii(hkl) 
for all i measurements. b. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure factor and Fc is the 
calculated structure factor. c. Rfree is the same as Rcryst except calculated with a subset, 5 %, of data that are 
excluded from refinement calculations. 
 
 
Figure 4.10 Crystals of ELIC and an example of the diffraction. 
A. Crystals of ELIC formed in the presence of bicuculline, 0.25 M potassium citrate, 30 % 
PEG 3350. B. Diffraction example from the 4 Å dataset. 
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The low resolution of the data meant refinement was difficult with satisfactory fitting of 
many side chains not possible. Refinement was conducted using jelly-body refinement with 
automatically generated weighting and strict NCS restraints (Murshudov et al., 2011). 
Analysis of the (2Fo-Fc) and (Fo-Fc) maps did not reveal any density that could be reliably 
assigned as the ligand. For this reason further refinement was not conducted. An example 
of the 2Fo-Fc electron density maps is shown in Figure 4.11. 
  
Figure 4.11 Electron density map of ELIC 
Density map (2Fo-Fc), where Fo and Fc are the observed and calculated structure factors 
respectively, for the transmembrane region of one ELIC subunit. TM1-3 had well ordered 
density whereas TM4 did not. Very few side chains had adequate density for accurate 
modeling. The left hand image has the model in place, on the right is the density without 
the model. Map contoured at 1 σ. 
 
4.5 Discussion 
BLI has previously been shown to be a viable technique for monitoring the binding of small 
molecule compounds to protein targets (Martin et al., 2011, Wartchow et al., 2011). The 
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work presented here shows that the technique is also applicable to large membrane protein 
receptors and could be used for future HTS of pLGICs. The strength of this technique for 
screening these types of target is the small quantities of protein required to conduct the 
screen and compound libraries can be tested in relatively little time. Taking just over 6 days, 
using 96 sensors and around 2 mgs of protein, 3241 compounds were screened. The hit rate 
(0.8%) was comparable for that found when BLI was used to screen a library against a 
soluble protein target, where a hit rate of 1.3% was reported against eIF4E (Wartchow et al., 
2011).  
The limitations of the technique are that it may not be sensitive enough to detect binding of 
compounds below a mass of 150 Da with a target of this size. This was observed with 
GABA, acetylcholine and cysteamine where no BLI response was detected. The technique 
therefore may not be applicable for fragment screening in which the average weight of 
compounds is close to 200 Da as for example in the University of Dundee, DDU fragment 
library.  Another draw back of using this technique in regards to pLGICs is that the way the 
compound modulates receptor function cannot be inferred. Nevertheless, the use of BLI in 
a screening pipeline where hits are then tested by electrophysiology would identify the 
effect of the compounds on the receptors.  
The ion channel library had a composition of 4 and 17% of the compounds similar to ones 
that had been highlighted using the ChEMBL database as binding anionic and cationic 
pLGICs respectively (Mok and Brenk, 2011). The overall hit rate of the screen against 
ELIC was 0.8%, though this would have been higher if clustered compounds had been 
included in the secondary screen. A higher hit rate from the screen, reflecting its 
composition, may therefore have been expected, though the actual hit rate could be 
explained by the specificity of the ligands for ELIC. As many of the compounds identified 
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from the ChEMBL database were not commercially available, compounds thought to be 
bioactive templates that were available were used (Mok and Brenk, 2011). If these 
analogous compounds had lower affinity for pLGICs this may also explain the lower 
number of hits from BLI. A literature search of compounds related to DDD00104826 using 
ChEMBL (http://www.ebi.ac.uk/chembl/) found a compound with about 70 % similarity. 
This compound had previously been found to bind to the sigma receptor (Zampieri et al., 
2009). Sigma receptors bind morphine and its derivatives which are also known to have 
both competitive and non-competitive antagonist actions at 5-HT3 receptors (Shin et al., 
2007; Fan, 1995; Wittmann et al., 2006; Baptista-Hon et al., 2012). This may suggest a 
common mode of action between morphine and DDD00104826. For compounds 
DDD00105795 and DDD00106009, the closest analogues were both noted as ligands for 
the relaxin receptor and glucagon receptor, both GPCRs.  
The screen also showed that ELIC could be used as a surrogate for GABAA receptors. 
Though the compound identified with BLI had an inhibitory effect on GABAA receptors 
and not a biphasic one as seen with ELIC, the fact that the compound elicited a response 
with both receptors suggests that further screening may lead to more GABAA modulating 
compounds being discovered.  
Despite being unable to replicate the biphasic response of ELIC against flurazepam as 
described by Spurny et al, the fact that the DDD00104826 analogue induced a similar 
response may suggest they are acting in a similar way. Flurazepam is thought to bind in two 
distinct ways to ELIC, an intra-subunit binding site that facilitates potentiation and an inter-
subunit binding site that is linked to inhibition (Spurny et al., 2012). In GABAA receptors 
flurazepam binds in an inter-subunit binding site between α and γ subunits (Pritchett et al., 
1989; Sigel 2002). Overlaying the recently solved crystal structure of the GABAA β3 
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receptor with that of ELIC with flurazepam bound reveals the region corresponding to the 
intra-subunit binding site is occluded in GABAA receptors by a loop formed in the β5 strand 
from the neighbouring subunit, Figure 4.12 (Miller and Aricescu et al., 2014). There are 
however conserved residues in this region between ELIC and GABAA receptor subunits. 
An intrasubunit binding site similar to that in ELIC has also been reported in nAChRs 
(Dellisanti et al., 2007). The potentiation of ELIC response to GABA with the 
DDD00104826 at 10 µM may be due to binding in the intra-subunit site, which might not 
be accessible in GABAA β3.    
 
Figure 4.12 A loop in the GABAA β3 receptor blocks the site corresponding to a 
flurazepam binding site in ELIC. 
ELIC (grey) with flurazepam (green carbons) bound in an inter-subunit binding pocket. The 
GABAA β3 structure (purple) shows a loop from the β5 strand blocking the corresponding 
site. In ELIC, flurazepam binding to this site has been linked to potentiation of currents. 
 
The analogue of compound DDD00104826 had an inhibitory effect on GABAA receptors. 
This is not a clinically useful effect, as GABAA antagonists tend to be convulsants. The 
effects seen with this compound are similar to that seen with gabazine, an inhibitor of 
GABAA receptors (Ueno et al., 1997). Unlike another GABAA inhibitor, bicuculline, the 
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compound did not exhibit inverse agonistic effects (McCartney et al 2007). A better 
understanding of how the compound modulates receptor function could be discerned by 
performing more in depth competition assays to establish whether the compound acts as a 
competitive or non-competitive antagonist.  
Finding a suitable crystallisation condition for ELIC with the compound could also shed 
light on the mode of binding and mechanism of action. Several techniques could be 
employed to try and gain better diffracting samples. For example the crystals could be 
dehydrated, improving crystal packing and leading to higher resolution data (Salunke et al., 
1985). Alternatively, a halogenated analogue of the compound could allow the anomalous 
dispersion signal to determine the location of the ligand even with only-low resolution data.  
Advances made in expressing GlyR could lead to the use of BLI in high throughput 
screening of this target. Insertion of the BAP sequence and subsequent biotinylation will 
need to be monitored to ensure it does not disrupt proper formation of the receptor. If this is 
successful it could lead to the development of new chemical modulators of GlyRs.  
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5 Glycine receptor surrogates for ligand screening and 
crystallographic studies 
5.1 Synopsis 
To complement attempts to gain recombinant HsGlyR for ligand binding and structural 
studies, surrogates based on AChBP were designed. The advantage of using AChBP is that 
it is a soluble homologue of the ECD of pLGICs. This results in simpler purification of the 
protein without the need for detergents, also making it an easier target for crystallisation. 
This makes it a potentially useful tool for studying ligands that bind to the orthosteric 
binding site of pLGICs.  
During this work data were published wherein this strategy had successfully been used to 
make a 5-HT3A surrogate, shown to selectively bind granisetron, an antagonist of such 
receptors (Kesters et al., 2013). This suggests that a similar GlyR surrogate could be made. 
Using the homology model of HsGlyR α1, residues thought to be important in ligand 
recognition were identified. Four different potential surrogates were then designed, with 
amino acids in AChBP mutated to replicate the corresponding residues in HsGlyR. 
The four GlyR surrogates were tested with DSF for thermostability and potential ligand 
binding capability. A screen was conducted with BLI to discover compounds that bind to 
the targets, with ligands that preferentially bind a surrogate over the WT identified. 
Crystallisation was performed to try and gain structures with ligands present. This resulted 
in the structure of one of the surrogates, though no ligand was observed. Crystals of a 
second surrogate were gained but more work will need to be conducted to improve 
diffraction. Informed by the structural data, a fifth surrogate has also been developed with 
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five mutations. This surrogate is more stable than the others, and could be used for future 
studies. 
5.2 Construct design, expression and purification 
5.2.1 Identification of ligand binding residues and surrogate design 
The development of surrogates for GlyR focused on the orthosteric ligand-binding site. The 
homology model of HsGlyR offered some insight into which residues could potentially be 
important for glycine binding. The structure of CeGluCl (PDB code 3RIF) had a glutamic 
acid bound in the orthosteric site. This structure was superimposed onto the homology 
model and the glutamic acid changed to a glycine to ascertain which residues of GlyR 
could potentially interact with the ligand, Figure 5.1. 
 
Figure 5.1 Stereo image of the orthosteric binding site of the HsGlyR homology model. 
Residues F72, F91, F187, Y230 and F235 create the aromatic cage conserved throughout 
pLGICs. Residues R93 and E185 possibly facilitate binding of the zwitterionic ligand, 
glycine (green carbons). 
 
Previous studies have highlighted the importance of an aromatic cage in ligand recognition 
of pLGICs (Brejc et al., 2001, Pless et al., 2011, Pan et al., 2011). In HsGlyR, F72, F91, 
F187, Y230 and F235 are thought to form the aromatic cage and contribute to cation-π 
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interactions with the amine group of glycine (Pless et al., 2008). The glycine sits within the 
aromatic cage in the homology model, with the amine 5 Å from F187, which is implicated 
in the cation-π interaction. The amine is around 5 Å from E185, therefore potentially 
interacting with this residue also.  
The principle subunit face contributes E185 and helps to create a largely electronegative 
area in the binding site whilst R93 lines the complementary subunit face and contributes to 
the mainly electropositive surface area of this part of the binding pocket, Figure 5.2. As 
glycine is zwitterionic, this suggests the glutamic acid may interact with the amine moiety 
of glycine, with the arginine interacting with the carboxylic acid group (Grudzinska et al., 
2005). The arginine is conserved between CeGluCl and GlyR whereas the residue 
corresponding to E185 is not, being an alanine in CeGluCl (A149). Mutation of R93 to a 
lysine reduces the glycine EC50 for glycine from 0.19 mM to 41 mM whereas the R93A 
mutation reduced the EC50 to greater than 250 mM. The mutation E185D also results in a 
glycine EC50 of greater than 250 mM highlighting the importance of these residues 
(Grudzinska et al., 2005). 
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Figure 5.2 Electrostatic surface potential of the glycine-binding site.  
A. The principle face of the GlyR orthosteric binding site contributes a mainly 
electronegative surface (red). R93 from the complementary subunit binding site is shown 
(grey carbons) along with glutamic acid from the CeGluCl structure (green carbons). B. 
The complementary face of the binding site contributes an electropositive surface (blue). 
E185 is shown on the principle subunit (cyan). Electrostatic surface potential calculated 
using APBS plugin for PyMOL, electrostatic charge contoured at 70.72 kT/e and -70.72 
kT/e (Lerner and Carlson, 2006). 
 
Aplysia californica AChBP was chosen as a template for surrogates of the GlyR ECD. The 
affinity of AcAChBP for strychnine of 38 nM, is close to that of GlyR, 16 nM (Brams et al., 
2011b). This suggests that only conservative changes might be needed to convert AChBP 
to a GlyR surrogate. The large number of crystal structures of AcAChBP (42 at time of 
writing) compared to LsAChBP (21 at time of writing) was another reason this protein was 
chosen. The larger number of structures with various ligands suggests this protein may be 
more amenable to crystallographic studies. To determine which residues to mutate, the 
homology model of HsGlyR was superimposed onto the crystal structure of wild type 
AChBP (PDB code 2BYN, Hansen et al., 2005). To recreate the aromatic cage of GlyR, 
two residues were mutated to phenylalanine, T53F and W164F. The residue Y110 in 
AChBP had an alanine at the corresponding position on the GlyR model, therefore the 
mutation Y110A was also made. I135 was mutated to a serine to correspond to GlyR. This 
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was in a region were it could potentially form hydrogen bonds with ligands. These four 
mutations (T53F, Y110A, I135S, W164F) combined to make the first AChBP mutant, 
AChBP-A. These residues correspond to F72, A129, S157 and F187 in HsGlyR α1, Figure 
5.1. A full list of the surrogates and their mutations is given in Table 5.1. 
The arginine (R93) on the complementary binding face of GlyR corresponds to Q74, 
therefore this residue in AChBP-A was mutated to arginine to try and replicate the 
electropositive surface seen in the HsGlyR model. This mutant was called AChBP-B and 
contained five mutations (T53F, Q74R, Y110A, I135S, W164F). Mutation studies of 
individual residues within the binding site of HsGlyR α1 show that mutating F72 and R93 
to alanine resulted in a three-fold decrease in strychnine inhibition of glycine evoked 
currents for both mutations (Brams et al., 2011b). Furthermore, mutations of A129 and 
S157 similarly resulted in a ten-fold reduction in strychnine potency for each mutation. 
Mutating F187 to an alanine resulted in a loss of function of the glycine receptor. A mutant 
of HsGlyR, R93A, resulted in a change of glycine EC50 from 0.19 mM with the WT to 
greater than 250 mM with the mutant. The mutation F91A had the same result, changing 
the glycine EC50 to greater than 250 mM (Grudzinska et al., 2005), and so this residue was 
identified for future surrogates.  
A surrogate with nine mutations was also created to further replicate GlyR. This involved 
all five changes described above plus four others. Tyrosine residues 72 and 212 of AChBP 
were mutated to phenylalanine to further replicate the aromatic cage of GlyR. These 
residues correspond to F91 and F235 in GlyR. AChBP contains a disulphide bond within 
loop C which forms one side of the binding site. This disulfide is not present in GlyR and 
structural comparisons led to the decision to mutate them to the corresponding GlyR 
residues. Cysteines, 207 and 208, were mutated to threonine and glycine (T232 and G233 
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in HsGlyR) respectively. This mutant will be referred to as AChBP-C (T53F, Y72F, Q74R, 
Y110A, I135S, W164F, C207T, C208G, Y212F). The positions of all the mutations on 
AChBP are shown in Figure 5.3.  
Table 5.1 HsGlyR surrogate mutations. 
Mutant name Mutations Corresponding residue in HsGlyR α1 
AChBP-A T53F, Y110A, I135S, W164F F72, A129, S157, F187 
AChBP-B T53F, Q74R, Y110A, I135S, W164F 
F72, R93, A129, S157, 
F187 
AChBP-C 
T53F, Y72F, Q74R, 
Y110A, I135S, W164F, 
C207T, C208G, Y212F 
F72, F91, R93, A129, 
S157, F187, T232, G233, 
F235 
AChBP-D T53F, Q74R, Y110A, I135S, G162E, 
F72, R93, A129, S157, 
E185 
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Figure 5.3 The residues 
targeted for creation of GlyR 
surrogates using AChBP. 
The structure of AChBP is 
shown with mutated side chains 
carbons coloured cyan. WT 
residues are coloured black. The 
structure of AChBP WT (PDB 
code 2BYN, Hansen et al., 
2005) was used with residues 
mutated with COOT (Emsley 
and Cowtan, 2004).   
 
 
 
Only preliminary data have been recorded for AChBP-D that incorporates the G162E 
change to replicate the electronegative surface on the principle binding site surface. In 
HsGlyR the residue E185 contributes to this electronegative surface. W164 was 
reintroduced to AChBP to try and increase the stability of the mutant. This mutant is 
discussed in section 1.2.3.1. 
5.2.2 Expression and purification of AChBP and mutants 
All of the constructs, including one encoding wild type AChBP, were expressed using the 
baculovirus system. The protein was secreted into the media and purification was 
performed with a single affinity chromatography step. SEC was not needed for purification 
but a sample of WT AChBP was run on a superdex 75 16/600 column to gauge the 
oligomeric size of the protein. A symmetrical peak was seen for the protein and it eluted at 
120 ml, corresponding to the expected mass of a pentamer (125 kDa), Figure 5.4 A. Native 
gel analysis was then used to investigate the oligomeric state of AChBP and the mutants. 
Each of the mutant and the wild type proteins gave similar results on the native gel, with a 
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prominent band relating to a pentamer at approximately 150 kDa and secondary band at 
around 300 kDa that could potentially be two pentamers interacting, Figure 5.4 B. Though 
the bands are at around 150 kDa, the fact that the mutants have identical profiles on the 
native gel as with WT AChBP suggests they also form pentamers. AChBP WT has also 
previously been reported as migrating similarly to the 150 kDa standard (Buchapudi et al., 
2012). A typical yield from one litre of Sf9 culture was 2.5 mgs of protein after purification.  
 
Figure 5.4 AChBP SEC trace and native gel 
A. SEC trace for AChBP-WT showing a sharp symmetrical peak corresponding to the 
expected mass of a pentamer (125 kDa) B. A composite image of several gels aligned to 
match the protein standards in lane 1. Lane 2 WT AChBP, lane 3 is AChBP-A, lane 4 
AChBP-B, lane 5 AChBP-C. The bands highlighted with the black box correspond to the 
expected mass of a pentamer (125 kDa). The red box is roughly double this and could 
correspond to association of two pentamers.  
 
5.2.3 Differential scanning fluorimetry  
In order to determine if the mutations had any effect on protein stability, differential 
scanning fluorimetry was employed. Various ligands were also tested with the protein to 
investigate whether they increased stability (Niesen et al., 2007). Wild type protein 
appeared to be highly stable giving a Tm of about 90°C, with the melting curve only just 
starting to plateau at the end of the analytical window. Addition of 20 µM strychnine 
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appeared to shift the melting curve beyond the temperature range available, resulting in no 
melting curve actually being observed, Figure 5.5 A. As the mutations destabilized the 
surrogates the technique could be used to analyse the effect of the mutations on ligand 
binding and stability, as the melting curves were then in the experimental range 
AChBP-A, with four mutations had an apparent Tm of 55°C, showing that the changes had 
a large destabilizing effect (ΔTm= -35°C). Addition of 20 µM strychnine increased stability 
of the protein, increasing the Tm to around 81°C (ΔTm= +26°C, compared to AChBP-A), 
Figure 5.5 B. This suggests that the mutant is capable of binding strychnine despite the 
reduced thermal stability compared to WT. 
 
Figure 5.5 Stability assays of various AChBP constructs. 
A. Wild type AChBP in presence (red line) and absence (blue line) of strychnine. B C and 
D similarly show AChBP-A, AChBP-B and AChBP-C respectively. The controls of buffer 
and buffer with 20 µM strychnine show these have no effect on fluorescence.  
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The introduction of five mutations resulted in a large decrease in stability compared to the 
WT. An accurate Tm is difficult to calculate for AChBP-B due to what appears to be a two-
step unfolding. This feature is present but not as pronounced for AChBP-A. The bimodal 
unfolding could be a result of the break up of the pentamer giving the initial increase in 
fluorescence, followed by the unfolding of individual subunits to give the secondary peak. 
As the mutations are at the interface between subunits this may account for the potential 
breakdown of the oligomeric state. The addition of strychnine had a dramatic effect on the 
protein, giving a Tm of around 80°C, comparable to that observed for AChBP-A with 
strychnine, Figure 5.5 C.  
AChBP-C was the least stable of the three surrogates. The Tm for both apo-receptor and 
with strychnine present was ~35°C. That no increase in stability is seen with addition of 
strychnine suggests the protein is not able to bind this ligand, Figure 5.5 D. For this reason 
no further work was conducted with AChBP-C. 
To test whether DSF could be used to determine if the mutations were stabilized by small 
ligands, and if an increase in stability in the presence of glycine had been introduced, 
several compounds were tested. AcAChBP WT has Ki for nicotine and acetylcholine of 
0.77 and 64.4 µM respectively (Brams et al., 2011a). A literature search revealed no data 
on the affinity of GABA and glycine for AChBP. Nevertheless, these ligands were used to 
determine if they could confer stability to the surrogates. With AChBP WT, 20 µM nicotine 
and 1 mM acetylcholine both gave a thermal shift of ΔTm +2°C, Figure 5.6 A. No shift was 
observed for 1 mM glycine or 1 mM GABA. In the presence of 1 mM acetylcholine  a ΔTm 
of +2°C was observed for AChBP-A, but no shift was detected for 20 µM nicotine or 1 mM 
glycine and 1 mM GABA, Figure 5.6 B. AChBP-B did not show any discernable thermal 
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shift with any ligand except strychnine. This may be due to the early break down of the 
pentamer, with the smaller ligands, nicotine, acetylcholine and glycine not having the 
stabilizing effect of the much larger strychnine, Figure 5.5 C. That glycine and GABA had 
no observable effect on stability may be due to their size. With BLI, these ligands were not 
observed binding to the proteins, suggesting a limitation of these techniques to detect 
compounds that are ~100 Da or smaller.  
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Figure 5.6 DSF results of AChBP WT and A with various compounds. 
A. AChBP WT showing a ΔTm= +2°C for nicotine and acetylcholine. B. Nicotine no longer 
confers stability to the AChBP-A. C. The compounds used in DSF experiments and their 
molecular mass. 
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5.2.3.1 AChBP-D  
The use of DSF identified that mutated versions of AChBP are significantly destabilized. 
Structural analysis, which is reported later, of AChBP-A suggested that the W164F 
mutation might be a major contributor to this observation. Therefore W164 was mutated 
back in to AChBP-D and an additional mutation, G162E introduced to try and replicate the 
electronegative surface potential seen in the principle subunit binding site of the HsGlyR 
model due to E185 in GlyR. It was hoped that the introduction of the mutation G162E, 
would help to reduce the early breakdown of the pentamer, thought to have been seen with 
AChBP-B. This mutant will be known as AChBP-D. As with the other mutants DSF was 
employed to see if the mutations conferred stability to the surrogate. The apo-protein, as 
well as the protein on the presence of 20 µM strychnine and 5 mM glycine were tested. 
AChBP-D is clearly more stable than the other surrogates, with a Tm of around 80°C 
compared to 55°C for AChBP-A. Only a single peak was observed suggesting that the 
breakdown of the pentamer as perhaps seen with AChBP-B, Figure 5.7, is not a 
complicating factor. Though glycine at 5 mM gave no appreciable increase in stability, it 
appears the protein is capable of binding and being stabilized by 20 µM strychnine with a 
ΔTm = +5°C.  
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Figure 5.7 DSF result for AChBP-D. 
The result shows that AChBP-D is inherently more stable than AChBP-B, with no early 
breakdown of the pentamer observed. Strychnine also appears to bind and stabilize the 
protein. 
 
Future work on AChBP derived surrogates of HsGlyR α1 will focus on this protein, with 
the increased thermostability potentially having an influence on crystallisation (Ericsson et 
al., 2006). That the protein apparently still has the ability to bind strychnine means that it 
should be used for ligand binding studies to determine if it is a good GlyR surrogate. 
5.3 Ligand screening with BLI 
The use of streptavidin biosensors was successful in allowing a screen of ELIC using BLI, 
therefore attempts were made to produce biotinylated AChBP. A C-terminus BAP tag was 
introduced for in vivo biotinylation, though this resulted in precipitation of the protein. 
Therefore the C-terminal His-tag introduced for affinity purification was used along with 
Ni-NTA biosensors (FortéBio). The advantage of these biosensors was that the Ni-NTA 
resin could be recharged and fresh protein loaded, allowing for sensors to be used multiple 
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times. On the other hand the sensitivity for small molecule screening is reported to be less 
than that seen for the “super streptavidin” biosensors (FortéBio), and there was potential for 
ligands to interact with the Ni-NTA.   
Strychnine was used as a positive control during screening as this gave a well defined 
response (Figure 5.5 A), which could be used to assess the quality of hits. Generally 
compounds that gave a response greater than three times that seen for the positive control 
were discarded for being an anomalous signal (Wartchow et al., 2011). The KD calculated 
for strychnine interacting with AChBP-WT was 43.8 ± 0.35 nM, based on 8 measurements. 
This is similar to the KD of 38 nM reported for AChBP WT using radioligand binding 
assays (Brams et al., 2011a). This close agreement suggests that BLI is suitable for ligand 
discovery and characterization for these targets. For AChBP-B the KD was 1.14 ± 0.83 µM. 
The response measured was the same as that seen for AChBP WT but the off rate was 
increased, Figure 5.8 A. This resulted in a larger KD and may suggest the instability of the 
protein is effecting off rates seen for ligand binding. 
The ion channel compound library was screened as it was with ELIC, Chapter 4. Both 
AChBP WT and AChBP-B were used as targets to try and identify any ligands in particular 
that preferentially bound to either receptor. In this way compounds that showed specificity 
for AChBP-B could be used see if they modulate a GlyR response. The compounds were 
screened initially at a concentration of 10 µM with hits clustered by structural similarity. 
From the clustered compounds, the ones with the lowest KD were used for a secondary, 
concentration dependent screen. Strychnine was used at the end of each plate as a control to 
determine if the sensors and protein were still active. His-tagged TEV protease was used on 
reference sensors to help identify non-specific protein binding. 
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The primary screen revealed certain compounds that appeared to bind to both targets and 
some that bound preferentially to each protein, Figure 5.8. Hits for the targets were 
combined and clustered. The hits numbered 249 compounds (7.68%), and this was reduced 
to 100 compounds (3.1%) after clustering.  
 
Figure 5.8 Selected binding profiles from the AChBP primary screen. 
In the traces, blue lines equate to AChBP WT, purple to AChBP-B and red the TEV 
protease reference. A. Strychnine was used as a positive control. B. A compound that 
shows near equal binding to both receptors. C. Possible AChBP WT specific compound. D. 
Possible AChBP-B specific compound. 
 
The concentration dependent screen revealed a number of compounds that were false 
positives or anomalous binders. Once these had been removed the overall hit rate was 1.5% 
with a total of 48 compounds. Of these 20 were deemed to be specific for AChBP WT, six 
specific for AChBP-B and 22 that bound to both targets. The range of calculated KD values 
for these compounds was between 0.1 µM and 170 µM. A full list of these compounds is 
given in Appendix A. 
Several of the compounds identified in the primary screen as potential ligands for either or 
both proteins gave similar results in the secondary screen, Figure 5.9. Compound 
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DDD00019954 was flagged in the primary screen as binding to AChBP-B selectively, with 
a KD of 0.37 µM. No response was seen with this compound against AChBP WT. 
Conversely DDD00104031 appeared to be selective for AChBP WT with no response to 
AChBP-B. In the secondary screen this was confirmed and the KD calculated at 0.1 µM. 
DDD00105746 gave similar responses for both receptors in the primary screen and this was 
reflected in the follow up screen, giving a KD 12 µM for AChBP WT and 4 µM for AChBP-
B. 
 
Figure 5.9 Concentration dependent screening results. 
Example traces from the concentration dependent screen. A – DDD00019954 against 
AChBP-B. B - DDD00104031 against AChBP WT. C and D – DDD00105746 for AChBP 
WT and AChBP-B respectively. Traces from these compounds from the primary screen are 
shown in Figure 5.4 B-D.  
 
The compounds from the traces in Figure 5.8 and 5.9 and their structures are shown in 
Figure 5.10. No similar compounds to DDD00019954 or DDD00104031 had been left out 
of the secondary screen after clustering. Compound DDD00105746 had four similar 
compounds identified by clustering that were left out of the follow up screen. Two of these 
show responses against both proteins and two were specific to AChBP WT. The two 
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compounds specific to AChBP WT contains an amide linker between two aryl groups 
whereas the two that hit both proteins had an amine linker. The additional bond with the 
amide linker may therefore cause a steric hindrance, resulting in the specificity. 
 
Figure 5.10 Compounds identified from the BLI screen. 
DDD00019954 found to bind to AChBP-B, DDD0010431 found to bind to AChBP WT, 
DDD00105746 bound to both WT and mutant proteins.  
 
Further experiments will need to be performed with these compounds to identify how they 
bind to AChBP and whether specific binders of AChBP-B have a greater affinity for GlyR 
than the compounds that specifically bind AChBP WT.  This could include crystallising the 
protein in the presence of these ligands to identify the mode of binding. Suitability of the 
AChBP mutants as GlyR surrogates could be confirmed by electrophysiology. If the 
compounds from the screen modulated GlyR function and if the compounds that 
specifically bound to AChBP-B had a greater potency toward GlyR, then the quality of the 
surrogates would be established. 
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5.4 Structural studies using crystallography 
Crystallisation trials of AChBP-A and B were conducted using several commercial screens. 
The proteins were purified as discussed in Chapter 2 and then concentrated to 10 mg ml-1. 
Screens were set up with both apo-protein and protein in the presence of various ligands. 
Crystal structures of AChBP have previously been solved with lobeline and strychnine 
(Hansen et al., 2005, Brams et al., 2011b), and since strychnine was shown by DSF to have 
a large stabilizing effect on the mutants, these were used for crystallisation screening. 
Bicuculline is known to bind to several pLGICs and was therefore used to try and gain 
crystals. 
5.4.1 AChBP-A crystallography 
A large number of conditions produced crystals with various morphologies. Crystals were 
harvested and frozen direct from the drops in which they grew. In total 28 crystals of 
AChBP-A were tested for diffraction. Many of these crystals diffracted to between 4 and 7 
Å resolution. The best crystal diffracted to 2.9 Å and a dataset was collected from it. Data 
processing and refinement statistics for AChBP-A are shown in Table 5.2. 
The structure was solved by molecular replacement followed by a single round of rigid 
body refinement. Further refinement was conducted with maximum-likelihood restrained 
refinement using automatically generated weighting and strict NCS restraints throughout. 
After each round of refinement, the electron and difference density maps were inspected 
and the model manipulated with dual rotamers added where necessary. Dual rotamers were 
assigned for D106 in chains A, B, D and E, R114 all chains, E152 and K174 in chains A 
and C. After several rounds of restrained refinement, water, N-acetyl glucosamine and PEG 
molecules were added. Due to the limited resolution a conservative approach to water 
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inclusion was adopted. Refinement was stopped when the Rwork and Rfree statistics did not 
significantly change and when there were no features in the difference density maps that 
suggested further correction was needed. The model quality and geometry was assessed 
with MOLPROBITY (Davis et al., 2007). The Ramachandran plot revealed 98.9 % of 
residues were in the allowed regions and a MOLPROBITY score in the 86th percentile was 
obtained. 
Table 5.2 Data collection and refinement statistics for AChBP-A. 
Data collection  
Beamline ESRF ID23-1 
Wavelength (Å) 0.97625 
Space group C2221 
a, b ,c (Å) 141.15, 142.80, 142.02 
Resolution (Å) 47.34-2.90 (3.06-2.90) 
No. reflections recorded 276432 (41755) 
Unique reflections recorded 32111 (46755) 
Completeness (%) 99.9 (99.9) 
Multiplicity 8.6 (9) 
<I/σI> 10.8 (1.8) 
Wilson B (Å2) 66.44 
Residues/waters 1035/50 
Rmerge (%) 0.182 (1.412) 
Rmeas 0.206 (1.578) 
Refinement  
Rwork / Rfree (%) 18.74/24.94 
Average B-factors main/side chain 
(Å2) 
65.1/ 71.3 
Average B-factors solvent (Å2) 42.3 
Average B-factors NAG/PEG (Å2) 111.1/95.3 
R.m.s deviations  
Bond lengths (Å) 0.0228 
Bond angles (°) 1.966 
 Values in parentheses refer to the highest resolution shell. a. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑I Ii(hkl); 
where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value of Ii(hkl) 
for all I measurements. b. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure factor and Fc is the 
calculated structure factor. c. Rfree is the same as Rcryst except calculated with a subset, 5 %, of data that are 
excluded from refinement calculations. 
 
At the onset of analysis the consequences of the mutations were clear. The three residues 
that had been mutated to smaller side chains showed negative density for that part of the 
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model, Figure 5.11 B-D. An omit map was created wherein T53 was deleted. The resultant 
density in the difference map was suggestive of a larger side chain, expected for 
phenylalanine rather than the threonine, Figure 5.11 A.  
 
Figure 5.11 Density maps for the four mutations in AChBP-A 
A. The Fo-Fc omit map for T53F. B-D. The 2Fo-Fc and Fo-Fc map after the first round of 
refinement, showing the larger side chains of the WT protein are not present in the electron 
density. 
 
After refinement three of the mutants had reasonable density in the 2Fo-Fc map, Figure 5.12 
A.  On the other hand, no density was observed for the side chain at residue 164, the 
position of the W164F mutation, Figure 5.12 B. This suggests that the side chain is not 
ordered. In the wild type structure, the W164 side chain forms a hydrogen bond with the 
main chain carbonyl of I135 on a neighbouring subunit, a residue that has been mutated to 
serine in AChBP-A. The disorder observed with the mutation W196F might be a 
contributing factor in the reduced stability recorded for AChBP-A and B seen in the DSF 
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experiments. The loss of the H-bond and reduction of van der Waals (VDW) interactions 
between W164 and I134 due to the mutations could all contribute to the reduction of 
thermal stability observed when comparing AChBP WT and AChBP-A, Figure 5.13 A and 
B.  
 
Figure 5.12 The 2Fo-Fc map of two mutations in AChBP-A. 
A) The mutation, T53F, had well defined density. B) AChBP-A (purple carbons) and the 
tryptophan side chain from WT AChBP (cyan) in its corresponding position. F164 had no 
density around the side chain, suggesting it was disordered. W164 in WT forms a hydrogen 
bond with I135 (Ser135 in the mutant). Map contoured at 1σ. 
 
Three of the orthosteric binding sites in the pentamer had density in the 2Fo-Fc and Fo-Fc 
maps suggesting the placement of a ligand. None of these could reasonably be assigned as 
bicuculline. The density could potentially be PEG from the reservoir conditions, though 
addition of PEG into the density resulted in high B-factors for these molecules (Average 
95.3 Å2). The structure of AChBP used as a template for molecular replacement reported 
PEG in the binding site (Hansen et al., 2005), with the crystal growing in conditions 
containing PEG 4000, therefore the density seen in the AChBP-A structure is likely to be 
poorly ordered PEG.  
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An overlay of AChBP-A and the WT structure reveal the mutations have not perturbed the 
binding site to any large extent, with all loops and residues in similar positions. Similarly, 
an overlay of AChBP-A with the homology model of HsGlyR shows that the residues 
mutated with the intention of replicating the glycine-binding site are in reasonable 
agreement, Figure 5.13 C. Without the presence of a ligand it is difficult to draw 
conclusions about the quality of AChBP-A as a GlyR surrogate, though the fact the 
mutations line up well with residues in the homology model is promising.  
 
Figure 5.13 Comparison of AChBP WT and HsGlyR model with AChBP-A. 
A. AChBP WT showing the residues that were mutated with VDW spheres shown in light 
orange. B. AChBP-A showing the mutated residues and VDW spheres, highlighting the 
decrease in VDW contacts in the mutant, potentially leading to a reduction in stability. C. 
Stereo image of an overlay of AChBP-A (purple carbons) with the HsGlyR model (grey 
carbons) showing that all residues occupy similar positions. The glycine (green carbons) 
positioned as in Figure 5.1. Residues numbered according to AChBP-A.  
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5.4.2 Crystallographic study of AChBP-B 
AChBP-B crystallised in a variety of conditions. These crystals were small (50 µm), with 
diverse morphology, were difficult to harvest and gave no diffraction in-house. In an 
attempt to gain larger, better diffracting crystals, several optimization screens were set up in 
both 96 well sitting drop and 24 well hanging drop plates. Four reservoir conditions gave 
crystals with various morphologies, 0.1-0.35 M potassium formate with 15-30% PEG 3350, 
0.1-0.35 M MgCl2 with 15-30% PEG 3350, HEPES pH 6.8-8 with 15-30% PEG 6000 and 
Tris pH 7-9 with 15-30% PEG 6000 (Figure 5.14).   
 
Figure 5.14 Crystallisation hits from optimization screening. 
All crystals grew in the presence of 0.5 mM strychnine over the period of a week. The 
black line in each picture equates to 200 µm. A. 0.15 M potassium formate and 30% PEG 
3350. B. Tris pH 7-9 with 15-30% PEG 6000. C. HEPES pH 6.8-8 with 15-30% PEG 6000 
D. 0.1-0.35 M MgCl2 with 15-30% PEG 3350. Each drop consists of a 1:1 ratio (0.1:0.1 
µL) of reservoir and protein/strychnine solution. 
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Many of the crystals diffracted to around 7 Å resolution, with one diffracting to around 4 Å. 
This crystal came from the drop shown in Figure 5.14 A. The crystals grew after several 
weeks at 20°C and were harvested and tested for diffraction with and without 
cryoprotection. The reservoir conditions made up to include 30 % glycerol was used as a 
cryoprotectant, however crystals treated in this way either showed low-resolution or no 
diffraction. This suggests the cryoprotectant had a destructive effect on the crystals and 
possible optimization of various cryoprotectants could be investigated in the future. 
The image in Figure 5.15 B, shows the diffraction gained from the crystal. The space group 
was tentatively assigned as I23 with unit cell length a = 206.7. A structure of AcAChBP 
WT has previously been solved in this space group with similar unit cell dimensions (PDB 
code 2BQT Rucktooa et al., 2012). The crystal that gave the diffraction shown in Figure 
5.15 B was stored for future testing at a synchrotron X-ray source. 
 
Figure 5.15 Crystals and diffraction image of AChBP-B. 
A. Crystals grown in the presence of strychnine. B. Diffraction pattern from a crystal 
harvested from the drop in A. The ring marks a resolution of 4 Å. 
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5.5 Discussion 
5.5.1 Surrogate design  
The use of AChBP mutants as a surrogate for HsGlyR shows potential for gaining insights 
into how ligands interact with the glycine-binding site. The W164F mutation appears to 
contribute significantly to a reduction in stability seen with the mutants. AChBP-D, the 
mutant in which this tryptophan is retained, is almost as stable as the wild type, with a Tm of 
80°C compared to 90°C. The dual mutations of G162E and Q74R in AChBP-D may also 
help to increase stability, balancing the positive and negative electrostatic surfaces in the 
complementary and principle subunit orthosteric binding sites, suggested by the homology 
model. 
The fact that the stabilizing effect of nicotine binding to AChBP WT is lost with the 
AChBP-A mutant suggests the residues mutated are contributing to ligand recognition. 
Studying the structures of the L. stagnalis AChBP with nicotine and acetylcholine bound 
(Celie et al., 2004; Olsen et al., 2014), suggests that the mutation I135S could be 
contributing to the loss of nicotine recognition. In LsAChBP and AcAChBP a methionine 
and isoleucine, respectively, contribute hydrophobic interactions with the nicotine. By 
changing these residues to incorporate a serine means that such interactions are lost. 
Acetylcholine forms a water mediated H-bond with the main chain carbonyl of I134. The 
carbonyl group of acetylcholine may be able to interact with the serine side chain in the 
mutant directly, retaining the stabilizing effect seen with the wild type protein.  
5.5.2 Ligand screening with GlyR surrogates 
The use of BLI to screen this family of proteins appears to be a valid way of determining 
new ligands that bind to these targets. The KD of strychnine for AChBP WT calculated with 
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this technique closely matched that observed using a radioligand binding assay (Brams et 
al., 2011b). It would be important to validate the BLI results with a complementary assay. 
Techniques like isothermal titration calorimetry, and if W164 is present, tryptophan 
fluorescence can be used for this purpose (Hansen et al., 2002). Whether the compounds 
determined to preferentially bind to the surrogate translate to GlyR specific ligands has yet 
to be proven though future electrophysiology work would validate this.  
The use of Ni-NTA biosensors appeared to be reasonable for use in screening. As with 
ELIC, molecules under 150 Da were not observed binding and so fragment screening may 
be problematic. The advantage of these sensors was that they could be regenerated and 
fresh protein bound, resulting in a smaller number of sensors being used. A disadvantage 
was that after each plate the sensors had to be regenerated so as to ensure the protein had 
not been stripped by any compounds that could potentially chelate the Ni2+ resin, thereby 
removing the protein. Future work could focus on producing biotinylated protein that does 
not precipitate thereby allowing for the use of SSA biosensors. These sensors are more 
sensitive for kinetic experiments, and possibly allowing for the detection of compounds 
under 150 kDa.   
The hit rate with AChBP was higher than that seen with ELIC (1.5 and 0.8% respectively). 
A higher hit rate may have been expected with ELIC as the inclusion of the transmembrane 
domain introduces more potential ligand binding sites. That an increased rate was seen for 
AChBP could reflect the reduced sensitivity between the two sensor types and possible 
compound interaction with the Ni-NTA biosensors. ELIC is also a much larger protein 
(~180 kDa not including the micelle) than AChBP (~125 kDa) and so sensitivity for 
detecting ligands may be reduced.  Validation of the hits determined for AChBP will need 
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to be performed to ensure the compounds are binding and to give a better idea of actual hit 
rate. 
5.5.3 Structural studies of GlyR surrogates using crystallography 
Gaining the crystal structures of the mutants with selected compounds would help to 
identify if and how they are interacting with the receptors. A crystal of AChBP-B with 
strychnine shows promise for gaining high resolution diffraction. This might be 
accomplished if improved crystals can be obtained and used in a synchrotron X-ray source. 
If the receptor has strychnine bound and has clear density for the ligand, a comparison of 
the binding with AChBP WT (Brams et al., 2011b) can be made, which can then be used to 
help draw conclusions on how strychnine binds to GlyRs.  
Crystallisation of the compounds found to bind specifically to either WT or mutant AChBP 
would reveal the reason for the preferential interactions. If the specificity can be confirmed 
and validated with electrophysiology work, these surrogates could be used for further 
screening and gaining structural insights of GlyR ligand recognition. 
This work suggests that there is potential for GlyR surrogates to be used for screening and 
gaining insight into ligand binding of GlyR. Future work should focus on the use of 
AChBP-D as this appears to be the most promising surrogate made in this work. Screening 
with AChBP-D could also be validated with tryptophan fluorescent assays as W164 is 
present in the binding site. This technique has been used previously to investigate binding 
in AChBPs (Hansen et al., 2002).  
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6 Conclusion and future work 
The increasing awareness of the role that GlyRs play in a wide variety of processes is 
driving a large interest in discovering more information on the structural mechanisms of 
function and new chemical modulators of these receptors. This could lead to the 
development of novel anaesthetic and analgesics and a greater understanding of how 
receptor disruption underlies certain diseases. In this study, the foundation has been set 
for future work on ligand screening and crystallisation of HsGlyR with the expression 
of a modified receptor in baculovirus. A new technique for high throughput screening of 
these multimeric membrane bound targets has been demonstrated, and surrogates of 
GlyR that could be used for structural and ligand binding studies have also been created.  
Difficulties faced in expressing and purifying these receptors, in sufficient quantities 
was the first obstacle to overcome. A large number of constructs failed to either express 
or that were stable enough for further work. Success in expressing HsGlyR α1 with a 
truncated intracellular loop has set the groundwork for future efforts that could lead to 
crystallisation trials. A similar construct of the human GABAA β3 and CeGluCl was 
successfully crystallised and the structure solved (Miller and Aricescu, 2014; Hibbs and 
Gouaux, 2011), suggesting a similar success may be obtained with GlyR Con4. Future 
work on this protein should focus on improving yields so that crystal trials can 
commence. Once sufficient material can be produced, antibodies could be raised against 
the protein that could be used as an aid to crystallisation. This strategy was successfully 
used to gain the structure of CeGluCl and mouse 5-HT3A (Hibbs and Gouaux, 2011; 
Hassaine et al., 2014). Early crystals of these proteins without the antibodies did not 
diffract to a high enough resolution for structure determination (Hassaine et al., 2013). 
With the antibodies present, the protein was sufficiently stabilised, and intermolecular 
contacts were improved, resulting in diffraction grade crystals. Other strategies to yield 
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crystals of these receptors could include the use of lipid sponge phase or bicelles to 
reconstitute the protein into a lipid environment (Engström et al., 1998; Ujwal and 
Bowie, 2011). This approach can allow for type I crystals to form, wherein crystal 
contacts can be made in both the soluble domain and the hydrophobic membrane 
spanning domain. Typically with detergent solubilised proteins, type II crystallisation is 
observed where crystal contacts are only made with the soluble domains (Ostermeier 
and Michel, 1997).  
The use of BLI as a ligand screening technique for these targets identified a new 
chemical modulator of pLGICs. Used as part of a screening pipeline with hits validated 
using electrophysiological studies, this technique is promising for future ligand 
screening. Focus could shift to gaining HsGlyR for screening, which could be done by 
replacing the ILD with the BAP sequence. The protein could then be expressed with 
baculovirus and biotinylated in vivo. If this construct can be expressed and purified, 
then more targeted screening toward GlyR modulators can begin.  
The surrogate AChBP-D could also be used to try and identify ligands that bind GlyR. 
The increased stability of this surrogate over the others that have been created could 
lend itself to producing well diffracting crystals. This protein could also be screened as 
with AChBP-B and the subsequent hits compared with previous results. Crystal 
structures of these compounds with the surrogate could then inform of the binding mode. 
Electrophysiology with several pLGICs could be conducted to see if any effect on 
function is observed. This will allow for the validation of the screen, and if compounds 
modulate GlyR function, the quality of the surrogate could be inferred.  
Parallel to these studies, attempts could be made to crystallise various pLGICs and the 
surrogates with the compounds identified in the screens. Information garnered from 
these structures could identify the site of action and lead to a more informed strategy of 
drug design. By using halogenated analogues of the compound identified in the ELIC 
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screen, DDD00104826, the site of binding may be identified even with the low 
resolution crystals discussed in Chapter 4. By using the anomalous signal of such 
compounds, the position of a bromine or iodine can be determined.  
 Further electrophysiological studies could also be conducted with DDD00104826. 
Discovering whether it acts as a competitive or non-competitive antagonist of GABAA 
receptors will give an idea of whether the compound is binding in the orthosteric 
binding site.  
By developing a method for high throughput screening of pLGICs and creation of a 
surrogate, informed creation of early stage lead compounds could be performed with 
structure based ligand design. This could pave the way for generating new reagents to 
better understand pLGIC function and to support early stage drug discovery. 
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Appendix A 
BLI screening results for ELIC 
Compound name Compound structure KD (µM) 
DDD00106009 
 
0.84 
DDD00106270 
 
1 
DDD00104826 
 
1.12 
DDD00106596 
 
2.5 
DDD00061162 
 
2.5 
DDD00104745 
 
3.5 
DDD00105795 
 
14 
DDD00104824 
 
15 
DDD00104684 
 
16 
DDD00058968 
 
20 
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Compound name Compound structure KD (µM) 
DDD00103952 
 
20 
DDD00104568 
 
25 
DDD00106678 
 
26 
DDD00084073 
 
28 
DDD00106157 
 
28 
DDD00074313 
 
32 
DDD00069294 
 
40 
DDD00104652 
 
45 
DDD00003109 
 
46 
DDD00104131 
 
47 
DDD00106598 
 
47 
 Appendices 
162 
Compound name Compound structure KD (µM) 
DDD00104894 
 
54 
DDD00106380 
 
71 
DDD00092983 
 
82 
DDD00048224 
 
170 
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BLI screening results for AChBP WT and AChBP-B 
Compound name Compound structure KD (µM)* Target 
DDD00104031 
 
0.1 AChBP WT 
DDD00019954 
 
0.37 AChBP-B 
DDD00105602 
 
0.7 AChBP WT 
DDD00105946 
 
0.7 / 3 Both 
DDD00104508 
 
0.7 / 3.5 Both 
DDD00105669 
 
1.8 / 14 Both 
DDD00106687 
 
1.8 / 23 Both 
DDD00105701 
 
1.9 / 8.6 Both 
DDD00104083 
 
2 AChBP WT 
DDD00104194 
 
2.1 AChBP WT 
DDD00104572 
 
2.5 / 3.9 Both 
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Compound name Compound structure KD (µM)* Target 
DDD00105099 
 
2.5 / 13 Both 
DDD00106549 
 
14 / 2.8 Both 
DDD00106558 
 
3 AChBP WT 
DDD00105232 
 
3.1 AChBP-B 
DDD00104125 
 
3.2 AChBP WT 
DDD00105365 
 
3.2 / 11 Both 
DDD00105654 
 
3.4 AChBP WT 
DDD00105532 
 
3.4 AChBP WT 
DDD00106586 
 
3.6 AChBP WT 
DDD00105212 
 
3.8 / 18 Both 
DDD00105746 
 
12 / 4.1 Both 
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Compound name Compound structure KD (µM)* Target 
DDD00104082 
 
4.2 / 16 Both 
DDD00103976 
 
4.7 / 17 Both 
DDD00104240 
 
4.8 AChBP WT 
DDD00104289 
 
4.8 AChBP WT 
DDD00105728 
 
5.6 AChBP WT 
DDD00104307 
 
6 AChBP-B 
DDD00060561 
 
6.6 AChBP WT 
DDD00081451 
 
7.8 / 43 Both 
DDD00105693 
 
8 AChBP-B 
DDD00105302 
 
8.1 AChBP-B 
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Compound name Compound structure KD (µM)* Target 
DDD00104670 
 
8.2 / 11 Both 
DDD00106659 
 
9.8 / 10 Both 
DDD00105364 
 
11 AChBP-WT 
DDD00077566 
 
12 AChBP WT 
DDD00104704 
 
13 / 34 Both 
DDD00106871 
 
14 AChBP WT 
DDD00079221 
 
46 / 18 Both 
DDD00083983 
 
20 AChBP WT 
DDD00106677 
 
24 AChBP-B 
DDD00104146 
 
25 AChBP WT 
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Compound name Compound structure KD (µM)* Target 
DDD00104536 
 
26 AChBP WT 
DDD00105002 
 
30 AChBP WT 
DDD00106240 
 
36 AChBP WT 
DDD00105988 
 
120 / 45 Both 
DDD00104166 
 
50 / 170 Both 
DDD00066053 
 
57 AChBP WT 
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The bifunctional diaminohydroxyphosphoribosylaminopyrimidine deaminase/
5-amino-6-(5-phosphoribosylamino)uracil reductase (RibD) represents a
potential antibacterial drug target. The structure of recombinant Acinetobacter
baumannii RibD is reported in orthorhombic and tetragonal crystal forms at 2.2
and 2.0 A˚ resolution, respectively. Comparisons with orthologous structures in
the Protein Data Bank indicated close similarities. The tetragonal crystal form
was obtained in the presence of guanosine monophosphate, which surprisingly
was observed to occupy the adenine-binding site of the reductase domain.
1. Introduction
Acinetobacter species are a significant and increasingly important
cause of hospital-acquired infections (Gaynes & Edwards, 2005),
owing in part to a remarkable ability to resist antibiotic challenge
(Peleg et al., 2008). Some strains are resistant to almost all available
antibiotics, leading to an urgent need for novel treatments for this
pathogen. As part of a wide-ranging project to advance early-stage
drug discovery against Pseudomonas aeruginosa and closely related
Gram-negative organisms such as A. baumannii (Eadsforth et al.,
2012; Moynie et al., 2013), we have adopted a structure-based
approach to drive the assessment of potential targets (Hunter, 2009).
We identified that several genes encoding enzymes in the riboflavin-
biosynthetic pathway are essential in Gram-negative bacteria such as
P. aeruginosa (see, for example, Liberati et al., 2006). This was
supported by single gene knockout studies in the closely related
A. baylyi (de Berardinis et al., 2008). Riboflavin is a precursor for the
biosynthesis of flavins, which are essential cofactors for a diverse
range of key redox reactions (Macheroux et al., 2011). Animals rely
on dietary sources to acquire riboflavin, while bacteria generally
synthesize it de novo. This essential aspect of bacterial metabolism
is absent in mammals and therefore suggests that this biosynthetic
pathway might represent a potential source of antimicrobial drug
targets (Mack & Grill, 2006; Long et al., 2010). We selected a
bifunctional enzyme, diaminohydroxyphosphoribosylaminopyrimi-
dine deaminase (EC 3.5.4.26)/5-amino-6-(5-phosphoribosylamino)-
uracil reductase (EC 1.1.1.193), called RibD, in this pathway as a
potential target in Gram-negative bacteria.
Riboflavin synthesis is a multistep pathway starting from guanosine
triphosphate (GTP; Fischer & Bacher, 2005; Abbas & Sibirny, 2011).
In bacteria, the second and third stages of this metabolic process
involve zinc-dependent deamination and an NADPH-dependent
reduction at the ribosyl group, respectively (Fig. 1). The bifunctional
enzyme RibD, termed RibG in some bacteria such as Bacillus subtilis,
catalyzes these two reactions. Fungi and archaea possess two mono-
functional enzymes instead of a bifunctional RibD/RibG system.
RibD is constructed from an N-terminal deaminase domain, which
carries a Zn2+ ion, and a C-terminal NADPH-binding reductase
domain. There is no evidence of crosstalk between the domains, as
replacement of the bifunctional RibD by monofunctional enzymes in
Escherichia coli still gave detectable turnover. In addition, knockout
of the deaminase activity by mutagenesis of the zinc-binding residues
did not affect the reductase activity (Magalha˜es et al., 2008).
Structures of the bifunctional enzymes from E. coli (EcRibD;
Stenmark et al., 2007), B. subtilis (BsRibG; Chen et al., 2006, 2009)
and Thermotoga maritima (PDB entry 2hxv; Joint Center for Struc-
tural Genomics, unpublished work) have been reported. Structures of
the monofunctional reductases from Methanocaldococcus jannaschii
(Chatwell et al., 2006) and Shewanella sp. (PDB entry 3ky8; Joint
Center for Structural Genomics, unpublished work) have been
deposited in the PDB. The structure of EcRibD has been reported in
the apo form and in complex with NADPH and ribose-5-phosphate,
while that of BsRibG has been reported in the apo form, with
NADPH and in complex (separately) with the products of the
reductase and deaminase domains. All of these complexes were
obtained by crystal soaking and the ligands are present at low
occupancy or in only one of several subunits in the asymmetric unit.
We sought to generate a recombinant source of RibD to investigate
its structure and to obtain a template for early-stage drug discovery.
Initially, we worked with P. aeruginosa RibD, but did not obtain
crystals despite extensive screening (data not shown). However,
recombinant A. baumannii RibD (AbRibD) was obtained in high
yield and the ordered crystals enabled us to derive structures in two
crystal forms.
2. Materials and methods
2.1. Protein expression and purification
The A. baumannii ribD gene was amplified by PCR from genomic
DNA (strain ATCC 19606) using 50-CTCGAGATGTCTGAGTTAA-
AACAAGATCAATACTGG-30 and 50-GGATCCTCATACTTTCT-
CTTGCGTAGG-30 as the forward and reverse primers, respectively.
These oligonucleotides include 50 XhoI and 30 BamHI restriction
sites, respectively, which are indicated in bold. The PCR product was
ligated into pCR-Blunt II-TOPO (Invitrogen) and then subcloned
into a modified pET15b vector (Novagen), which produces an
N-terminally histidine-tagged protein with a Tobacco etch virus
(TEV) protease site. The hexahistidine tag, TEV cleavage site and
additional residues from the choice of cloning sites added 24 amino
acids at the N-terminus. The untagged protein consists of 362 amino
acids and the tagged sample consists of 386 residues.
AbRibD was produced using E. coli strain BL21(DE3) (Strata-
gene). Cells were grown in 1 l Luria–Bertani medium supplemented
with 50 mg ml1 carbenicillin. Gene expression was induced at 293 K
using 1 mM isopropyl -d-1-thiogalactopyranoside and growth
continued for 16 h at room temperature. The cells were harvested by
centrifugation for 25 min (4000g at 277 K), resuspended in lysis
buffer (50 mM Tris–HCl pH 7.5, 250 mM NaCl, 20 mM imidazole)
containing DNase I (0.1 mg) and a single tablet of EDTA-free
protease-inhibitor cocktail (Roche) and lysed using a French press at
110 MPa. Insoluble debris was separated by centrifugation (39 000g
for 25 min at 277 K) and the soluble fraction was loaded onto a 5 ml
HisTrap HP column (GE Healthcare) pre-charged with Ni2+. A linear
concentration gradient was applied to the column and AbRibD
eluted in two peaks at concentrations of 80 and 150 mM imidazole.
Fractions were analyzed using SDS–PAGE; the two peaks were kept
separate during the following steps. Attempts to remove the His tag
resulted in precipitation of the protein; therefore, this was avoided
and the sample was further purified using a Superdex 200 26/60 size-
exclusion column (GE Healthcare) equilibrated with 50 mM Tris–
HCl, 250 mM NaCl pH 7.5. Selected fractions were pooled, dialyzed
into 20 mM Tris–HCl, 50 mM NaCl pH 7.5 and concentrated to
10 mg ml1 using Amicon Ultra devices (Millipore). The protein
concentration was determined spectrophotometrically using a
theoretical extinction coefficient of 31 775M1 cm1 at 280 nm
calculated using ProtParam (Gasteiger et al., 2005) based on just the
362 amino acids. The extinction coefficient at 280 nm for all 386
residues was estimated to be 33 265M1 cm1 and that assuming that
all cysteine residues were reduced was 32 890M1 cm1. These
values affected the second decimal place of the concentration, which
we consider to be insignificant given the other sources of inaccuracy.
The high level of sample purity was verified by matrix-assisted laser
desorption/ionization time-of-flight (MALDI–TOF) mass spectro-
metry and SDS–PAGE (data not shown).
2.2. Crystallization and data collection
Crystallization trials were carried out by sitting-drop vapour
diffusion with a Rigaku Phoenix automated dispenser and commer-
cially available screens. In addition to the apo form, attempts were
made to crystallize binary complexes with NADPH or guanosine
monophosphate (GMP) by incubating the protein with the ligands at
5 mM, which is about a 20-fold molar excess, for 1 h prior to setting
up trials. Initial hits were optimized using hanging-drop vapour
diffusion and the best crystals of the apo protein (form I) were
obtained with the reservoir conditions 0.9M ammonium phosphate,
0.075M sodium acetate pH 4.5 from drops consisting of 1 ml protein
solution and 1 ml reservoir solution. Crystals were obtained from the
sample containing GMP (form II) with the reservoir conditions 0.2M
ammonium sulfate, 0.125M sodium cacodylate pH 5, 30% poly-
ethylene glycol 8000. No crystals were observed in the presence of
NADPH. For reasons that are unclear, crystals were only obtained
from the sample comprising the second peak from the Ni2+ column.
Large block-shaped crystals, which were later shown to represent two
crystal forms, typically appeared at 293 K within a few days. The
crystals attained dimensions of approximately 0.3  0.2  0.2 mm.
Prior to data collection, the crystals were briefly soaked in a sample
of reservoir solution adjusted to contain 30%(v/v) glycerol. The other
components of this solution were therefore diluted. The crystals were
then mounted on a goniostat and maintained at 100 K in a flow of
cooled nitrogen, and their diffraction properties were characterized
using a Rigaku MicroMax-007 rotating-anode generator with an
R-AXIS IV++ image plate. Diffraction data were collected in-house at
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Figure 1
The reactions catalyzed by RibD. The sites of deamination and reduction are circled.
a wavelength of 1.5418 A˚, integrated using XDS (Kabsch, 2010) and
scaled with SCALA (Evans, 2006).
2.3. Structure solution, refinement and modelling
A search model for molecular replacement based on EcRibD
(PDB entry 2g6v; Stenmark et al., 2007), which shares 46% sequence
identity with AbRibD, was prepared in which nonconserved side
chains were truncated to alanine using CHAINSAW (Stein, 2008).
The structure of form I, with two molecules in the asymmetric unit,
was solved using Phaser (McCoy et al., 2007). The two molecules were
treated independently during refinement. Rounds of model manip-
ulation using Coot (Emsley & Cowtan, 2004) interspersed with
refinement using REFMAC5 (Murshudov et al., 2011) were used to
complete the protein model with the addition of water molecules,
Zn2+ and phosphate ions and the incorporation of dual conformers.
Translation–libration–screw (TLS) refinement using three domains
per subunit was added in the final stages of refinement; domain
assignment was carried out using the TLSMD server (Painter &
Merritt, 2006). The first TLS domain spans the entire N-terminal
domain, while the C-terminal domain was divided into two TLS
segments. The second crystal form was solved by molecular
replacement (Phaser) using a subunit from crystal form I as the
search model and was refined using the strategy described for form I,
with the addition of sulfate in place of phosphate and the additional
ligands cacodylate, oxalate and GMP. Crystallographic statistics are
presented in Table 1.
3. Results and discussion
3.1. General comments and overall structure
A highly efficient E. coli recombinant expression system for
AbRibD was constructed and a purification protocol was established
that provided in excess of 100 mg per litre of culture. Two species of
the protein were identified in the first purification step using
structural communications
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Table 1
Crystallographic statistics.
Values in parentheses are for the highest resolution shell.
Form I Form II
Resolution range (A˚) 53.34–2.20 51.62–1.99
Unit-cell parameters (A˚) a = 148.99, b = 189.55,
c = 76.41
a = b = 73.00,
c = 201.46
Space group C2221 P43212
Measured reflections 159099 (22070) 504963 (63390)
Unique reflections 54441 (7963) 38040 (5291)
Multiplicity 2.9 (2.8) 13.3 (12.0)
Wilson B (A˚2) 34.2 33.0
Completeness (%) 99.0 (99.7) 99.5 (96.1)
hI/(I)i 6.4 (1.9) 24.7 (4.1)
Rmerge† 0.092 (0.439) 0.064 (0.622)
No. of protein residues (chain A/B) 357/356 354
No. of waters 176 127
No. of Zn2+ ions 2 1
No. of acetate ions 1 1
No. of phosphate ions 4 —
No. of sulfate ions — 2
No. of oxalate ions — 2
No. of cacodylate ions — 1
No. of Cl ions — 1
No. of GMP molecules — 2
Rwork‡/Rfree§ (%) 21.28/25.04 21.40/23.67
DPI} (A˚) 0.16 0.12
Average B factors (A˚2)
Overall (chain A/B) 37.2/46.2 44.78
Side chain (chain A/B) 39.2/49.3 45.73
Main chain (chain A/B) 37.2/47.7 43.86
Water 35.7 40.3
Zn2+ 32.6 54.5
Acetate 30.8 34.0
Phosphate 39.4 —
Sulfate — 65.5
Oxalate — 53.4
Cacodylate — 50.2
Cl — 33.82
GMP — 59.48
R.m.s.d., bond lengths (A˚) 0.011 0.010
R.m.s.d., bond angles () 1.30 1.29
Ramachandran plot analysis†† (%)
Favourable 97.2 97.4
Outliers 0.0 0.3 [Gly170]
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
the ith measurement of reflection hkl and hI(hkl)i is the mean value of Ii(hkl) for all i
measurements. ‡ Rwork =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where Fobs is the observed
structure-factor amplitude and the Fcalc is the structure-factor amplitude calculated from
the model. § Rfree is the same as Rwork except calculated with a subset (5%) of data that
were excluded from refinement calculations. } The diffraction-component precision
index (DPI) as defined by Cruickshank (1999) †† According to MolProbity (Chen et
al., 2010).
Figure 2
(a) The AbRibD subunit structure. Secondary-structure elements are coloured as
follows: blue -strands and purple helices for the reductase domain and cyan
-strands and gold helices for the deaminase domain. The Zn2+ ion is indicated by a
grey sphere and the phosphate ion by orange (P) and red (O) spheres. (b) The
AbRibD dimer. The subunits are coloured green and blue and the active sites are
indicated by the phosphate and Zn2+ ions.
Ni2+--affinity chromatography, only one of which gave rise to crystals.
We are unable to explain these observations. The expected mass of a
subunit of the tagged construct is 42 038 Da and the samples
appeared to be identical on SDS–PAGE, with an approximate mass of
40 kDa, and displayed a similar mass in MALDI–TOF mass spec-
trometry (42 441 and 42 485 Da). Both samples also appeared to be
homogeneous samples of approximate mass 58 kDa in gel filtration
and we judge it likely that this species represents an RibD dimer. The
overall structure of AbRibD is an arch-like dimer and most certainly
not a uniform globular entity. Such an unusual assembly may explain
the reduction in apparent mass when analyzed by size-exclusion gel
chromatography.
Two distinct crystal forms of AbRibD were obtained. Crystal form
I, the apoenzyme, belonged to the orthorhombic space group C2221
with two subunits (A and B) in the asymmetric unit. Each subunit
consists of two domains (Fig. 2a). The two subunits are related by a
noncrystallographic twofold axis (Fig. 2b). The second form, which
crystallized in space group P43212, has one subunit in the asymmetric
unit, with a crystallographic twofold generating the same dimer as
observed in form I. Both crystal forms have an estimated Matthews
coefficient of 3.2 A˚3 Da1 and a solvent content of about 60%.
The N-terminal reductase domain spans residues 1–150 (coincident
with the first TLS domain in both crystal forms) and the C-terminal
domain spans residues 151–361. No electron density was observed for
the residues forming the N-terminal His tag in either crystal form.
Continuous electron density was observed for residues 2–359 in chain
A and residues 2–358 in chain B for crystal form I. Residues 173 and
174 could not be modelled in form II, which was otherwise complete
from residues 2 to 357.
The N-terminal domain consists of a five-stranded mixed -sheet
flanked by three -helices on one side (2, 3 and 4) and two
-helices (1 and 5) on the other. A short -helix (6) forms the
linker to the C-terminal domain, which contains a central nine-
stranded predominately parallel -sheet (strand 14 is antiparallel)
with a pronounced twist. Two helices (7 and 8 on one side and 10
and 11 on the other) lie on each side of the sheet, in addition to
several long loops with short 310-helical or -helical segments and one
further -helix (9) (Fig. 2a). The secondary structure is matched
onto the primary structure in Fig. 3.
Chains A and B overlay with an r.m.s.d. of 0.74 A˚ over 353 aligned
C atoms. This indicates a high degree of similarity, especially
considering that noncrystallographic restraints were not applied
during refinement. The largest differences arise in the positions of
two loops, one involving residues 106–113 close to the active site of
the deaminase domain and the other involving residues 167–174 close
to the reductase active site. These differences are described in more
detail below. Chain A of the apoprotein overlays with the unique
chain of form II with an r.m.s.d. of 0.92 A˚ over 349 aligned C posi-
tions and the dimer of form I overlays with the dimer (generated by
the operation of a crystallographic twofold) of form II with an r.m.s.d.
of 1.5 A˚ over 691 aligned C atoms.
A chain of apo EcRibD superimposes on chain A of apo AbRibD
with an r.m.s.d. of 1.4 A˚ over 321 aligned C atoms, while BsRibG and
AbRibD align with an r.m.s.d. of 2.0 A˚ over 327 C atoms. This degree
of similarity is commensurate with the levels of sequence identity.
AbRibD shares 46% sequence identity with EcRibD and 40% with
BsRibG.
A number of ligands are included in the crystallographic models;
with one exception, these were deliberate additions. The exception is
oxalate, which was observed in crystal form II. Oxalate is a common
contaminant of polyethylene glycols owing to polymer breakdown
(Jurnak, 1986) and crystal form II was obtained in the presence of
polyethylene glycol 8000. We made a similar observation previously
in the analysis of PurB (Fyfe et al., 2010).
3.2. The oligomeric state
EcRibD is dimeric (Stenmark et al., 2007) and BsRibG is tetra-
meric (Chen et al., 2006). Analysis of the AbRibD crystal structures
using the PISA (Protein Interfaces, Surfaces and Assemblies) server
(Krissinel & Henrick, 2007) suggests that the crystallographic dimer
of AbRibD (Fig. 2b) is of biological relevance. The interface is
formed solely by residues in the C-terminal domain, burying
approximately 11% of the surface area (1930 A˚2) of each subunit
(in both crystal forms). The interface is formed primarily by a long
stretch of residues from Val312 to Leu354, consisting of a long loop
joining strands 12 and 13 and of parts of 8 and 9. An additional
stretch of residues Ser159–Ile174 is also involved at the interface. 23
hydrogen bonds are formed at the interface, which is significantly
larger in area with more interactions than the comparable interface
observed in EcRibD (interface area of 1310 A˚2 with only three
hydrogen bonds). One subunit–subunit interface in BsRibG is similar
to that of AbRibD, burying approximately 2000 A˚2 per subunit and
forming 20 hydrogen bonds.
3.3. The deaminase domain
The deaminase domain of RibD has significantly more conserved
residues than the reductase domain (Fig. 3). For example, the
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Figure 3
Sequence conservation in RibD. A total of 550 sequences annotated as both EC 3.5.4.26 and EC 1.1.1.193 in the UniProt database (http://www.uniprot.org/) were filtered at
90% sequence identity and aligned usingMUSCLE (Edgar, 2004). Residues that are conserved in at least 70% of the 550 sequences are shown on a black background. The
Zn2+-binding residues are marked with a star and assigned secondary-structure elements are shown with the same colour scheme as used in Fig. 2. This figure was prepared
using ALINE (Bond & Schu¨ttelkopf, 2009).
deaminase domains of AbRibD and EcRibD share 58% sequence
identity, compared with 35% for the reductase domain and 46%
overall. The Zn2+-binding site of the deaminase domain is located at
the base of an opening in the structure lined with conserved residues
(Fig. 4). Although no extra Zn2+ was present in the bacterial culture
or during purification of the protein, well defined electron density
with an OMIT difference density peak height of over 30 compared
with 7 for a well defined carbonyl O atom was observed in the active
site. This is consistent with the presence of Zn2+. The ion displays
tetrahedral coordination by a conserved zinc-binding motif
comprising His54, Cys79 and Cys88 and a water molecule in form I.
An additional strong electron-density feature was observed coordi-
nated to the Zn2+ in crystal form II. Examination of difference
anomalous Fourier maps in similar fashion to nicotinamidase (data
not shown; Fyfe et al., 2009) suggested that this is cacodylate, which
has replaced the water molecule. The peak height in an anomalous
difference Fourier map was significantly higher than that of the
cysteine S atoms, with a peak height of 8.5 at the arsenic position
compared with 4.5–5.6 for sulfur. The f 0 0 signal is estimated to be 0.5
and 1.0 electrons for S and As3+, respectively, at a wavelength of
1.5418 A˚.
Electron density consistent with the presence of an oxyanion
binding to His54 was noted in both crystal forms. In form I this was
assigned as phosphate since 0.9M ammonium phosphate was used in
crystallization and in form II as sulfate since 0.2M ammonium sulfate
was used in this case. The oxyanions, which represents the first ligands
observed in the deaminase domain of RibD, interact with conserved
residues and may represent the phosphate-binding site of the
substrate.
The interactions of the phosphate group differ in subunits A and B
(Fig. 4). In subunit A, the phosphate accepts hydrogen bonds from
the side chains of Asn28, His54, His81, Thr85 and the main-chain
amide of Arg84. In subunit B, the side chain of His81 points away
from the active site, while the side chain of Arg84 is now within
interaction distance of the phosphate. In form II, the side chain of
Arg84 is oriented away from the active site, while His81 adopts a
conformation intermediate between the two observed in form I. All
residues interacting with the oxyanions are strictly conserved in RibD
sequences, with the exception of Arg84, which is sometimes replaced
by lysine (Fig. 3). Indeed, mutation of Lys79 in BsRibG, which
corresponds to Arg84 in AbRibD, to alanine abolished deaminase
activity (Chen et al., 2009).
His81, Arg84 and Thr85 form part of the canonical RibD Zn2+-
binding sequence PCXHXG(R/K)TPPC. The Zn2+ coordination
sphere involves His54, Cys79, Cys88 and a water molecule in the apo
form. Asn28 forms a hydrogen bond to the highly conserved His47
to form part of the substrate-binding site. A twofold to threefold
reduction in activity was observed in BsRibG when the corresponding
residues were individually mutated to alanine (Chen et al., 2006).
These residues have been proven to be essential for binding substrate
and may interact with the 5-amino and ribose groups, respectively
(Magalha˜es et al., 2008). The substrate pyrimidine is likely to bind
sandwiched between His54 on one side and Pro29 and Leu76 on the
other, with the side chains of Asn28 and His47 providing hydrogen-
bonding capacity to assist this placement. Positioned at the other side
of the deaminase active site are the catalytic Zn2+ and Glu56. These
may act in concert to activate a water to generate a nucleophilic
hydroxide that is then able to attack the substrate in a similar fashion
as proposed for cytidine deaminase (see, for example, Ko et al., 2003).
The loop between 4 and 4 differs in position in subunits A and B
(crystal form I). This is a well conserved sequence that includes
Asp106 (present as glutamate in a few sequences). This side chain
may assist catalysis by interacting with the ‘leaving’ amine, so the
different positions of this loop may possibly represent ‘open’ and
‘closed’ conformations of the active site. They certainly indicate that
there is conformational freedom in this part of the structure.
Closely related structures were identified using the Secondary
Structure Matching (SSM) server (Krissinel & Henrick, 2004). A
search using the N-terminal domain alone matched members of the
cytidine deaminase superfamily, with r.m.s.d.s in the range 1.3–1.8 A˚
for approximately 110 aligned C atoms. This structural similarity
gives some insight into the mechanism of this domain, as other
members of this superfamily have been extensively studied. The
main-chain carbonyl of Thr127 in E. coli cytidine deaminase (PDB
entry 1af2) is thought to form a leaving-group pocket together with
Pro128 (Xiang et al., 1997). The proline is conserved in RibD (Pro78);
it is in fact part of the canonical motif described above. The threonine
is replaced by glutamic acid (residue 77 inAbRibD, strictly conserved
in RibD sequences), with the side chain locked into position by
interactions with the main-chain atoms of residues in 4. Given the
structural similarities of the enzymes, it may be instructive to test
whether cytidine deaminase inhibitors (see, for example, Ludek et al.,
2009) could provide templates for the development of RibD inhibi-
tors.
3.4. The reductase domain
The active site in the reductase domain is located approximately
30 A˚ from the Zn2+-binding site on the opposite side of the subunit
from the deaminase domain (Fig. 2b). Our attempts at cocrystalli-
zation and soaking crystals with ligands targeted to bind in the
reductase active site, for example NADPH, were unsuccessful (data
not shown). Complex structures obtained by cocrystallization and
soaking experiments in other laboratories showed that the cofactor
NADPH binds in a long surface-exposed groove between 8 and 11
(see, for example, Stenmark et al., 2007). There is significant variation
in the orientation of the adenine with respect to the rest of the ligand,
possibly reflecting the limitations of soaking experiments and the
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Figure 4
The coordination of Zn2+ and oxyanion binding in the deaminase active site.
Residues involved in coordination are shown in stick representation: C, grey; N,
dark blue; O, red; P, orange; S, yellow. Residues with grey C atoms indicate subunit
A of form I, cyan C atoms indicate subunit B of form I and magenta C atoms
indicate form II. The catalytic Zn2+ is shown as a grey sphere and the catalytic water
is shown as a red sphere. Dashed lines represent potential hydrogen-bonding
interactions and the metal-ion coordination is depicted in continuous grey lines.
comparatively low resolution of the analyses. In both cases the
resolution was 3.0 A˚. The NADPH–BsRibG structure (PDB entry
2d5n; S.-J. Chen, Y.-C. Chang & S.-H. Liaw, unpublished work)
displayed NADPH binding in only one of the four molecules in the
asymmetric unit, while in NADPH–EcRibD (PDB entry 2o7p;
Structural Proteomics in Europe, unpublished work) part of the
nicotinamide-binding region was disordered in one subunit and the
orientation of the nicotinamide group varied significantly between
the subunits. This observation may be explained by difficulties in
modelling the electron density of the nicotinamide ring close to the
side chain of a tryptophan (Trp170B) at 3 A˚ resolution.
The substrate-binding site is between two loops. The first joins 6
to 7, which caps one end of the active site (Fig. 2a). The reductase
domain has previously been identified as being structurally similar to
dihydrofolate reductase (DHFR; Chen et al., 2009) and the 6–7
loop overlays with the Met20 loop in E. coli DHFR, which undergoes
large conformational changes throughout the catalytic cycle (Sawaya
& Kraut, 1997). The second, very long, loop joins 8 to 8 (via a
310-helical section).
In similar fashion to what was observed in the deaminase active
site, the oxyanions phosphate and sulfate were identified in the
reductase active sites in forms I and II, respectively. These anions
occupy the same position as the phosphate groups of the soaked
ligands reported in the EcRibD and BsRibD structures. The phos-
phate interacts with the side chains of Arg188 and Arg211 and the
main chain of Gln207. In subunit B, an additional interaction is
formed with Arg181 (Fig. 5). A difference in the position of Arg181 in
subunit B compared with subunit A is accompanied by movement of
Trp174 into the active site, and a comparison with the substrate
analogue binding position in BsRibG (PDB entry 3ex8; Chen et al.,
2009) indicates this tryptophan is important in defining the active site.
The pyrimidine moiety could fit well sandwiched between the
NADPH nicotinamide and Trp174. This arginine–tryptophan pair is
strongly conserved in RibD sequences (Fig. 3). In crystal form II
Trp174 is not visible in the electron density, suggesting a degree of
flexibility in this part of the active site consistent with the altered
positions noted in form I.
Other conserved residues in this active site include Lys156, Ser172,
Thr176, Asp204 and Glu290 (Figs. 2 and 5). Thr176 is well placed to
interact with an amino group on the pyrimidine ring of the substrate.
Based on the structure of BsRibG with product, Chen et al. (2009)
suggested that Glu290 (also Glu290 in AbRibD) initiates the reac-
tion, while Stenmark et al. (2007) identified the corresponding residue
as Asp204 in EcRibD. Further work would be required to address this
point.
Crystal form II was obtained in the presence of 5 mM GMP, which
had been added as a potential substrate analogue for the deaminase
reaction. Unexpectedly, a GMP molecule was observed in the
NADPH-binding site of the reductase domain, occupying the
adenine-binding pocket (Fig. 6). There are no direct hydrogen bonds
involving the purine moiety and the enzyme; rather, it is positioned
by van der Waals interactions with Leu271 and Leu295 on one side
and the side chain of Arg231 on the other. Other residues that help to
construct this cavity include Ala298, Glu302, Leu229, Gln269, Ile268
and Pro270.
A second GMP, refined with an occupancy of 0.5, was observed
positioned in a depression on the surface of the protein formed
between 7 and 14 (data not shown) and distant from either active
site. Binding interactions appear to be dominated by van der Waals
interactions between the purine and His186 and Trp187. We do not
think that the GMP binding we observe is of biological relevance;
rather, it is a consequence of the crystallization conditions with the
high level of GMP present.
SSM analysis using the reductase domain identified the closest
match as the equivalent monofunctional protein from M. jannaschii
(PDB entry 2azn; Chatwell et al., 2006) with an r.m.s.d. of 1.5 A˚ over
194 C atoms. The next closest are various type I DHFR proteins,
with an r.m.s.d. range of 1.8–2.2 A˚ over approximately 150 C atoms.
The closest matching DHFR is from T. maritima (PDB entry 1cz3;
Dams et al., 2000), with an r.m.s.d. of 1.7 A˚ over 152 C atoms, a
Z-score of 11.7 and a sequence identity of 22%; this DHFR does not
have the flexible active-site loop seen in other DHFR structures.
4. Concluding remarks
An efficient recombinant expression system for the potential anti-
bacterial drug target AbRibD has been obtained and protocols have
been established for purification and crystallization. Two ordered
crystal forms have been obtained and the scene is set for a structure-
based approach to ligand discovery. Given the structural and
mechanistic similarities between RibD, cytidine deaminase and
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Figure 5
The reductase active site. The same colour scheme is used as in Fig. 4.
Figure 6
GMP binding in the adenosine-binding pocket. The same colour scheme is used as
in Fig. 4 and in addition the C atoms of GMP are coloured slate blue.
DHFR, it may be possible to exploit known inhibitors to provide
starting points relevant to antibacterial drug discovery.
This work was funded by the European Commission Seventh
Framework Programme (FP7/2007–2013) with contributions from
The Wellcome Trust (grant Nos. 082596, 083481 and 094090).
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